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Summary 
The mechanisms by which tumor cells are killed by rituximab remain unclear. An understanding of these 
mechanisms would improve the efficacy of rituximab therapy in B-CLL, and may lead to optimization of 
monoclonal antibody therapy for other diseases. To identify the signalling pathways affected by rituximab, 
differentially abundant cellular proteins (± rituximab) were identified from lipid rafts, the cell surface and total 
cell lysates of MEC1 cells. 
 
Three different methods have been used to identify proteins from the LRs proteome from the human CLL cell 
line, MEC1. Firstly, LRs proteins were enriched and identified using sucrose gradient ultra-centrifugation and 
2DLC-MS/MS. To confirm protein localization to LRs, proteomes were compared before and after cholesterol 
depletion by MβCD using iTRAQ-labelling coupled to 2DLC-MS/MS. LRs proteins were also identified by 
immuno-precipitation using rituximab cross-linked to CD20. In total, 643 proteins were found in LRs of CLL 
cells (580 from the sucrose gradient method, 181 depleted by MβCD and 199 isolated by immuno-precipitation), 
64 proteins were identified by all 3 methods. This comprehensive list of LRs proteins, includes 30 proteins with 
no previous association to the LRs. Out of these 30 novel proteins, we propose that LSP1, RAC2, IFI30, 
Neurabin II, SIPA1, GPSM3, GNG11, SHKBP1, SPARC, ST6GAL1 and CD74/ROS fusion proteins are 
potential therapeutic targets on CLL. These proteins have roles in cell migration, adhesion, signalling pathways, 
apoptosis, transcription regulation, protein synthesis and degradation in cancer cells. 
 
The chimeric antibody rituximab is the first CD20-targeted agent to be approved by the FDA for the treatment of 
B-cell malignancies. When rituximab binds to CD20 at the cell surface, CD20 translocates to the LRs, increases 
21 proteins and decreases 10 in LRs, increases 4 and decreases 14 CD antigens at the cell surface, and increases 
10 and decreases 5 proteins in whole cell lysates. Rituximab induces accumulation of cytoskeletal proteins 
(actin, spectrins, myosin, vimentin and tubulin) in LRs, LRs specific proteins (RFTN1, FLOT2, FLOT1) and the 
actin structure modulator AKAP2. Aggregation of these proteins in LRs facilitates actin polymerization that 
results in formation of an apical shape of the cell at the LRs. Some of the 21 proteins found to move into LRs 
after rituximab treatment include CD20, LDHA, CD228, TRIM21, C4A, ATP1A1, ABCD3, ATP6V0D1, 
TUBA1C and SLC16A1. The movement of these proteins to LRs may be attributed to an effect of rituximab, or 
as CD20 binding partners. Some of these proteins may be involved with down-stream signaling or cell apoptosis. 
 
Up-regulation of the protein CSTB and down-regulation of PABPC1 and PARP1 seen in whole cell lysates, may 
result in cellular proliferation as CSTB inhibits downstream effector caspases and cell apoptosis. In addition, 
Low levels of PARP1 may lead to reduced pro-inflammatory mediators, tissue damage and reperfusion injury 
and reduced expression of PABPC1 that correlates with tumor progression and poor prognosis. On the other 
hand, up-regulation of other proteins such as, CLT, ENO1 and TPI and down-regulation of NPM1 and SS-B and 
in whole cell lysates may activate a mechanism of action of rituximab by inhibiting cell survival and 
proliferation and increasing sensitivity to chemotherapy. CLT prevents constitutive expression of the pro-
inflammatory and tumorigenic factor IL-8, ENO1 is a negative regulator of the c-Myc proto-oncogene, that 
regulates expression of many genes, some of which are involved in cell proliferation, TPI1 protein is known to 
increase the sensitivity of cells toward chemotherapy, SS-B over-expression led to increased MDM2 and 
enhanced resistance to apoptosis and is correlated with proliferation, migration and invasion. NPM1 can act as 
coactivator of NFκB and its over-expression promotes cell growth and proliferation.  
 
Some of the CD antigens whose expression changed at the cell surface could help rituximab induce apoptosis, 
e.g., down-regulation of CD23, ADAM10, CD55 and CD46. Some of these proteins may be involved in 
initiation of the complement system, and inhibition of cell proliferation and survival. Whereas, other 
differentially abundant CD antigens may make cells resistant to apoptosis, e.g., up-regulation of CD72, CD22 
and IL-8 and down-regulation of CD95, CD80, CD86, CD19, CD21 and CD50. The strength of BCR signaling 
  x 
can generate many outcomes including cell death, survival, proliferation and differentiation; the threshold of 
BCR response is controlled by both stimulatory and inhibitory factors. The stimulatory receptors such as the 
CD19/CD21/CD81 complex, an essential B-cell co-receptor that functions synergistically to enhance signaling 
through the B-cell Ag receptor in response to T cell-dependent, complement-tagged Ags. The inhibitory 
receptors such as, CD22 and CD72, are negative regulators of B-cell responses.  
 
A prominent feature of B-CLL cells is the high expression of CD23, which is related to cell survival and is 
regulated by Notch2. Down-regulation of CD23 and loss of Notch2 activity are early steps in proteasome 
inhibitors-induced apoptosis of B-CLL lymphocytes. ADAM10 cleaves notch, which travels to the nucleus and 
activates the transcription of CD21 and CD23. Thus down-regulation of ADAM10 inhibits metastasis and 
invasiveness. Down-regulation of ADAM10 to 0.76-fold at the MEC1 cell surface after rituximab treatment 
could explain CD21 and CD23 down-regulation. In addition, reduction of ADAM10 and CD23 in MEC1 cells 
by rituximab may inhibit proliferation and survival. 
 
Rituximab decreased CD80 and CD86 at the cell surface that may suppress a T-cell response to CLL and 
lymphoma. In addition, rituximab inhibits the apoptosis pathway that could be initiated by CD95 on MEC1 cells, 
as rituximab decreases CD95 levels at cell surface. However, this pathway could be activated by combination 
treatment of rituximab with fludarabine, which is known to induce Fas and Fas-L mRNAs.  
 
Membrane-bound complement regulatory proteins (mCRPs) CD55, CD46 and CD59, are often detected at 
elevated levels on tumor cells. CD59 restricts formation of the membrane attack complex by preventing C9 
protein polymerization through binding to C8 and C9. CD55 inactivates the C3 and C5 convertases by 
accelerating the decay of these proteases, whereas CD46 acts as a cofactor for inactivation of cell-bound C4b 
and C3b by serum factor I. Therefore the down-regulation of mCRPs contributes to the sensitivity of CLL cells 
to rituximab. After rituximab treatment, CD46 and CD55 levels are slightly reduced (Figure 4.2 and Table 4.4), 
whereas, CD59 increases (data not shown). These changes in CD46 and CD55 would not be enough to sensitize 
the cells to complement attack, as CD59 prevents complement activation by binding to C9 and therefore inhibits 
complement dependent cytotoxicity (CDC). CD50 is a ligand for leukocyte function-associated antigen-1 (LFA-
1) and a potent signaling molecule. Myeloma cells down-regulate CD50 to escape immuno-surveillance. MEC1 
cells may down-regulate ICAM-3 to 0.79-fold (Table 4.4 and Figure 4.2) after rituximab treatment to avoid NK 
cells. 
 
TRIM21 was up-regulated (20-fold, p<0.05) in the LRs after rituximab treatment and is known to bind human 
IgG. Activation or up-regulation of TRIM21 may have an essential role in turning off NF-κB signaling. TRIM21 
degrades IKBKB (IKK-B) and thus inhibits NF-κB2 and STAT3 transcription (Figure 5.4) that would result in 
Bcl2 inhibition or down-regulation. TRIM21 ubiquitinates IRF8, that would activate PAX5, CIITA and BCL6, 
and deactivate c-Myc and Bcl2. Avoiding prolonged over-production of pro-inflammatory cytokines, 
chemokines, and adhesion molecules, subsequently decreasing cellular resistance to apoptosis by down-
regulation of Bcl2, NFKB2 and STAT3. 
 
Rituximab up-regulates GNAS, GNAI3, AKAP and the spectrins (SPTAN1 and SPTBN1) in LRs and activates 
Syk resulting in phosphorylation and activation of RAC1. This may have resulted in the accumulation and 
polymerization of actin in LRs (Figure 4.6) with initiation of signaling pathways by activation of NF-kB and 
STAT3. That may result in activation of anti-apoptotic proteins such as c-Myc, CCND1 and Bcl2. In addition, 
activation of Syk activates PI3K, which induces the expression of STAT3, p-STAT3, YY1 and may induce 
BcL2, c-Myc, CCND1 and NF-κB and may inhibit expression of PAX5, resulting in cell proliferation. 
 
Identification of these differentially abundant proteins provides potential targets for therapeutic antibodies and 
contributes to a greater understanding of the mechanism of action of rituximab. 
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CHAPTER 1 
1 General Introduction 
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1.1 Chronic lymphocytic leukemia 
B-cell chronic lymphocytic leukemia (CLL), an incurable malignancy of mature B-
lymphocytes, is the most frequently observed leukemia in the Western World [1, 2]. B-CLL is 
characterized by clonal proliferation of cells that are long-lived and arrested in the G0/early 
G1 phases of the cell cycle, resulting in accumulation of neoplastic B-lymphocytes in the 
blood, bone marrow, lymph nodes, and spleen. The block in apoptosis may be attributed to 
the over-expression of the oncogenic protein B-cell lymphoma 2 (Bcl-2) (commonly seen in 
CLL) [3]. CLL cells have a characteristic surface immunophenotype that includes expression 
of CD20 and CD23 with CD5 [1, 4-6], low levels of CD22 and the B-cell-receptor (BCR) 
consisting of immunoglobulin associated with a CD79a/CD79b heterodimer [6-8]. Ninety 
percent of CLL cases are found in people 50 years or older, the average age at diagnosis is 65, 
with only 10-15% under 50 years. CLL is rarely diagnosed in a patient of less than 35 years, 
with more men than women affected. The course of the CLL is variable, some patients have a 
normal life span, others die within five years from diagnosis [9]. 
1.2 Symptoms 
CLL develops slowly and many people don't have symptoms in the early stages, and the 
disease is picked up by routine blood test. In advanced CLL, many blood stem cells develop 
into abnormal lymphocytes that replace the bone marrow's normal blood making cells. As a 
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result, patients do not make enough red blood cells, leukocytes, and platelets [1, 9, 10]. The 
symptoms appear as, 
• Anemia, a reduction in the numbers of red blood cells, with tiredness, weakness, and 
shortness of breath. 
• Thrombocytopenia, a reduction in the number of platelets, that help the blood to clot, a 
deficiency can cause bruises and severe bleeding. 
• Neutropenia, a reduction in leukocytes with an increased risk of infection. Patients 
with CLL may have very high leukocyte count because of excess lymphocytes 
(lymphocytosis), the leukemia cells do not protect against infection like normal white 
blood cells. 
• Weight loss 
• Fever 
• Night sweats 
• Swollen lymph nodes in the neck, under the arms or in the groin, due to accumulation 
of lymphocytes. 
• Pain or discomfort under the ribs on the left side, due to an enlarged spleen. 
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1.3 Prognostic markers 
Many prognostic markers have been identified that predict outcomes for patients with CLL at 
an early clinical stage. These include an absence of mutations in the gene encoding the 
immunoglobulin heavy chain (IGVH), high ZAP70 and CD38 levels, and mutations of p53 or 
its activator ATM kinase (ataxia telangiectasia mutated) that affect apoptotic pathways [11, 
12]. Patients with unmutated IGVH tend to have a more advanced disease and more 
aggressive course of the disease, with a shorter remission and survival [13-15]. High levels of 
ZAP-70, correlate with poor prognosis and is a surrogate marker for IGVH mutation status 
[16, 17]. ZAP-70 level correlates with IGVH mutational status, disease progression and 
survival [18]. ZAP70 and CD38 levels analysis provided complementary prognostic 
information identifying three patient subgroups: ZAP70 and CD38 negative cases with an 
excellent prognosis, discordant cases (either ZAP70 or CD38 positive) with an intermediate 
risk, and ZAP70 and CD38 positive cases with a poor prognosis [19].  Also patients with p53 
[20] or ATM [21] mutations are associated with treatment resistance and clinically aggressive 
CLL. 
1.4 Treatment 
CLL is a slow-growing leukemia and stable cases, particularly in the early stages, do not need 
treatment. Some patients have aggressive disease with relatively rapid increases in the number 
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of malignant cells in the blood, and require treatment, most commonly with fludarabine and 
rituximab. Patients with stable disease often require only careful monitoring. 
Younger patients, with CLL may receive chemotherapy, steroids and monoclonal antibody 
followed by a stem cell transplant. In recent years, the treatment of B-CLL has been improved 
with the development of monoclonal antibodies against surface CD antigens, Cluster of 
Differentiation (CD) antigens (Human Cell Differentiation Molecules-HCDM, 
http://www.hlda8.org). For example, antibodies against CD20 (rituximab, mabthera), CD52 
(alemtuzumab; Campath-1H) and CD80 (galiximab) are effective for treatment of CLL and 
Non-Hodgkins lymphoma (NHL) [22, 23]. Immunotoxins such as BL22 directed against 
CD22, may be useful in the treatment of CLL [24].  
Although treatment with rituximab alone does not have a high response rate in CLL patients 
[25], in a phase II clinical trial, patients who received rituximab in addition to standard 
chemotherapy (fludarabine) experienced outcomes far better than those patients who received 
rituximab or fludarabine alone [26-28]. Furthermore, compared with conventional 
chemotherapy, rituximab is associated with markedly reduced haematological events such as 
severe neutropenia, as well as associated infections [29]. Yet the mechanism underlying the 
action of rituximab and it’s synergistic relationship with standard chemotherapeutics, such as 
fludarabine, is unclear. 
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1.5 Rituximab 
During the last two decades therapeutic antibodies have been the hope for cancer therapy. A 
variety of engineered antibody molecules derived from various immunoglobulin’s selectively 
targeting highly expressed molecules on the tumor cell surface have received The Food and 
Drug Administration (FDA) approval for treatment of cancers such as leukemias. Some of 
these monoclonal antibodies block a receptor at the tumor cell surface such as a growth factor 
receptor [30], while others contain a toxin or drug, such as Mylotarg or a radioisotope such as 
131I-tositumomab [31]. These types of monoclonal antibodies have achieved some efficacy in 
the treatment of CLL and other cancers. Problems such as the specificity of the antibody and 
the toxicity of the drug decrease the efficacy of treatment.  
Rituximab also known as rituxan or mabthera is a type 1 chimeric IgG1 (mouse/human) 
monoclonal antibody against CD20 [32, 33]. Rituximab is a highly purified 1328-amino acid 
protein that is produced in mammalian cell culture using Chinese Hamster Ovary (CHO) 
cells. This IgG1 kappa monoclonal antibody contains murine light and heavy chain variable 
regions (Fab domain), and human gamma 1 heavy chain and kappa light chain constant 
regions (Fc domain) (Figure 1.1). The molecular weight of this antibody is 144,544 Daltons, 
calculated from the primary sequence of the reduced, non-glycosylated form. The light chain 
consists of 213 amino acids and heavy chain consists of 451 amino acids. The therapeutic 
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advantage of chimeric antibodies (for example, rituximab) compared with murine mAbs is the 
reduction of immunogenicity providing a longer half-life. Other important features of 
chimeric mAbs are their ability to bind human complement (C1q), and the mediation of 
human effector functions such as complement-dependent cytotoxicity (CDC) and antibody-
dependent cellular cytotoxicity (ADCC) resulting in a potentially more effective destruction 
of tumor cells [32-34]. 
In CLL patients, rituximab is given as an intravenous infusion once weekly for 4 weeks at 
doses of 375 mg/m2. The recommended dosage for CLL, 375 mg/m2 the day prior to the 
initiation of Fludarabine and cyclophosphamide (FC) chemotherapy, then 500 mg/m2 on Day 
1 of cycles 2-6 (every 28 days). 
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Figure 1.1 Rituximab design. Rituximab is a chimeric monoclonal antibody with the Fab portion coming from 
a mouse monoclonal antibody. Binding regions from original murine anti-human CD20, consisting of variable 
regions of immunoglobulin heavy and light chains, are fused to human IgG1 heavy-chain and human kappa 
light-chain constant regions. The Fc portion from human IgG1 was selected for its ability to fix complement and 
activate antibody-dependent cellular cytotoxicity. 
1.5.1 Applications 
In 1997, the chimeric antibody rituximab (Rituxan) became the first CD20-targeted agent to 
be approved by the FDA for the treatment of B-cell malignancies [35]. In 2010 it was 
approved by the European Commission for maintenance treatment after initial treatment of 
Follicular lymphoma. Rituximab is currently approved for use in hematological cancers such 
as, CLL and NHL, in autoimmune diseases such as rheumatoid arthritis (RA) [36], immune 
thrombocytopenic purpura [37], systemic lupus erythematosus [38], myasthenia gravis [39], 
multiple sclerosis [40]  and Sjogren syndrome [41]. In transplant recipients, rituximab is used 
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for treatment of post-transplant lymphoproliferative disorder, to desensitize HLA and blood 
group-incompatible (ABOi) transplants and for the prevention and treatment of acute 
rejection [42].  
1.5.2 Mechanism of action 
While the exact mechanism of action of rituximab is unknown, experimental evidence 
supports 4 different mechanisms in its clinical activity [43]. These include:  
• Complement-dependent cytotoxicity (CDC), once the Fab region of rituximab is 
bound to CD20 it activates the complement cascade. Leading to development of the 
membrane attack complex (MAC), which forms a hole in the cell membrane, causing 
cell lysis and death [43]. 
• Antibody-dependent cell-mediated cytotoxicity (ADCC), The Fc domain of rituximab 
binds to Fc receptors on macrophages, NK cells or neutrophils leading to a signalling 
cascade that results in the release of Granzyme B and perforin that induce apoptosis of 
the antibody-coated cell [43]. 
• Activation of Src family tyrosine kinases by rituximab binding to CD20 results in 
redistribution of LRs thus trans-activating Src kinases such as, LYN, Fyn and Lck and 
initiating down-stream signaling pathways, resulting in apoptosis [44, 45] (Figure 
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1.2). 
• Activation of the Fas apoptotic pathway, rituximab up-regulates Fas expression by 
down-regulation of the transcription factor Yin-Yang 1 (YY1) through inhibition of 
the p38 mitogen-activated protein kinase (MAPK) signaling pathway and nuclear 
factor kappa B (NF-κB) [46] (Figure 1.2). 
• Rituximab inhibits the expression of the anti-apoptotic gene products Bcl-2/BclxL and 
Mcl-1 by inhibiting p38-MAPK, NF-κB and extracellular signal regulated kinase 1/2 
(ERK1/2) pathways, and activates pro-apoptotic gene product Bcl-2-associated death 
promoter (Bad) by inhibiting Protein kinase B (Akt) [47, 48]. Rituximab also inhibits 
the B-cell receptor, (BCR) signaling cascade involving LYN, Syk, PLCγ2, Akt, and 
ERK [49]. Inhibition of these pathways makes cells sensitive to chemotherapy with 
fludarabine [50] (Figure 1.2). 
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Figure 1.2: The signaling pathways affected by rituximab. CD20–rituximab can redistribute lipid rafts, 
transactivate these kinases, and initiate downstream signaling pathways resulting in apoptosis. The redistribution 
of lipid rafts can also inhibit the p38 MAPK, ERK-1/2, NF-κB, and Akt signaling pathways. p38 MAPK, ERK-
1/2 and NF-κB inhibition resulting in the reduction of anti-apoptotic genes Bcl-2, Bclxl, XIAP, and Mcl-1, also 
inhibition of p38 MAPK lead to the reduction of the Interleukin 10 receptor (IL10-R), which down-regulates p-
STAT3 and BcL2. Inhibition of Akt activates apoptotic gene Bad, making B-lymphocytes susceptible to 
apoptosis [47, 48]. Inhibition of the NF-κB pathway down-regulates the transcription factor YY1, enhancing the 
transcription of Fas and DR5 and facilitating FasL- and TRAIL-induced apoptosis [46]. Downward red arrows 
indicate a decrease of expression, whereas, upward red arrows indicate increase of expression.  
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1.5.3 Mechanism of resistance  
Rituximab mechanisms of resistance have not been clearly identified. Several mechanisms 
have been postulated, including loss of CD20 cell surface expression [51-53], upregulation of 
proliferative and anti-apoptotic signaling pathways such as, NF-kappaB, PI3K, Akt and 
ERK1/2 [48, 54], inhibition of CDC by the complement inhibitors CD55 and CD59 [55-57], 
up-regulation of anti-apoptotic Bcl-2, Bcl-xL and Mcl-1 and down-regulation of the pro-
apoptotic proteins, Bak and Bax [48, 54, 58]. 
1.6 CD20 
CD20 is a cell surface non-glycosylated hydrophobic phosphoprotein and a member of the 
membrane-spanning 4-A (MS4A) family, consisting of three isoforms of 33, 35 and 37 kDa 
with differential phosphorylation states (on serine and threonine residues) [59-61]. CD20 is 
widely expressed through B-lymphocyte development from the pro-B phase until maturity 
(Figure 1.3), in normal or malignant B-cells [62]. CD20 is a tetraspanin membrane protein 
with a large extracellular loop (residues 142 to 182) and intracellular N- and C-terminal 
regions (Figure 1.4), that forms oligomers on the cell surface [63-65]. CD20 functions as a 
calcium channel, involved in cell activation and cell-cycle progression by interaction with Src 
family kinases [64, 66-68]. CD20 expression at the cell surface of malignant B-cells makes it 
a target for monoclonal antibody (mAb) therapy. CD20 is important as a target for therapeutic 
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antibodies, such as rituximab, ibritumomab-tiuxetan, and tositumomab, used in the treatment 
of B-cell lymphomas and leukemias. The expression pattern of CD20 (mature B-cells, but not 
on stem cells, pro-B-cells or plasma cells) means that after treatment, the B-cells can recover 
and immunoglobulins continue to be produced by plasma cells. 
Many of the antigens aberrantly expressed on B-cell CLL cells appear to be localized or 
translocated to LRs, where they may carry out abnormal functions. LRs are also an important 
binding site for therapeutic antibodies (e.g anti-CD20 rituximab) used to treat CLL patients 
[69]. The anti-CD20 monoclonal antibody rituximab, binds CD20 through the alanine-N-
proline (ANP) motif at residues 170-172 in the large extracellular loop of CD20 (Figure 1.4) 
resulting in translocation of the CD20-rituximab complex into LRs [70]. This movement 
increases intracellular Ca2+ levels and downstream apoptotic signalling [69]. In addition, 
several anti-cancer drugs have been shown to suppress growth and induce apoptosis of 
tumour cells through alteration of LRs such as, edelfosine [71], avicin D [72], resveratrol [73] 
and liver X receptors [74].  
Treatment with rituximab alone does not give high response rate in CLL patients [25], in a 
phase II clinical trial, patients who received rituximab plus fludarabine had much better 
outcomes than patients who received rituximab or fludarabine alone [26-28]. Furthermore, 
compared with chemotherapy, treatment with rituximab is associated with markedly reduced 
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hematological toxicity such as severe neutropenia, as well as associated infections [29]. Yet 
the mechanism of action underlying this therapy is still unclear.  
 
Figure 1.3: The cell surface expression of CD20 during stages of B-cell ontogeny. CD20 is expressed during 
the mid stages of ontogeny and virtually disappears at the plasma cell stage. 
 
Figure 1.4: CD20 protein expressed on B-cells. CD20 is an integral membrane tetraspanin that crosses the cell 
membrane 4 times. CD20 contains small and large external loops and internal N and C termini. Rituximab binds 
at residues 170-172 in the large extracellular loop of CD20 resulting in translocation of CD20 to lipid rafts 
(yellow colored membrane). The green, purple and blue blobs are examples of integral membrane proteins. 
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1.7 Lipid rafts 
Lipid rafts (LRs) were conceived as functional membrane micro-domains around two decades 
ago [75]. Although their existence was controversial for many years, investigations of the 
structure and function of LRs now appear at the forefront of cell biology and bio-membrane 
research [76, 77]. LRs are defined as small (10–200 nm), highly heterogeneous sterol, 
sphingolipid (sphingomyelin), cholesterol and protein-enriched membrane micro-domains 
[78-82]. Cholesterol interacts preferentially with sphingolipids due to their structure with 
saturated hydrocarbon chains. Although not all of the phospholipids within the raft are fully 
saturated, enrichment of phospholipids with saturated fatty acids enables the close packing of 
lipids within rafts because 1) sphingolipids also contain saturated fatty acid side chains, and 
2) cholesterol and saturated fatty acids are able to pack closely, and consequently, are more 
rigid than the plasma membrane [83, 84]. Some types of proteins were found associated with 
the LRs, proteins with GPI anchors and src family kinases, that are modified by addition of 
fatty acids that allow them to bind the plasma membrane [85, 86]. LRs are dynamic structures 
and can move in the plasma membrane, joining to form a large raft or breaking down into 
smaller ones. LRs are located in the plasma membrane [77] and play important roles in 
various cellular functions, mediating cell signaling in both T-cells [87-89] and B-cells [90, 
91] and function in secretory and endocytic pathways [92]. Many of the antigens aberrantly 
expressed on CLL cells appear to be localized or translocated to LRs to carry out their 
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abnormal functions. Renaudineau and colleagues established that CD5 and the B-cell receptor 
co-localize in LRs for the early signaling events leading to apoptosis, and described several 
mechanisms that could underlie defective signaling from CD5 in CLL cells [93]. Proteins are 
recruited to LRs in response to various stimuli, e.g., radiation [94], hormones [95] and 
therapeutic antibodies [70]. This recruitment is primarily mediated by a GPI 
(glycosylphosphatidylinositol) anchor and acylation of certain trans-membrane domains [96]. 
LRs can act as a cellular portals, linking endocytic pathways to the exogenous environment 
and allowing the internalisation of viral particles [97] and toxins [98]. The distribution of LRs 
or sphingolipid-based micro-domains over the cell surface depends on the cell type. In B-
lymphocytes, LRs appear to be concentrated in microvillus-rich regions [99].  
LRs have been implicated in a variety of diseases, including Alzheimer’s, prion diseases and 
cancer [100]. Raft micro-domains provide a signalling pathway platform capable of various 
cellular pro- and anti-apoptotic pathways, that may be initiated upon LRs distribution [101, 
102]. Indeed many receptor tyrosine kinases are localised in LRs [88, 103-106] highlighting 
the importance of this membrane micro-domain in cancer signalling. Many of the antigens 
aberrantly expressed on CLL cells appear to be localized or translocated to LRs, where they 
may carry out abnormal functions [107]. This membrane domain also is an important binding 
site for therapeutic antibodies (e.g., anti-CD20 Rituximab) used to treat CLL patients [69]. 
Rituximab binds to CD20 on CLL cells resulting in translocation of the CD20-rituximab 
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complex into LRs [70]. As this movement increases intracellular Ca2+ levels, it triggers 
downstream apoptotic signalling [69]. In addition several anti-cancer drugs have been shown 
to suppress growth and induce apoptosis of tumour cells through LRs remodelling, such as 
edelfosine [71], avicin D [72], resveratrol [73] and liver X receptors [74]. Due to their 
functional importance and the potential for isolating new drug targets, proteomic analyses on 
this membrane domain is important. However, as these structures are cholesterol-rich, 
proteomic analysis have been challenging to date [108].  
The protein composition of LRs remains contentious with high levels of contaminating 
proteins often co-purified with LRs proteins. Differentiating between LRs proteins and 
contaminants was approached by quantifying LRs proteins using stable isotope labelling by 
amino acids in cell culture (SILAC) [109] before and after treatment with methyl beta 
cyclodextrin (MβCD). This approach led to the identification of 165 proteins for HeLa, 196 
for 3T3, and 294 for Jurkat cells by triple label SILAC analysis [110]. 
1.8 Proteomic techniques to study cellular responses to rituximab  
Proteomics is the study of proteins and their interactions in a cell, fluid or tissue using 
techniques such as two dimensional (2D) gel electrophoresis and liquid chromatography 
coupled with tandem mass spectrometry (LC-MS/MS). Profiling cell surface proteomes of 
cancer cells, including the LRs, has attracted significant interest due to the potential of 
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identifying novel targets for diagnostics and therapeutics. Exploring the composition and 
dynamic nature of this membranous structure in CLL cells under different drug treatment 
conditions will enable elucidation of the mechanisms by which rituximab functions, enabling 
better customization of CLL treatment and identification of patients most likely benefit from 
treatment with rituximab. 
1.8.1 Liquid chromatography  
LC is used to separate peptides in a mixture based on their interactions with stationary and 
mobile phases [111]. In normal phase chromatography, the stationary phase is polar, and 
polar solutes will adhere more to the stationary phase. When the solvent or gradient of 
solvents passes through the column, less polar components will be eluted faster than the more 
polar ones.  The components can then be collected separately, in order of increasing polarity. 
Coupling multiple High Performance Liquid Chromatography (HPLC) based phases in 
capillary or nanoflow scale allows high-speed, high-resolution and high-sensitivity separation 
of macromolecules and enables separation and of low-abundance species and post-
translationally modified proteins [112]. The two types of LC used in this thesis are reversed 
phase (RP-LC) and two-dimensional (2D-LC). 
RP-LC is performed using HPLC with molecules separated on the basis of hydrophobicity. 
The separation mechanism in reversed phase chromatography depends on the hydrophobic 
  19 
binding interaction between the solute molecule in the mobile phase and the hydrophobic 
stationary phase. A gradient of increasing organic solvent (e.g. acetonitrile) decreases the 
polarity of mobile phase and reduces the hydrophobic interaction of the solute with the 
stationary phase. Peptides and proteins with less hydrophobicity are eluted first followed by 
more hydrophobic peptides [113].  
2D-LC is used to analyse complex samples, most commonly strong cation exchange (SCX) 
chromatography for the first dimension and reversed phase for the second dimension. The 
SCX stationary phase usually contains aliphatic sulfonic acid groups that are negatively 
charged in aqueous solution. All the peptides are positively charged by adjusting the pH to be 
lower than most peptide isoelectric points (pH 2-4). Peptides are eluted from SCX with a salt 
gradient, increasing salt (ammonium acetate or ammonium formate) concentration decreases 
the strength of ionic interactions between peptides and the SCX stationary phase [114].  
Two types of 2D-LC were used in this project, online and offline. In offline, the fractionation 
from the SCX column can be triggered on a time basis or by peak parameters and the 
fractions are collected into a 96 well plate before later reinjection and analysis by reverse 
phase. In online, 2D-LC is performed using a SCX column in series with a RP column, the 
sample is loaded onto the SCX column, peptides are eluted stepwise by injecting salt of 
increasing ionic strength from the SCX column in the first dimension onto a trap column. The 
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trap column enriches the peptides and removes salt. An analytical RP gradient is flushed 
through the trap column to the reverse phase column and the peptides are eluted into the ESI 
mass spectrometer [115, 116]. The offline method has several advantages over the online 
method, more peptide fractions and greater quantity can be collected, fractions can be 
reanalyzed and fraction collection can be more interactively optimized. 
1.8.2 Mass spectrometry  
MS is an analytical technique that provides identification and quantitation of proteins in large 
scale proteomics projects with high sensitivity and accuracy [117]. MS separates peptide ions 
according to their mass to charge ratio (m/z). It can also characterise post-translational 
modifications of peptides and abundance. The identification of a peptide by MS requires it’s 
mass, ion intensity above threshold and a list of fragment masses [118]. The measurement of 
fragment ions occurs in tandem MS or MS/MS, where the peptide is broken into fragments by 
collision-induced dissociation, and each peptide fragment m/z is measured. Mass 
spectrometers consist of an ion source, a mass analyser, and a detector. 
1.8.2.1 Ionization 
MS identifies the peptides according to their mass- to-charge ratio (m/z). Therefore, peptides 
must be ionized first. The two main methods for peptide ionization are Electrospray 
Ionisation (ESI) and Matrix- Assisted Laser Desorption Ionisation (MALDI).  
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In ESI, The mixture of peptides is pumped at low flow rates through a hypodermic needle at 
high voltage to form an aerosol composed of small charged drops. Ions can be generated from 
charged liquid droplets through two proposed models, the drop evaporates in the interphase 
with the mass spectrometer, passing through a heated capillary or with warm nitrogen counter 
current [119, 120] and then droplets turn into completely desolvated ions [121]. ESI is often 
combined with ion traps and triple quadrupole mass analysers [117]. MALDI is a laser-based 
soft ionization method. The sample is embedded in a chemical matrix, usually α-cyano-4-
hydroxycinnamic acid or dihydrobenzoic acid. And then hit by a pulsed UV laser beam, the 
energy is absorbed by the matrix, which is partially vaporised and carries intact analyte molecules 
into the gas phase where proton exchange occurs from the analyte to the matrix, resulting in 
singly charged ions [119].  
1.8.2.2 Tandem Mass Spectrometry (MS/MS) 
The initial MS spectrum determines the molecular masses of the peptides in a mixture. But 
the data would not be accurate or comprehensive enough to distinguish between several 
entries in the database. Therefore, the peptides are fragmented and sequenced. MS/MS uses 
two mass spectrometers in tandem. Peptides are individually selected from the mixture in the 
first mass analyzer (MS1) and dissociated by collision with an inert gas, such as argon or 
nitrogen. After which the m/z ratios of the fragments are measured by the second mass spectrometer 
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[122]. During peptide fragmentation, bond cleavage occurs through the lowest energy 
pathway, at the amide bond [123]. This results in b- or y-ions where the N and C terminal 
retain the charge respectively [124]. Peptide fragment ions are indicated by a, b, or c if the 
charge is retained on the N terminal and by x, y or z if the charge is maintained on the C 
terminal [123] (Figure 1.5). Peptide sequences can be obtained by manual annotation of the 
MS/MS spectra and the parent protein identified by database searching [125]. 
 
 
Figure 1.5: Peptide sequencing by fragmentation. If the broken bond is between the CO group of one amino 
acid and the NH group of another, the N- terminal part is called a fragment of type b, or simply b-ion, and the C-
terminal part is called a y-ion. If the broken bond is between the α C of one amino acid and the CO group of the 
same amino acid, the N-terminal part is called an a-ion, and the C-terminal part is called an x-ion. If the broken 
bond is between the NH group of one amino acid and the α C of the same amino acid, the N-terminal part is 
called c-ion, and the C-terminal part is called the z-ion. 
  23 
1.8.3 Flow cytometery 
Flow cytometery is used to analyse multiple parameters in single cells, with applications such 
as, immunephenotyping, cell counting and sorting, and biomarkers detection, flow cytometry 
performs the analysis by passing thousands of cells per second into a laser beam and the light 
that is emitted from each cell is measured. A number of detectors are aimed at the point where 
the cell stream passes through: one in line with the light beam (Forward Scatter or FSC) and 
several perpendicular to it (Side Scatter (SSC) and one or more fluorescent detectors), the 
data gathered can be analysed statistically by software to define cellular characteristics such 
as size, complexity and phenotype. FSC correlates with the cell size and SSC depends on the 
granularity or internal complexity of the cell (e.g., the shape of the nucleus, amount and type 
of cytoplasmic granules, or membrane roughness). Each cell passing through the beam 
scatters the light, and fluorescent antibodies attached to the cells may be excited to emit light 
at a longer wavelength than the light source. Fluorescent dyes conjugated to monoclonal 
antibodies, are used to determine levels of surface CD antigens on each cell. 
1.8.4 Immunofluorescence  
Immunofluorescence (IF) is the technique used to detect a specific cell component by 
interaction of target antigens with specific antibodies that are chemically conjugated to 
fluorescent dyes such as fluorescein isothiocyanate (FITC) or tetramethyl rhodamine 
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isothiocyanate (TRITC). IF makes it possible to visualize the distribution and localization of 
proteins, glycans and small biological and non-biological molecules within cells and in tissue. 
IF can also be used in combination with other, non-antibody methods of fluorescent staining, 
for example, use of DAPI to label DNA. IF is used for disease diagnosis, drug development 
and biological research. Immunofluorescence can be used on tissue sections, cultured cell 
lines, or individual cells. Several types of microscope can be used for analysis of 
immunofluorescence samples such as, epifluorescence microscopy and confocal microscopy. 
The two main methods for immunofluorescence labeling are called direct and indirect. In the 
direct method, the primary antibody against protein of interest is conjugated to a fluorophore. 
In the indirect method, the monoclonal antibody is unlabeled and a secondary antibody 
against the monoclonal antibody is conjugated to the fluorophore. 
1.8.5 Protein knock-down 
Stealth RNAi™ siRNA is the new-generation RNAi chemistry that provides higher 
specificity and increased stability in serum and cell culture than standard small interfering 
RNA (siRNA). siRNA is a class of double stranded RNA, 20-25 base pairs in length. RNAi 
may serve as an antiviral defense mechanism, and also plays a role in the formation and 
maintenance of heterochromatin during mitosis and meiosis, and regulates endogenous gene 
expression [126, 127]. The Dicer enzyme catalyzes production of siRNAs from long dsRNAs 
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[128]. In an ATP-dependent step, the siRNAs become integrated into a multi-subunit protein 
complex, known as the RNAi induced silencing complex (RISC), which guides the siRNAs to 
the target RNA sequence [129, 130]. In RNAi knock-down, the double stranded siRNA is 
complementary to the target mRNA, the siRNA is transfected into the cells by lipid based 
(lipofectamine) fusion with the cell membrane, or by electroporation, forming pores in the 
cell membrane. Once the siRNA inside the cell, it forms the RISC complex, which unwinds 
the siRNA duplex, then single stranded siRNA coupled RISC binds to mRNA in a sequence 
specific manner, resulting in mRNA cleavage by a RISC element called a slicer. The cleaved 
mRNA can be detected by the cell as being aberrant and is destroyed thus silencing the 
expression of the gene from which the RNA was transcribed [129]. 
1.8.6 DotScan™ CD antibody microarrays 
A microarray of CD antibodies (DotScan) captures live cells enabling simultaneous screening 
of a large panel (~140) of CD antigens with high sensitivity and throughput [131]. Two 
identical arrays of antibodies are blotted onto a film of nitrocellulose on a glass microscope 
slide. Cells that have a CD antigen corresponding to its antibody are captured. Microarrays 
are scanned and the dot patterns of captured cells are visualized using the Medsaic 
DotReader, the intensity of cell binding is quantified using Medsaic software. The DotScan 
microarray enables rapid and extensive immunophenotyping and classification of leukemias 
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and lymphomas [132, 133].  
1.9 Cell lines 
1.9.1 MEC1 (chronic lymphocytic leukemia) 
The human MEC1 cell line, despite negative CD5 expression, is a good model for B-CLL 
[134]. MEC1 cells express the same light (κ) and heavy chains (µ, δ) as the parent B-CLL 
cells. The pattern of Bcl-2 family gene expression in MEC1 cells is shifted toward inhibition 
of apoptosis, as reported for clinical leukemic B-cells [135]. MEC1 cells have a deletion in 
chromosome 17p11, the locus for p53, one of the most frequent chromosomal aberrations in 
B-CLL [136]. Several functional abnormalities of B-CLL may be explained by abnormalities 
of the B-cell receptor (BCR). MEC1 cells and 75% of CLL clinical cases do not express the 
extracellular Ig-like domain of CD79b, part of the BCR [137]. Although immortalized cell 
lines are fundamentally different to primary leukemia cells, they have similar features of 
morphology, immuno-phenotype, karyotype, cytogenetics and molecular characteristics and 
are therefore suitable in vitro models for studying cellular and molecular events in leukemia. 
1.9.2 Raji cell line (Burkitt's lymphoma) 
The cell line Raji was derived from lymphoblasts from a typical Burkitt’s lymphoma of the 
left maxilla of a 12-year-old African boy in 1963 as the first continuous human hematopoietic 
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cell line [138]. The cells were undifferentiated lymphoblasts similar to those of other cultured 
cell lines from Burkitt tumors [139]. Raji cells express immunoglobulin M (IgM), CD10, 
CD19, CD20, and Bcl-6, and typically negative for CD5, CD23, TdT, and Bcl-2. Raji also has 
the t(8;14) translocation of the c-myc gene commonly found in patients with Burkitt’s 
lymphoma [140, 141]. 
1.9.3 IM9 cell line (EBV-transformed B-lymphoblastoid) 
IM9 was derived from bone marrow removed from a female patient with multiple myeloma in 
1967. The cell line is positive for CD19, CD20, surface Ig, CD lla and CD49e, but negative 
for CD38 and CD28. The cells synthesize IgG and have receptors for insulin, calcitonin and 
human growth hormone. They also express surface markers and receptors characteristic of B-
lymphocytes. IM9 are Epstein-Barr Virus positive and express Bcl-2 mRNA [142]. 
1.10 Aims 
Rituximab binds to CD20 on B-CLL cells resulting in translocation of the CD20-rituximab 
complex into lipid rafts [70]. This movement increases intracellular Ca+2 levels and 
downstream apoptotic signalling [69] through activation of complement-dependent 
cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), activation of Src 
family tyrosine kinases [44, 45] and activation of the Fas apoptotic pathway [46]. Despite the 
undeniable value of rituximab for therapy of B-cell malignancies, it is not effective for all 
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patients, but may make the B-CLL cells in resistant patients sensitive to chemotherapy [50]. 
The mechanisms of rituximab action remain unclear. However, research into the mechanisms 
would improve the efficacy of rituximab therapy in B-CLL, and may lead to optimization of 
monoclonal antibody therapy for other diseases.  
One aim of this thesis was to gain further understanding of the mechanisms of rituximab in 
CLL by  
1) Identifying the LRs protein profile of CLL cells. 
2) Investigating CD20 translocation to LRs after rituximab treatment. 
3) Identifying the differentially abundant proteins after rituximab treatment in LRs, whole cell 
lysates and cell surface CD antigens.  
4) Analysing the effect of the differentially abundant proteins on the cell proliferation and 
apoptosis.  
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2 Materials and Methods 
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2.1 Materials 
2-mercaptoethanol  Sigma-Aldrich (St. Louis, MO, USA) 
96-well polypropylene V-well plate Greiner (Frickenhausen, Germany) 
Acetonitrile  Sigma-Aldrich (St. Louis, MO, USA) 
Ammonium persulfate  Sigma-Aldrich (St. Louis, MO, USA) 
Benzonase (ultra-pure) Sigma-Aldrich (St. Louis, MO, USA) 
Bovine serum albumin  Sigma-Aldrich (St. Louis, MO, USA) 
Cellstar® 15 and 50 mL tubes Greiner (Frickenhausen, Germany) 
Di-sodium hydrogen orthophosphate Ajax Chemicals (Auburn, NSW, Australia) 
Disuccinimidyl tartrate  Thermo Fisher Scientific (Rockford, IL, USA) 
DNAse, RNAse free cell culture flasks (25 cm2, 
75 cm2 and 175 cm2), 
Greiner (Frickenhausen, Germany) 
DotScanTM Microarray Medsaic (Eveleigh, NSW, Australia) 
Dounce homogeniser (15 mL) Kimble Glass Inc. and Kontes Glass Co. 
(Vineland, NJ, USA) 
Ethanol, absolute Sigma-Aldrich (St. Louis, MO, USA) 
Ethylenediaminetetraacetic acid  Ajax Chemicals (Auburn, NSW, Australia) 
Foetal calf serum Invitrogen Life Technologies (Mulgrave, NSW, 
Australia) and JRH Biosciences inc. (Lenexa, 
USA) 
Formaldehyde Sigma-Aldrich (St. Louis, MO, USA) 
Formic acid Sigma-Aldrich (St. Louis, MO, USA) 
Gentamycin (50 mg/mL) Invitrogen Life Technologies (Mulgrave, NSW, 
Australia) 
Glycerol Sigma-Aldrich (St. Louis, MO, USA) 
Hydrochloric acid 32%  Sigma-Aldrich (St. Louis, MO, USA) 
Hydrophilic-lipophilic-balanced (HLB) cartridges Oasis (Milford, MA) 
ICAT Accessories – Column Hardware AB Applied Biosystems (Mulgrave, VIC, 
Australia) 
Immun-Blot TM PVDF Membrane Bio-Rad (Hercules, CA, USA) 
iTRAQ labels, 4plex and 8plex Applied Biosystems, Foster City, CA, USA 
iTRAQ reagent kit AB Sciex (Foster City, CA, USA) 
L-Glutamine Invitrogen Life Technologies (Mulgrave, NSW, 
Australia) 
Lipid raft labelling kit Invitrogen Life Technologies (Mulgrave, NSW, 
Australia) 
Lipofectamine RNAiMAX Invitrogen, Paisley, UK 
Magnesium dichloride Sigma-Aldrich (St. Louis, MO, USA) 
Methanol, absolute Sigma-Aldrich (St. Louis, MO, USA) 
Methyl beta cyclodextrin  Sigma-Aldrich (St. Louis, MO, USA) 
Microcentrifuge tubes (0.5 and 1.5 mL) Greiner (Frickenhausen, Germany) 
Morpholinoethane sulfonic acid  ICN biomedicals Inc (Ohio, USA) 
MultiCelTM trypan blue (0.5%) exclusion dye Trace Biosciences (Castle Hill, NSW, Australia) 
N,N,N’,N’-tetramethylethyl-ethylenediamine  Sigma-Aldrich (St. Louis, MO, USA) 
Non-sterile 5 mL polystyrene round- bottom tubes 
(FACS tubes) 
Becton Dickinson (Franklin Lakes, New Jersey, 
USA) 
Oasis HLB SPE column 3 cc and 1 cc Waters Corp, (Milford, MO, USA) 
Potassium chloride  Ajax Chemicals (Auburn, NSW, Australia) 
Potassium dihydrogen orthophosphate  Ajax Chemicals (Auburn, NSW, Australia) 
Potassium hydrogen carbonate Ajax Chemicals (Auburn, NSW, Australia) 
Precision Plus ProteinTM All Blue molecular 
weight standards 
Bio-Rad (Hercules, CA, USA) 
Protease inhibitor cocktail Sigma-Aldrich (St. Louis, MO, USA) 
Proxeon C18-tip Thermo Fisher Scientific (Rockford, IL, USA) 
Rituximab Roche, Basel, Switzerland 
  31 
RP Analytical column (ZORBAX 300SB-C18 
column - 0.1 x 150 mm, 3.5 µm particle size, 300 
Å pore size) 
Agilent Technologies, Palo Alto, CA, USA 
RPMI-1640 medium HEPES modification Sigma-Aldrich (St. Louis, MO, USA) 
SCX Column: BioSCX Series II, 0.8 x 50 mm, 3.5 
µm particle size, 300 Å pore size 
Agilent Technologies (Palo Alto, CA, USA) 
SiRNA TRIM21 Invitrogen Life Technologies (Mulgrave, NSW, 
Australia) 
Slides Livingstone international (Rosebery, NSW, 
Australia) 
Sodium azide BDH Chemicals Ltd. (Poole, UK) 
Sodium chloride Ajax Chemicals (Auburn, NSW, Australia) 
Sodium dodecyl sulfate  Sigma-Aldrich (St. Louis, MO, USA) 
Sodium fluoride  Sigma-Aldrich (St. Louis, MO, USA) 
Sodium hydroxide  Ajax Chemicals (Auburn,NSW, Australia) 
Sodium orthovanadate  Sigma-Aldrich (St. Louis, MO, USA) 
Sucrose Ajax Chemicals (Auburn, NSW, Australia) 
Trap Columns: (ZORBAX 300SB- C18 column - 
0.3 x 5 mm, 5 µm particle size, 300 Å pore size).  
Agilent Technologies, Palo Alto, CA, USA 
 
Triethylammonium bicarbonate  Sigma-Aldrich (St. Louis, MO, USA) 
Trifluoroacetic acid Sigma-Aldrich (St. Louis, MO, USA) 
Triton X-100 Sigma-Aldrich (St. Louis, MO, USA) 
Trypsin, seq. grade modified, porcine Promega (Sydney, NSW, Australia) 
Tween-20 Promega (Madison, WI, USA) 
2.2 Solutions 
Tris-buffered saline with Tween 20 (TBST) 
(Tris/HCl 25 mM, NaCl 137 mM, KCl 2.7 mM and 0.1% (v/v) Tween-20,  pH 7.6) 
4X Laemmli buffer  
(218 mM Tris-HCl, pH 8, 36% (v/v) glycerol, 8% (v/v) SDS, 0.01% (w/v) Bromophenol Blue 
and 10% (v/v) 2-mercaptoethanol) 
DST (disuccinimidyl tartrate) reaction buffer  
(20 mM sodium phosphate, 0.15 M sodium chloride, pH 8.0). 
Immuno-precipitation cell lysis buffer  
(10 mM sodium phosphate, 0.15 M sodium chloride, 2 mM EDTA, 50 mM NaF, 1% (v/v) 
sodium orthovanadate (Na3VO4), 1% (v/v) protease inhibitor cocktail and 1% (v/v) Triton X-
100). 
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Lysis buffer  
(Containing 25 mM morpholinoethane sulfonic acid pH 6.5, 150 mM NaCl, 1% (v/v) Na3VO-
4, 1% (v/v) protease inhibitor cocktail and 1% (v/v) Triton X-100) 
FACS buffer   
(PBS, pH 7.3, 0.1% (w/v) bovine serum albumin, 0.05% (w/v) sodium azide) 
Phosphate buffered saline (PBS, pH 7.3) 
(Sodium chloride 150 mM, potassium chloride 2.7 mM, potassium di-hydrogen 
orthophosphate 1.4 mM, di-sodium hydrogen orthophosphate 4.3 mM) 
RPMI 1640 cell growth medium, pH 7.3 
(RPMI 1640 medium 16.1g/L, gentamicin 0.005% (w/v), foetal calf serum (FCS) 10% (v/v), 
L-glutamine was added to a final concentration of 2 mM every two weeks) 
Gel composition 
(Tris-HCl 375 mM, acrylamide/bis 8-12% (w/v), ammonium persulfate 0.008% (w/v), 
TEMED 0.008% (w/v)) 
2.3 Methods 
2.3.1 Cell lines  
The following three human cell lines were available at the Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, Germany, and the 
American Type Culture Collection (ATCC), Manassas, VA, USA. 
• MEC1 (B-cell chronic lymphocytic leukaemia) 
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• IM9 (EBV-transformed B-lymphoblastoid) 
• Raji (B-cell Burkitt’s lymphoma) 
2.3.2 Growth of MEC1 cells 
Human MEC1 B-CLL cells (American Type Culture Collection 204508/S288c, Manassas, 
VA, USA) were grown using 25 cm2, 75 cm2 or 175 cm2 culture flasks with RPMI 1640 
medium (Hepes modification; Sigma Aldrich, St. Louis, MO, USA) supplemented with 
10% (v/v) fetal calf serum and 50 µg/mL gentamicin at 37oC in a non-humidified incubator 
(Heraeus, Hanau, Germany). The cells were harvested by centrifugation (300 xg, 5 min, room 
temperature, Eppendorf 5810R) every 2-3 days and the resulting cell pellet was resuspended 
with RPMI medium to density of (4-5 x 10
5 
cells/mL). Fresh cells were brought up from 
storage in liquid nitrogen at regular intervals (every 2-3 months) to replace older cultures. 
2.3.3 Cell counting 
Following resuspension of the pellet in 5 mL of RPMI medium, a 50 µL aliquot of cells was 
mixed with 50 µL of 0.4% (w/v) Trypan blue to visualize the dead cells, 10 µL of the mixture 
was piptted onto a Neubauer hemocytometer. Cells in the area bounded by triple lines were 
counted under the microscope and multiplied by the dilution factor, total volume and 10
4 
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(count x dilution facror x total volume x 10
4
= cell number). Cells that had taken up Trypan 
blue were excluded from the count as they were dead. 
2.3.4 Protein quantification 
The bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA) was used to 
quantitate total protein in cell lysates and sucrose density gradient fractions. Known 
concentrations of bovine serum albumin (BSA) were set up with protein samples of unknown 
concentration. The assay was carried out according to manufacturer’s instructions. Briefly, 
after addition of the sample to the required reagents (sample to working reagents ratio = 
1:20), the reaction mixture was incubated at 37oC for 30 min. The samples were then cooled 
to RT before the intensity of the color was measured with a micro plate reader (Multiskan EX, 
Thermo Fisher Scientific, Rockford, IL, USA) at a 560 nm. The data were then entered in 
Microsoft Excel to calculate the protein levels in the sample.  
2.3.5 Drug treatment 
2.3.5.1 Methyl-beta-cyclodextrin 
For MβCD treatment, MEC1 cells (3 x 105 cells/ml, 3 biological replicates) were washed 
thoroughly with PBS and re-suspended at a density of 4 × 105 cells/ml in serum-free RPMI. 
After 1 h, cells were washed and incubated with serum-free RPMI for 1 h at 37°C in the 
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absence (control cells) or presence (treated cells) of 1 mM MβCD (Sigma Aldrich, St. 
Louis, MO, USA).  
2.3.5.2 Rituximab  
For rituximab treatment, MEC1 cells were grown in triplicate cultures and treated with 
rituximab at (1, 10 and 100 µg/ml for 24 h at 37oC; Roche, Basel, Switzerland). Control 
cultures were untreated. Following treatment with MβCD or rituximab, cells were harvested 
by centrifugation for apoptosis assays and LRs isolation.  
2.3.6 Apoptosis detection  
Externalization of phosphatidylserine (PS) during apoptosis was quantified by Annexin V-PE 
binding, while the loss of cell membrane integrity was measured by binding of 7-amino-
actinomycin D (7-AAD) to DNA (Annexin V-PE apoptosis detection kit 1, BD Biosciences, 
San Diego, USA). Briefly, cells were washed twice with PBS and re-suspended at a density of 
106 cells/mL in a binding buffer (10 mM K.Hepes pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). 
Cells (5 x 104) were incubated with 2.5 µL of Annexin V-PE and 2.5 µL of 7-AAD for 15 
mins at room temperature. Cells were re-suspended in 450 µL of binding buffer and analysed 
with a FACScan flow cytometer (Becton Dickinson, San Jose, USA) and CellQuestTM  Pro 
software, Version 5.2 (BD Biosciences, San Diego, CA, USA). 
  36 
2.3.7 Isolation of lipid rafts 
LRs were enriched based on their insolubility in Triton-X-100 at 4°C and separated by 
sucrose density gradient ultracentrifugation. Cells were lysed in a cold lysis buffer (containing 
25 mM morpholinoethane sulfonic acid pH 6.5, 150 mM NaCl, 1% (v/v) Na2VO4, 1% (v/v) 
protease inhibitor cocktail and 1% (v/v) Triton X-100) and incubated on ice for 30 min. The 
lysate was then homogenised by 10 strokes of a Dounce homogeniser and mixed with 80% 
(w/v) sucrose solution to produce a 45% (w/v) sucrose-cell lysate mixture as the base of a 
sucrose gradient. This mixture was then layered with 35% (w/v) sucrose and finally 5% (w/v) 
sucrose, before ultracentrifugation at (186,000 xg, 21 h, 4°C). Nine 1 ml fractions were 
collected from the top of gradient tube and purified and concentrated using 3 kDa cut-off 
Amicon ultra-0.5 centrifugal filter device (Millipore, Kilsyth, VIC, Australia). A sample (500 
µL) of the fraction was added to the filtration device, placed into a 2 mL microcentrifuge 
tube. The device was centrifuged  (13,000 xg, 30 min, 4°C) and the flow-through buffer was 
discarded. Another 500 µL of 0.5 M triethylammonium bicarbonate (TEAB) pH 8.5, 0.1% 
SDS (w/v) was added twice to the filter device and centrifuged again to remove the sucrose 
and Triton X-100. The proteins were retained by inverting the filtration device in new tube 
and centrifuged (1000 xg, 2 min, 4°C).  Protein concentrations were determined using the 
BCA Protein Assay Kit (Pierce, Rockford, IL, USA) following the manufacturer’s 
instructions. 
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2.3.8 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western blotting of proteins 
Protein samples to be analyzed were mixed with Laemmli sample buffer (LB) (sample to LB 
ratio 1:4). Then heated at 95-99°C for 5 min. After denaturation, protein samples were loaded 
on 10-12% SDS-PAGE. The charged proteins were separated according to their size at a 
constant 100 mA. For Western blotting, proteins were transferred from the gel to Immuno-
Blot™ PVDF Membrane (Bio-Rad Laboratories, Hercules, USA) at 350 mA for 90 min using 
a Criterion™ Blotter (BioRad). After blocking with 5% (w/v) skim milk in TBST, 
membranes were incubated (4°C, 16 h) with primary antibodies diluted in TBST. After 
washing with TBST buffer (3 × 5 min), the membrane was incubated for 2 h at room 
temperature with a horse radish peroxidase (HRP)-conjugated secondary antibody: goat-anti-
mouse-HRP (Santa Cruz Biotechnology Inc, Santa Cruz, USA) or donkey anti-rabbit-HRP 
(Abcam, Cambridge, USA). The membrane was washed 3 times with 1X TBST (10 
min/wash).  Finally, proteins were visualized using a Rapid Step ECL Reagent (Merck, 
Whitehouse Station, NJ, USA) and ECL chemiluminescence film (GE Healthcare, 
Piscataway, NJ, USA). 
2.3.9 Removal of bound antibodies from PVDF membranes  
Membrane stripping is a method used for removing primary and secondary antibodies from a 
  38 
membrane. This allows the protein sample on the membrane to be re-probed with other 
antibodies to detect additional proteins of interest. The membrane was washed twice with 
milliQ water; each wash for 7 min on a platform rocker. The membrane was then incubated 
with 10 mL of 1% (v/v) HCl for 15 min at RT, followed by the wash procedure as above. The 
membrane was then blocked and re-probed with a different antibody. 
2.3.10 Total MEC1 cell lysate proteins collection and digestion  
Cells were lysed in cold MN buffer (25 mM morpho-lino ethane sulfonic acid (MES) pH 6.5, 
150 mM NaCl, 1% (v/v) Na2VO4 and 1% (v/v) protease inhibitor cocktail (Sigma-Aldrich, 
Castle Hill, Australia) supplemented with 1% (v/v) Triton X-100 (Sigma-Aldrich). After 30 
min on ice, the lysate was homogenised for 10 strokes and centrifuged (800 xg, 10 min, 4°C). 
The supernatant was transferred to a new tube and the protein (20 µg) digested and labelled 
with iTRAQ 4 plex as follows: un-treated sample 1, 114; treated with 1 µg rituximab sample 
2, 115; treated with 10 µg rituximab sample 3, 116; treated with 100 µg rituximab sample 4, 
117. After labelling, samples were combined and cleaned up using iCAT (AB SCIEX, Foster 
City, CA, USA) and HLB (Water, Rydalmere, Australia) following the manufacturer’s 
instructions. 
2.3.11 iTRAQ labeling 
The buffer used to prepare LRs extract was exchanged to 0.5 M triethylammonium 
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bicarbonate (TEAB) pH 8.5, 0.1% SDS (w/v) using 3 kDa cut-off filter. Proteins were then 
reduced with 10 mM tris-(2-carboxyethyl) phosphine (TCEP) for 60 min at 60°C, alkylated 
with 10 mM methyl methane thiosulfonate (MMTS) for 10 min at RT, before digestion with 
sequencing-grade trypsin  (1:25 trypsin to protein ratio; Promega, Madison, WI, USA) at 
37°C for 16 h. Digested peptides were dried in a Vacuum Centrifugal Concentrator 5301 
(Eppendorf, Hamburg, Germany), re-suspended in 5 µL 1 M TEAB, pH 8.5, and labelled with 
iTRAQ 4-plex reagents (AB SCIEX, Foster City, CA, USA) following the manufacturer’s 
protocol. iTRAQ reagents were dissolved in ethanol, 20 µL of this iTRAQ mix was added to 
each peptide sample to give a final ethanol concentration of 65% (v/v), then incubated at 
room temperature for 1 h. Labelled samples with a set of iTRAQ tags (114-117) were pooled 
as one sample. 
Labelled samples were combined and cleaned by strong cation exchange (SCX; ICAT 
cartridge; AB SCIEX, Foster City, CA, USA), all procedures were performed according to the 
manufacturer’s instructions. Briefly, the peptide sample (40 µg) was diluted to 1 mL in cation 
exchange buffer-load solution 1 (10 mM KH2PO4 in 25% (v/v) acetonitrile (ACN), pH 3.0), 
ensuring the sample was between pH 2.5-3.3. The cartridge was washed first with 1 mL of 
cation exchange buffer-load solution 2 (10 mM KH2PO4 in 25% (v/v) ACN/1 M KCl at pH 
3.0), and 2 mL cation exchange buffer-load solution 1 to remove TCEP, SDS and excess 
iTRAQ reagents. The peptides were eluted with 500 µL of cation exchange buffer-eluate (10 
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mM KH2PO4 in 25% (v/v) ACN/350 mM KCl, pH 3.0). Eluted peptides were desalted and 
concentrated by hydrophilic-lipophilic-balanced (HLB) (Waters, Milford, MA, USA) 
cartridges as per the instructions. Briefly, the cartridge was conditioned with 1 mL 100% 
(v/v) methanol, followed by 100% (v/v) ACN and then 5% (v/v) ACN with 0.1% (v/v) formic 
acid. The sample was diluted 5 times with 0.1% (v/v) formic acid in water, then loaded and 
washed twice with 2 mL 5% (v/v) ACN with 0.1% (v/v) formic acid. The sample was eluted 
with 0.5 mL 50% (v/v) ACN with 0.1% (v/v) formic acid, followed by 0.3 mL of 100% (v/v) 
ACN with 0.1% (v/v) formic acid. 
2.3.12 Offline peptide fractionation  
Prior to MS analysis, peptides were separated using a strong cation-exchange column 
(ZORBAX Bio-SCX series II, 3.5 mm, 50 x 0.8 mm, Agilent, Palo Alto, CA, USA) on an 
1100 HPLC system (Agilent, Palo Alto, CA, USA) in off-line mode. The peptides (40 µg) 
were loaded onto the column in SCX buffer A (25% (v/v) ACN, 0.05% (v/v) formic acid, pH 
2.5) and eluted with a gradient from 0-20% SCX buffer B (25% (v/v) ACN, 0.5 M 
ammonium formate, 2% (v/v) formic acid, pH 2.5) in 42 min (14 min, 20-100% B; 5 min, 
100% B). Thirty fractions were collected at 2-min intervals using a Probot micro-fraction 
collector (Dionex/LC Packings, Sunnyvale, CA, USA). The SCX fractions were analysed 
using an Agilent 1100 HPLC system interfaced with a QSTAR Elite mass spectrometer (AB 
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SCIEX, Foster City, CA, USA) as described earlier. 
2.3.13 Online peptide fractionation and mass spectrometry 
Labelled peptide mixtures were separated by SCX (ZORBAX Bio-SCX series II, 3.5 mm, 50 
x 0.8 mm, 300 Å pore size, Agilent, Palo Alto, CA, USA) on an Agilent 1100 HPLC system 
(Agilent, Palo Alto, CA, USA) interfaced with a QSTAR Elite mass spectrometer (AB 
SCIEX, Foster City, CA, USA) in on-line mode. Labelled peptides (20 µg) were loaded onto 
the column at 10 µL/min in SCX buffer A (5% (v/v) ACN, 0.05% (v/v) formic acid, pH 2.5) 
and eluted into 7 fractions with increasing salt gradients of 0%, 2.5%, 5%, 7.5%, 10%, 15%, 
20% and 100% SCX buffer B (5% (v/v) ACN, 0.5 M ammonium formate, 2% (v/v) formic 
acid, pH 2.5). Each fraction was loaded onto a C18 trap column (ZORBAX 300SB-C18, 300 
µm× 5 mm, 5 µm, Aligent) at 10 µL/min and washed for 7 min with SCX buffer A before 
switching the trap column in line with the C18 separation nano-column (ZORBAX 300SB 
C18, 3.5 µm, 150×0.1 mm, 300 Å pore size, Agilent). The peptides were eluted directly into 
the ionization source of the mass spectrometer at 0.6 µL/min with the following gradient: 0 
min, 5% RP solvent B (0.1% (v/v) formic acid in ACN); 8min, 5% B; 10 min, 15% B; 90 
min, 30% B; 105 min, 60% B; 115 min, 5% B; 120 min, 5% B; where RP solvent A was 0.1% 
(v/v) formic acid in dH2O. Data acquisition was performed in an information dependent 
acquisition mode (IDA) using Analyst QS 2.0 software (Applied Biosystems Inc., Foster City, 
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CA USA). In IDA mode, a TOF-MS survey scan was acquired (m/z 350-1750, 0.5 s), with the 
3 most abundant multiply charged ions (2+ to 4+, threshold counts >30) in the survey scan 
sequentially subjected to product ion analysis. Product ion spectra were accumulated for 2 s in 
the mass range m/z 100-1800 with a modified Enhance All mode Q2 transition setting 
favoring low mass ions so that the iTRAQ reporter ions (114-117) intensities were enhanced 
for quantification. Automatic collision energy and automatic MS/MS accumulation modes 
were used in the advanced IDA settings. Data acquisition was performed with an exclusion of 
30 s for previous target ions  (50 ppm mass tolerance).  
2.3.14 Data analysis  
iTRAQ MS/MS data were analysed using Protein Pilot 3.0 software (AB SCIEX), which uses 
the Paragon™ algorithm to perform protein identification. All MS/MS spectra were searched 
against a combined UniProtKB/Swiss-Prot database, version uni_-sprot_2009-11. Parameters 
set in ProteinPilot 3.0 included (i) sample type, iTRAQ 4-Plex, (ii) cysteine alkylation, 
MMTS, (iii) digestion, trypsin, allowing 2 missed cleavages, (iv) species, Homo sapiens, (v) 
instrument, QSTAR Elite. The following processing options were used: quantitative, bias 
correction, background correction, biological modifications and thorough identification 
search. A concatenated target-decoy database search strategy was also employed to estimate 
the rate of false positives. Only proteins identified with at least 95% confidence and an 
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unused Protein Score of >1.3 were reported. Relative peptide abundances were determined 
using the MS/MS scans of iTRAQ-labelled peptides, where the ratios of peak areas of the 
iTRAQ reporter ions reflect the relative abundances of the peptides and therefore, the proteins 
in the samples. 
The results obtained using the Protein Pilot 3.0 software were exported to Microsoft Excel for 
further analysis. A two-tailed student t-test was performed assuming equal variances between 
the control and MβCD-treated samples. The average ratios of control to MβCD samples were 
calculated and used to determine the identified protein levels following MβCD treatment. A 
decrease in protein level by a ratio of 0.75 or more with p<0.05 was considered significant 
(Table 3.3).  
2.3.15 Knock-down 
TRIM21, E3 ubiquitin ligase knock-down was necessary to assess TRIM21 function during 
rituximab treatment in MEC1, Raji and IM9 cells. Cells (2x105 /mL) were cultured in 6-well 
plates in RPMI medium without gentamicin the day prior to transfection. The transient siRNA 
knock-down was carried out on cells using 300-600 pmol of TRIM21 siRNA (3 mixed oligo) 
(Invitrogen, Paisley, UK). The siRNA and 2 µL of 1 mg/mL Lipofectamine RNAiMAX 
(Invitrogen, Paisley, UK) were separately diluted in 50 µL OPTI-MEM1 medium and 
incubated at RT for 5 min before they were mixed and re-incubated for 25 min at RT. The 
  44 
mixture containing siRNA/Lipofectamine complex was then added to the cells. Plates gently 
shaken for 1 min. Then cells were incubated for 24 h or 48 h at 37°C. A negative control was 
used following manufacturer’s instructions. MEC1 cells were collected and lysed for Western 
blotting. MEC1, IM9 and Raji cells were then treated with rituximab (10 µg, 24 h or 48 h). 
The target sequences for the human TRIM21 siRNA were 
GAAAGGAGUGAGUCCUGGAACCUGA, GACAAUUUGGUUGUGGAACAAACAA, 
CCACCUUCAGGUGCCUCCAUGCCAA 
2.3.16 Immunohistochemistry 
MEC1 cells were treated with rituximab (10 µg, 24 h) washed with 1X PBS and fixed with 
3.7% (w/v) paraformaldehyde (PFA) on a slide overnight. The cells re-fixed for 20 min and 
washed with H2O for 5 min at RT. Then the cells were washed twice with blocking buffer 
(1% (w/v) BSA, 2% (v/v) FBS in 10 mM MES buffer, 1.5 M NaCL, 50 mM EGTA, 50 mM 
MgCL2 and 50 mM glucose, PH 6.1). F actin was labeled with Alexa Fluor 594 Phalloidin for 
30 min in (0.2% (v/v) Triton X-100 and blocking buffer). Lipid rafts were labeled using 
Vybrant Alexa Fluor 488 Lipid Raft Labeling Kit (Invitrogen Life Technologies, Mulgrave, 
NSW, Australia) following the manufacturer’s instructions. Nuclei were labeled using DAPI 
in blocking buffer for 1 min at RT. Cells were washed 3X with PBS and then viewed using a 
Olympus BX51 fluorescence microscope. 
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2.3.17 DotScan™ CD antibody microarrays  
MEC1 cells were collected by centrifugation (400 xg, 5 min, RT), washed and resuspended at 
1x107 cells/ mL in PBS. A 300 µL sample of the suspension was incubated on the microarray 
(Medsaic Pty Ltd, Australia) for 40 min at 37°C. The unbound cells were washed off with 
fixative solution (4% (v/v) formaldehyde in PBS). The microarrays were then fixed for 20 
min in the fixative solution, washed again in PBS and scanned. Dot intensities of cells 
captured on antibody microarrays were quantified using a Medsaic Dot Reader TM and 
DotScan TM software (Medsaic Lty Ltd).  
2.3.18 Flow cytometery 
MEC1 cells (4x105) were treated with 10 µg of rituximab for 24 h at 37°C, then washed three 
times in PBS and centrifuged (350 xg, 3 min, RT). The MEC1 surface was blocked with 
FACS buffer (0.1% (w/v) BSA, 0.05% (w/v) NaN3 in PBS). The cells were then washed and 
aliquotted in 100 µL of FACS buffer. Cells (0.5 x 106, 100 µL) were incubated with 20 µL 
monoclonal antibodies conjugated to the fluorochrome phycoerythrin (PE) or fluorescein 
isothiocyanate (FITC) for 30 min at 4°C in the dark. Labelled cells were washed and 
resuspended in FACS buffer. Samples were analysed using a FACSCalibur flow cytometer 
(BD Biosciences, San Diego, CA, USA) with a 488-nm air-cooled argon-ion laser, running 
CellQuest™ Pro software, Version 5.2 (BD Biosciences, San Diego, CA, USA). 
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CHAPTER 3 
3 Profiling of the lipid raft proteome from human MEC1 chronic 
lymphocytic leukaemia cells 
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3.1 Introduction 
Lipid rafts are specialized micro-domains located in the outer plasma membrane of cells and 
play important roles in various cellular functions, including cell signalling, secretory and 
endocytic pathways. Cell surface profiling, in particular the lipid raft proteome, has attracted 
interest in oncology due to the potential use of raft proteins as novel targets for diagnostics 
and therapeutics. Three different methods have been used to identify the lipid raft proteome 
from the human chronic lymphocytic leukemia (CLL) cell line MEC1. Firstly, lipid raft 
proteins were enriched and identified using sucrose gradient ultracentrifugation and 2D liquid 
chromatography coupled to tandem mass spectrometry (LC-MS/MS). To confirm protein 
localization to the lipid raft, proteomes were compared before and after cholesterol depletion 
by methyl-β-cyclodextrin (MβCD) using isobaric tags for relative and absolute quantitation 
(iTRAQ)-labeling coupled to 2D LC-MS/MS. Lipid raft proteins were also identified by 
immuno-precipitation of cross- linked CD20, a tetraspanin protein that translocates to lipid 
rafts following treatment with the therapeutic antibody, rituximab. In total, 643 proteins were 
found in lipid rafts of CLL cells (580 following sucrose gradient ultracentrifugation, 181 
depleted by MβCD and 199 isolated by immunoprecipitation) and 64 proteins were identified 
by all 3 methods). These data represent the first comprehensive profile of the lipid raft 
proteome in CLL cells and include 30 proteins with no previous known association to the 
lipid raft. These proteins may represent novel diagnostic and therapeutic targets for CLL. 
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3.2 Methods 
3.2.1 Growth of MEC1 cells and drug treatment 
Human MEC1 CLL cells were grown as described in Section 2.3.2 and treated as follows. For 
MβCD treatment, cells were treated with 1 mM MβCD as described in Section 2.3.5.1. For 
rituximab treatment, MEC1 cells were grown in triplicate cultures and treated with rituximab 
at the saturation concentration (10 µg antibody/ml) for 24 h at 37oC (Roche, Basel, 
Switzerland). Following treatment with MβCD or rituximab, cells were harvested by 
centrifugation (3,000 rpm, 5 min, 22°C) for apoptosis assays (described in Section 2.3.6) and 
LRs isolation (described in Section 2.3.7).  
3.2.2 Western blotting 
After collection and concentration of nine 1 mL fractions (Section 2.3.7), Western blotting 
was performed (Section 2.3.8) to distinguish the fractions that contain the lipid raft markers. 
Briefly, fractions 1-9 (Figure 3.3A) were separated by 12% SDS-PAGE, and transferred to an 
Immuno-Blot™ PVDF membrane. After blocking with 5% (w/v) skim milk in TBST (25 mM 
Tris/HCl, 137 mM NaCl, 2.7 mM KCl and 0.1% (v/v) Tween-20, pH 7.6), membranes were 
incubated (4°C, 16 h) with primary antibodies against i) lipid raft markers, 1:1,000 anti-
caveolin-1 (CAV-1) monoclonal antibody (BD Biosciences) diluted in TBST, and 1:5,500 
anti–LYN monoclonal antibody (Sigma) diluted in 0.5% (w/v) skim milk in TBST; ii) a 
  49 
plasma membrane marker, 1:5,000 anti-CD71 (TfR1) monoclonal antibody (Biolegend, San 
Diego, USA) diluted in TBST; and iii) a cytoplasmic marker, 1:3,300 anti-β-actin monoclonal 
antibody (Abcam, Cambridge, USA) diluted in TBST. After the primary antibody, the 
membrane was washed 3 times with 1X TBST (10 min/wash). Blots were then incubated with 
a horseradish peroxidase (HRP)-conjugated secondary antibody: 1:12,000 goat-anti-mouse-
HRP (Santa Cruz Biotechnology Inc, Santa Cruz, USA) or 1:6,000 donkey anti-rabbit-HRP 
(Abcam, Cambridge, USA) diluted in TBST for 2 h at room temperature. The membrane was 
washed 3 times with 1X TBST (10 min/wash).  Finally, proteins were visualized using a 
Rapid Step ECL Reagent (Merck, Whitehouse Station, NJ, USA) and ECL 
chemiluminescence film (GE Healthcare, Piscataway, NJ, USA). 
3.2.3 Dot blots 
Dot blots were performed to confirm the presence of lipid rafts in the nine 1-ml fractions, 
which were collected from the top of the sucrose gradient tube after centrifugation (Figure 3.3 
A). PVDF membranes were pre-moistened in methanol for 2 min. Proteins (3 µl) were dotted 
directly onto the PVDF membrane and allowed to dry. The membrane was washed 3 times 
with 1X TBST (10 min/wash) before blocking with 5% (w/v) skim milk in TBST for 1 h at 
RT followed by 3 washes with 1X TBST (10 min/wash). The membrane was then incubated 
in peroxidase-conjugated cholera toxin subunit B that binds specifically to 
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monosialotetrahexosylganglioside (GM-1) (Sigma-Aldrich, St. Louis, MO, USA) for 1 h. 
Proteins were visualized using a Rapid Step ECL Reagent (Merck) and ECL 
chemiluminescence film (GE Healthcare). 
3.2.4 CD20 immuno-affinity precipitation 
MEC1 cells were treated with 10 µg/mL of rituximab at 37°C for 24 h. CD20 and rituximab 
were then cross-linked to the LRs by addition of 2 mM disuccinimidyl tartrate (DST) 
(ThermoFisher Scientific, Waltham, MA, USA) for 30 min and the reaction quenched with 1 
M Tris-HCl Ph 7.4. Cells were lysed in Immuno-precipitation cell lysis buffer (10 mM 
NaH2PO4, 0.15 M NaCl, 2 mM EDTA, 50 mM NaF, 1% (v/v) Na3VO4, 1% (v/v) protease 
inhibitor cocktail and 1% (v/v) Triton X-100). After 30 min on ice, the lysate was 
homogenised for 10 strokes and centrifuged (800 xg, 10 min, 4°C). The supernatant was 
transferred to a new tube and protein concentration determined as previously described 
(Section 2.3.4). The protein concentration was adjusted to 400 µg/mL with lysis buffer, 250 
µL of protein solution was incubated with 1.5 mg Dynabeads Protein G (Invitrogen, 
Carlsbad, California, USA) at 4°C with rotation for 12 h. CD20 and the LRs were then 
immunoprecipitated following the manufacturer’s instructions. 
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3.2.5 Protein identification by LC-MS/MS  
The buffer of purified LRs proteins (Section 2.3.7) and immunoprecipitated proteins (Section 
3.2.4) was exchanged to 0.5 M TEAB pH 8.5, 0.1% (w/v) SDS using a 3 kDa cut-off filter 
(described in Section 2.3.7). Proteins were reduced with 10 mM tris-(2-carboxyethyl) 
phosphine (TCEP) for 60 min at 60°C, alkylated with 10 mM methyl methane thiosulfonate 
(MMTS) for 10 min at RT, before digestion with sequencing-grade trypsin  (1:25, trypsin to 
protein ratio; Promega, Madison, MA, USA) at 37°C for 16 h. Digested peptides were 
cleaned using an ICAT cartridge (AB SCIEX, Foster City, CA, USA) and desalted using a 
HLB column (Waters, Milford, MA, USA) following the manufacturers’ instructions. The 
peptides were sequenced using a QSTAR Elite mass spectrometer (AB SCIEX, Foster City, 
CA, USA) in on-line mode (Section 2.3.13). 
The isolated lipid rafts of MEC1 cells treated with 1 mM MβCD and control were purified 
and buffer was exchanged to 0.5 M TEAB pH 8.5, 0.1% (w/v) SDS using a 3 kDa cut-off 
filter (described in Section 2.3.7). The isolated LRs proteins were reduced, alkylated and 
digested then labelled with iTRAQ 4-plex reagents (AB SCIEX, Foster City, CA, USA) 
following the manufacturer’s protocol (described in Section 2.3.11). Samples were labelled as 
follows: 114, untreated sample 1; 115, untreated sample 2; 116, 1 mM MβCD-treated sample 
1; 117, 1 mM MβCD-treated sample 2. The peptides were sequenced using a QSTAR Elite 
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mass spectrometer (AB SCIEX, Foster City, CA, USA) in on-line mode (Section 2.3.13). The 
data were analysed using Protein Pilot 3.0 software (AB SCIEX) (described in Section 
2.3.14). 
3.3 Results 
3.3.1 Effects of MβCD and rituximab on cell viability 
To analyze the in vitro effects of rituximab or MβCD on the viability of MEC1 cells, a dose-
response study was conducted (Figure 3.1). Rituximab had no effect on cell viability, 
whereas, MβCD decreased cell viability in a concentration-dependent manner. A low MβCD 
concentration (1 mM) was chosen for subsequent studies. At this concentration, MβCD 
efficiently removes cholesterol, with minor effects on cell viability (10% decrease) (Figure 
3.1). Apoptotic and dead cells were quantified using Annexin V-PE and 7-ADD (Annexin V-
PE Apoptosis Detection Kit I, BD Biosciences, San Diego, CA, USA) with flow cytometry 
(Figure 3.2). No significant cytotoxic effect was observed when cells were incubated with 
rituximab (10 µg/mL, 24 h), without increased apoptosis (control 12.3%, rituximab 13.9%) or 
necrotic cell death (control 7.1%, rituximab 8.3%). Similarly, MβCD treatment (1 mM, 1 h) 
did not induce apoptosis (control 10.8%, MβCD 7.3%). However, MβCD treatment induced 
some necrotic cell death (control 15.3%, MβCD 28.5%) (Figure 3.2).  
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Figure 3.1: Viability of MEC1 cells treated with MβCD or rituximab. (A) MEC1 cells were starved for fetal 
calf serum for 1 h and treated with 0, 0.5, 1,1.5 and 2.5 mM MβCD for 1 h at 37°C. (B) MEC1 cells were treated 
with 0, 1, 10 and 100 µg/mL of rituximab for 24 h at 37°C. Cell viability was determined by flow cytometry 
after staining of exposed phosphatidylserine with Annexin V and DNA with 7-ADD. The figures are 
representative of three independent experiments. Error bars indicate standard deviation. 
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Figure 3.2: Induction of cell death by MβCD or rituximab. (A) MEC1 cells were incubated in the presence 
(+) or absence (-) of 10 µg/mL of rituximab for 24 h at 37°C and analyzed by flow cytometry. (B) MEC1 cells 
were starved for fetal calf serum for 1 h then incubated in the presence (+) or absence (-) of 1 mM MβCD for 1 h 
at 37°C. The figure is representative of three independent experiments. 
 
 
A 
B 
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3.3.2 Lipid raft isolation 
LRs and associated proteins were isolated from the 5-30% (w/v) sucrose interface, whereas, 
remaining cellular material, including components of solubilized membranes and other 
cellular constituents remained in the higher density sucrose layers (i.e., 45%). The purity of 
the LRs enrichment was assessed by Western and dot blots using the 3 established LRs 
markers, CAV-1, LYN and GM1. CD71 and β-actin were used as non-LR associated cell 
surface and cytoplasmic markers, respectively. As shown in Figure 3.3, LRs were enriched in 
the low-density fractions 1–5 of the sucrose gradient indicated by the high abundance of 
CAV-1, LYN and GM1. LRs marker proteins were also abundant in the high-density fractions 
8-9, suggesting incomplete denaturation of LRs-associated proteins by Triton X-100. β-actin 
was detected in very small amounts and CD71 was not detected in the LR fractions (fractions 
1-5) indicating the high purity of the LRs.  
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Figure 3.3: Immuno-blot analysis of lipid rafts isolated from MEC1 cells. (A) Sucrose density gradient ultra-
centrifugation for isolation of LRs. The tube was fractionated from the top to bottom, an arrow indicates the LRs 
band. (B) Immun-oblot analysis using antibodies against the lipid raft markers LYN, caveolin-1 and ganglioside 
M1 (GM1), the plasma membrane marker transferrin receptor (CD71) and the cytoplasmic marker actin. The 
numbers indicate collected fractions. Fractions 1-5 showed the highest levels of LRs markers with low levels of 
the plasma membrane and cytoplasmic markers. 
3.3.3 Identification of LRs proteins  
2D-LC-MS/MS analysis of LRs proteins isolated in fractions 1-5 of the sucrose density 
gradient resulted in identification of 580 proteins (Table 3.1, Supplementary material Table 
1). We used BIOMYN (www.biomyn.de), UniProt (www.uniprot.org) and the Human Protein 
Reference Database (www.hprd.org) to categorise the identified proteins by sub-cellular 
localisation and biological function (Figure 3.4A). Proteins were localised to the cell 
membrane (39%), cytoplasm (29%), mitochondria (13%), ribosomes (6%), nucleus (5%) and 
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endoplasmic reticulum (3%). Identified proteins were clustered into several distinct groups 
involved in signal transduction/cell communication (25%), protein metabolism (19%), energy 
metabolic pathways (17%), transport (11%), cell growth/maintenance (9%), immune response 
(5%), regulation of nucleobases (4%), transcription (2%) and cell cycle (1%). The majority of 
these proteins were known as LR proteins (defined as showing high dependence on 
cholesterol for association with LR) or proteins associated with the LR (showing intermediate 
dependence on cholesterol for LR association).  However, 20 proteins identified here are 
potentially novel to the LRs, including those localised to the plasma membrane (90%) and 
cytoplasm (10%). The majority of novel LRs proteins are involved in signal transduction 
(57%) and immune response (24%) (Table 3.3). The isolation of LRs proteins was highly 
reproducible. Three independent sample preparations were performed with similar numbers of 
proteins identified in all 3 experiments, and matching identifications of more than 90% were 
obtained (Table 3.1). 
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Figure 3.4: Sub-cellular localization and biological processes of lipid raft proteins from MEC1 cells 
identified by LC-MS/MS. i) Cellular localization, and ii) biological processes were annotated based on the 
Human Protein Reference Database (www.hprd.org), PubMed (www.uniprot.org) and BioMyn 
(www.biomyn.de). (A), proteins isolated from LRs (B), proteins identified in LRs following MβCD-treatment 
(C), proteins identified from LRs following immuno-precipitation of CD20 with rituximab.  
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Table 3.1: The reproducibility of MEC1 lipid raft proteins enrichment by sucrose density gradient 
fractionation. Lipid raft proteins derived from three independent sample preparations were identified using LC-
MS/MS and ProteinPilot 3.0 software. 
Biological and 
technical replicates  
Number of proteins 
detected  
Number of proteins 
matched to master trial  
Match rate  
(%) 
 *MEC1 LRs sample 1  513  513  100  
MEC1 LRs sample 2 505 470 92  
MEC1 LRs sample 3 510  477  93  
*MEC1 LRs sample 1 was selected as master trial. 
 
3.3.4 Confirmation of LRs proteins by MS/MS following cholesterol 
depletion 
LRs are disrupted and disassembled by specific extraction of cholesterol using the cyclic 
oligosaccharide MβCD in preference to other lipids.  Therefore, comparative proteomic 
analysis of MEC-1 cells before and after MβCD treatment resulted in significant decreases in 
abundance of 181 proteins (Table 3.3; p<0.05). Of these depleted proteins, 85% (153 
proteins) were identified in our previous MS/MS analysis of sucrose gradient fractions 1-5 
(Figure 3.5). These proteins were categorized by the human protein reference databases 
(HPRD) predominantly as signal transducer proteins (41%) that are largely confined to the 
plasma membrane (77%; Figure 3.4B). We examined the post-translational modifications that 
may target each protein to the LR, using the web-based knowledge tools, BIOMYN, Uniprot 
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and HPRD (Table 3.3, Figure 3.6). Most of the proteins (71%) depleted by MβCD contain 
myristoylation, palmitoylation, prenylation and acetylation post-translational modifications 
(Table 3.3, Figure 3.6). In addition, many proteins are lipoproteins and/or glycoproteins. The 
depletion of LRs proteins by MβCD was highly reproducible between the 3 biological 
replicates (Figure 3.7). 
 
Figure 3.5: Venn diagram showing the numbers of proteins identified from the three isolation methods for 
LRs proteins. Proteins (580) were identified from sucrose density gradient fractions (total lipid raft); 181 
proteins were depleted by MβCD treatment, and 199 were isolated by CD20 immuno-precipitation with 
rituximab; 64 proteins were common to all 3 methods. 
 
  61 
 
Figure 3.6: The post-translational modifications of proteins identified in lipid rafts from MEC1 cells 
following MβCD treatment. The post-translational modifications were annotated from the Human Protein 
Reference Database (www.hprd.org), PubMed (www.uniprot.org) and BioMyn (www.biomyn.de).  The 
percentages of modifications are indicated. 
 
Figure 3.7: Reproducibility of differentially abundant proteins identified by LC-MS/MS analysis of LRs 
from MEC1 cells treated with MβCD. The fold-changes of three independent preparations (MβCD treatment 
n= 3, 1 mM, 1 h; p < 0.05) were compared and plotted against each other. Decreases in protein levels by 0.75-
fold (p<0.05) and less were considered to be biologically significant. 
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3.3.5 Immuno-precipitation of LRs proteins that interact with CD20 
following rituximab treatment 
2D-LC-MS/MS analysis of CD20 binding proteins, following their translocation to the LRs 
by rituximab treatment, identified 199 proteins (Supplementary Table 2). Of these proteins, 
82% (164) were identified in the sucrose density gradient fractions 1-5, 33% (65) were 
differentially abundant following MβCD treatment and 32% (64) of the CD20 binding 
proteins were identified by all 3 methods (Figure 3.5). Thirty-five proteins (18%) identified 
by CD20 immunoprecipitation were not isolated by the other 2 methods. Again, proteins were 
classified mostly to the plasma membrane (38%), cytoplasm (30%) and ribosomes (20%) and 
involved predominantly in protein metabolism (34%) and signal transduction (21%; Figure 
3.4C). The immune-precipitated LRs proteins were highly reproducible, 3 independent 
sample preparations yielded similar numbers of proteins with matching identification rates of 
95% and 96% were obtained (Table 3.2). 
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Table 3.2: The reproducibility of proteins identified from MEC1 LRs following immuno-precipitation 
with CD20 antibody. CD20-binding partners following the translocation of CD20 to the LRs by rituximab 
treatment were analyzed from three independent sample preparations and identified using LC-MS/MS and 
ProteinPilot 3.0 software. 
Biological and 
technical replicates 
Number of proteins 
detected 
Number of proteins 
matched to master trial 
Match rate 
(%) 
*IP sample 1 190 190 100 
IP sample 2 185 180 95 
IP sample 3 187 183 96 
* IP sample 1 was selected as master trial. 
Overall, 643 proteins have been identified from LRs of human MEC1 CLL cells. Of the 
proteins identified by the 3 methods, 30 are novel LRs proteins (Table 3.3). Six novel LRs 
proteins (LSP1, HLA-DQB1, HLA-DQA1/DRA, HLA-DRA, RAC2 and Ig kappa chain V-IV 
region B17) were identified following isolation by all 3 methods. These proteins have roles in 
cell migration, adhesion, signalling pathways, apoptosis, transcription regulation, protein 
synthesis and degradation in cancer cells. 
As illustrated in Figure 3.4, there is a larger percentage of signal transduction and cell 
communication proteins (e.g., guanine nucleotide-binding proteins, Ras-related proteins and 
kinases) identified in the MβCD analysis compared with the other methods (41% versus 25% 
and 21% in sucrose density gradient and immuno-precipitation, respectively). More plasma 
membrane proteins were identified as LRs-associated following cholesterol depletion by 
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MβCD. Conversely, the number of energy metabolism proteins identified in the LRs 
following MβCD treatment and immuno-precipitation decreased. Following the dissolution of 
LRs proteins by MβCD, increased or stable levels of mitochondrial, transcription, RNA and 
DNA-binding proteins were detected and excluded from the LRs protein list. Following the 
immuno-precipitation of CD20-bound proteins, the percentage of immune response proteins 
e.g., MHC complex proteins, increased as well as ribosomal proteins, that contribute to a 
higher percentage of protein metabolism related proteins.  
3.4 Discussion  
LRs are membrane micro-domains enriched in cholesterol and sphingolipid, implicated in 
diverse cellular processes including signalling [86], cytokinesis [143],  morphogenesis [144], 
response to the environment [94] and endocytic events [145]. Many of the surface antigens 
aberrantly expressed on B-cell chronic lymphocytic leukaemia (CLL) cells are localized or 
translocated to LR, where they may carry out abnormal functions [107]. To explore the 
composition and dynamic nature of the LRs in CLL cells, the LRs proteome has been isolated 
by 3 techniques from MEC1 cells and analysed by 2D-LC-MS/MS. Firstly, we analysed the 
LRs proteome following simple sucrose density gradient ultracentrifugation. Due to the 
presence of cholesterol and saturated fatty acids, LRs are more ordered and less fluid than the 
surrounding plasma membrane [146, 147]. This property renders LRs insoluble in non-ionic 
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detergents such as Triton X-100 [87, 148], a characteristic that allows separation from other 
membrane fractions. We treated cells with MβCD to confirm that proteins identified were 
localised to the LRs. LRs are disrupted by the extraction of cholesterol by MβCD, a surface-
acting agent that selectively and rapidly removes cholesterol from the plasma membrane in 
preference to other membrane lipids, and has been widely used to deplete cholesterol and 
dissociate LRs [149-151].  
3.4.1 Isolation of lipid rafts 
The dependence of raft integrity on cholesterol means that specific removal of cholesterol 
from cells profoundly alters raft structure. Indeed, 181 proteins showed significant depletion 
following MβCD treatment of which 85% (153) were also identified following sucrose 
density gradient ultracentrifugation. 2D-LC-MS/MS analyses were performed to identify 
CD20-binding partners following the translocation of CD20 to the LRs induced by rituximab. 
Overall, we identified 643 proteins, comparable to previous studies [152-154]. This is the first 
report of the LRs proteome from CLL cells. A recent study used SILAC labelling to quantify 
LRs proteins before and after MβCD treatment [109] that identified 165 LRs proteins for 
HeLa, 196 for 3T3, and 294 for Jurkat cells [110]. We used iTRAQ to label LRs proteins 
before and after MβCD treatment, 2D-LC-MS/MS analysis identified 181 LRs proteins in 
MEC1 cells (Table 3.3). Of these, 30 proteins are novel to the LRs (Table 3.3), with 6 
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proteins isolated by all 3 procedures; LSP1, HLA-DQB1, HLA-DQA1/DRA, HLA-DRA, 
RAC2 and Ig kappa chain V-IV region B17. Indicating that these proteins localize to the lipid 
rafts in MEC1 cells. 
Contamination of LRs fractions by abundant cytosolic, mitochondrial and nuclear proteins is 
a common problem [110, 155]. For sucrose density gradient centrifugation, significant 
contamination from mitochondria, nuclei, ribosomes, ER and cytoplasmic proteins was 
detected (Figure 3.4A). For immuno-precipitation the percentage of contaminants was 
reduced except for ribosomal proteins, higher at 20% and RNA/DNA binding proteins at 11% 
(Figure 3.4C). For MβCD treatment, only associated LRs proteins such as actin, F-actin 
(polymer form), tubulin and vimentin were decreased [76, 156, 157] (Figure 3.4B). However, 
cholesterol-dependence of LRs may not include all raft proteins since some LRs resist 
disruption by lowering cholesterol [158]. 
Interactions between LRs and the cytoskeleton are essential for cellular processes such as 
signal transduction and cell communication, endocytosis, cell morphology, cell adhesion, 
immune response and cell motility. Indeed LRs proteins identified here are involved in 
processes important to cancer including apoptosis, immune response and antigen presentation 
and cell survival. The functions of some of these proteins are discussed below.  
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3.4.2 Lipid raft proteins involved in apoptosis 
One of the proteins isolated from the LRs by all 3 enrichment methods is lymphocyte specific 
protein (LSP1), a cytoplasmic membrane-bound protein and a specific marker of human 
leukocytes. Following activation by anti-IgM, LSP1 translocates to the cytosol [159] where it 
binds PKCβI, thereby preventing ERK2 activation, resulting in apoptosis [160]. Anti-IgM 
binding to B-CLL cells results in the translocation of IgM to LRs leading to activation of the 
MEK1/MAPK pathway and cell proliferation [161]. LSP1 localisation to the LRs may 
function to inhibit the MEK1/MAPK pathway following cell activation with the potential to 
induce apoptosis in CLL. 
SH3KBP1-binding protein 1 (SHKBP1), a Calcineurin B-like (CBL)-interacting protein that 
enhances TNF-mediated cell apoptosis [162], was also localized to the LRs. SHKBP1 
regulates epidermal growth factor receptor (EGFR) activation, elevated levels are a prognostic 
marker for head and neck, ovarian, cervical, bladder and esophageal cancers [163], EGFR 
was the first growth factor receptor to be proposed as a target for cancer therapy [164].  
Signal-induced proliferation-associated protein 1 (SIPA1), is a specific GTPase activator 
protein (GAP) for the Ras-related regulatory proteins, RAP1 and RAP2 that are converted by 
SIPA1 to the inactive GDP-bound state [165]. RAP1-GAP was found to be a tumor 
suppressor by converting RAP1 to the inactive, GDP-bound, state [166]. Activation of SIPA1 
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at the plasma membrane LRs results in tumor suppression. A deficiency of SIPA1 in the 
mouse resulted in high levels of RAP1 activation in T-cells upon anti-CD3 stimulation 
leading to age-dependent progression of T-cell immunodeficiency and leukemia development 
[167]. RAP1 also counteracts the mitogenic functions of RAS by interacting with RAS GAPs 
at the plasma membrane suppressing RAS functions [168]. In addition, RAP1 is an important 
player in adhesion and migration of lymphocytes [169]. 
G-protein-signalling modulator 3 (GPSM3) localizes at the plasma membrane of the human 
acute monocytic leukemia cell line, THP-1, and regulates the assembly and function of G-
protein heterotrimers (Gα-GDP/Gβγ), that control G-protein coupled receptors (GPCRs) at 
the cell surface [170-173]. Thus, GPSM3 can modulate GPCR signaling, leading to the 
progression of many cancers and their spread to distant organs [174]. We have identified a 
number of members of the heterotrimeric G protein complexes, GNAI2, GNAI3, GNB2, 
GNB1, GNB2L1, GNG11 and the modulator GPSM3, are all located in LRs, GPSM3 and 
GNG11 are novel to LRs. GNG11 is also a transducer of various transmembrane signaling 
systems in the plasma membrane. Interestingly, the over-expression of GNG11 immediately 
induces cellular senescence in normal human fibroblasts [175]. Targeting LRs proteins 
involved in apoptosis and/or their modulators may enhance apoptosis of CLL cells. 
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3.4.3 Lipid raft proteins involved in the immune response and antigen 
presentation 
Ras-related C3 botulinum toxin substrate 2 (RAC2) is a plasma membrane-associated small 
GTPase [176] that modulates NADPH oxidase activation and is found only on hematopoietic 
cells. RAC2 regulates growth factor-induced survival through activation of Akt and a change 
in levels of the Bcl-2 family members Bad and Bcl-XL [177]. The translocation of RAC2 
from the cytosol to the plasma membrane mediated by angiotensin II in human neutrophils is 
necessary to prevent ROS production and activation of p38MAPK, ERK1/2 and JNK1/2 
[178]. We find that RAC2 is located in membrane LRs, suggesting an active form in CLL 
cells. Cross-talk between RAC2 and the MAPK pathway is likely to be depend on other 
signaling pathways, such as those mediated by PI3K, Ca2+ elevation or calcineurin (CaN) 
activation [178]. 
 RAC2 is activated by cytotoxic necrotizing factor 1 (CNF1), that then interacts with Rip 
kinases to drive the immune response and activate the NF-κB and IRF pathways [179]. RAC2 
is required for IFN-γ production during normal T-cell activation and Th1-cell differentiation, 
through simultaneous activation of the NF-κB and p38 pathways [180]. IFN-γ induces IFN-γ-
inducible lysosomal thiol reductase [181], IFI30, facilitates the generation of MHC class II-
restricted epitopes, and MHC class I recognition of disulfide bond-containing antigens by 
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CD8+ T-cells [181-183]. In melanoma cells, IFI30 levels regulate antigen processing and the 
hierarchy of immune-dominant epitope presentation [184], with higher IFI30 levels increasing 
antigen processing and presentation via HLA class II molecules, thereby enhancing CD4+ T-
cell recognition [185]. When tumor cells escape immune surveillance, tumor antigens are not 
recognized by the immune system. Activation of IFI30 in CLL may result in increased 
antigen processing and presentation via HLA class II molecules. Enhanced tumor antigen 
presentation by CLL cells to the immune system may result in CLL cell killing. 
CD74-ROS, a fusion of the N-terminus of CD74 with receptor tyrosine kinase ROS, was 
identified in LRs of MEC1 cells. ROS is an important modulator of signal transduction 
pathways that regulate cellular proliferation, differentiation, migration and survival [186] and 
the CD74/ROS fusion protein was shown to drive proliferation and survival of a sub-group of 
non-small cell lung cancers [186, 187]. CD74 associates with major histocompatibility 
complex, human leukocyte antigen (HLA) class II, and facilitates peptide presentation [188]. 
HLA class II antigens bind peptides derived from antigens for recognition by CD4 T-cells 
[189], a crucial part of the anti-tumoral immune response. The HLA class II gene includes 
highly polymorphic HLA-DR, DQ and DP genes [190]. HLA-DQB1, HLA-DQA1/DRA and 
HLA-DRA were identified in MEC1 LRs by all 3 methods and are novel to the LRs 
proteome. HLA-DQB1 and HLA-DQA1 form the DQ heterodimer, a cell surface receptor for 
antigen presentation. In B-CLL up-regulation of HLA-DQA1 is correlated to apoptosis 
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resistance in response to DNA damage [191]. In addition, the HLA-DQA1 gene harbors a 
susceptibility locus for risk of familial CLL [192]. HLA-DQB1 is also associated with a 
higher risk for CLL [193] and is a susceptibility allele in acute lymphoblastic leukemia [194]. 
Localization of HLAs to LRs may initiate tyrosine kinase signaling pathways in B-cells [195] 
and enable access to the endocytic/exogenous route.  
3.4.4 Lipid raft proteins involved in cell survival 
Neurabin II, a protein phosphatase 1 regulatory subunit, is a scaffold protein localized to the 
cell membrane that interacts with actin and protein phosphatase 1 (PP1) [196, 197]. More 
than 30 Neurabin II binding partners have been identified, including cytoskeletal and cell 
adhesion molecules, enzymes, regulators of G-protein signaling, membrane receptors, ion 
channels and the tumor suppressor ARF [198]. In this study, neurabin II, protein phosphatase 
1 catalytic subunit A (PPP1CA), protein phosphatase 1G (PPM1G) and protein phosphatase 1 
regulatory subunit 18 (PPP1R18) were identified in the LRs of MEC1 cells by MβCD 
treatment and sucrose density gradient fractionation. PP1 regulates cell cycle progression by 
activating the growth suppressing function of retinoblastoma protein (Rb) [199] and 
conversely, promoting cell survival by dephosphorylating p53 and negatively regulating the 
p53-dependent death pathway [200]. Neurabin II suppresses growth in human and mouse 
cells by inhibiting PP1 activity [201]. Loss of Neurabin II correlates with reduced PPP1CA 
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that maintains elevated pRb and contributes to a functional increase in p53 activity to arrest 
cellular proliferation [202]. In the absence of p53, reduced Neurabin II promotes 
tumorigenesis. MEC1 cells possess a truncated form of p53 that may be non-functional [203]. 
Induction of the protein phosphatases and regulators in the LRs (neurabin II, PPP1CA, 
PPM1G and PPP1R18) may trigger a tumor suppressor signal via Rb providing a novel 
therapeutic approach for p53-mutated tumors. 
Basement-membrane protein 40, SPARC, is a calcium-binding glycoprotein that regulates 
cell growth [204] by binding to the extracellular matrix and cytokines [204, 205]. The role of 
SPARC in cancer progression is controversial. Over-expression of SPARC in tumors such as 
breast [206], prostate [207], melanomas [208] and CLL after treatment with lenalidomide 
[209], correlates with cancer progression and poor prognosis [210]. Furthermore, knock-down 
of SPARC in human melanoma blocks tumor formation [208]. Whereas, SPARC has been 
reported as a tumor suppressor in neuroblastoma through inhibition of cell proliferation, 
invasiveness, and angiogenesis [211]. The translational significance of the inhibitory effect of 
tumor cell and host SPARC on carcinogenesis, progression, and metastasis makes SPARC a 
viable candidate in the adjuvant and/or neoadjuvant settings as a single agent or in 
combination with standard of care radiation or chemotherapies. 
β-galactoside α-2,6-sialyltransferase 1 (ST6GAL1, CD75) [212], mediates addition of α-2,6-
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linked sialic acid to glycoproteins [213], and differentiation of the cell surface antigens HB-6, 
CDW75, and CD76 on lymphocytes [214]. ST6GAL1 is associated with metastasis and poor 
prognosis and is over-expressed on colorectal [215] cervical [216], breast [217],  
choriocarcinoma [218], but not CLL [219]. The mechanism by which ST6GAL1 facilitates 
tumor progression is not clear, but sialylation of the Fas death receptor by ST6GAL1 inhibits 
Fas-mediated apoptosis in colon carcinoma cells [220]. In addition, ST6GAL1 deficiency 
diminishes B-cell immune responses in mice by inducing immunoglobulin M (IgM) antigen 
receptor endocytosis in the absence of immune stimulation [221]. 
Immunoglobulin (Ig) heavy and light chains are produced by B-cells to neutralize foreign 
particles, and are secreted from cells or bound to the B-cell receptor (BCR) complex [222]. In 
CLL, secreted Ig and abnormal light chain ratios are associated with poor survival [223, 224]. 
Membrane-bound IgM induces phosphorylation of CD79a and CD79b by the Src family of 
PTKs, including LYN [225], which is concentrated in LRs and may facilitate phosphorylation 
of the LRs-localized BCRs [226]. Blocking these immunoglobulins could inhibit CLL 
progression. In this study, Ig kappa chain V-IV region B17, a protein encoding a variable 
region important in conferring antigenic specificity and associated with the antigen-binding 
site, was localized to the LRs of CLL cells. In addition, Ig kappa chain V-IV region B17 
could interfere with the function of therapeutic antibodies, e.g., rituximab, that moves to the 
LRs with CD20. Therefore, Ig kappa chain V-IV region B17 may prevent rituximab from 
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binding with CD20 and thus stop rituximab action and cell killing.  
Based on the Human Protein Reference Database, PubMed and BioMyn databases, proteins 
identified here possess post-translational modifications such as glycosyl phosphatidylinositol 
(GPI)-anchoring, fatty acylation and lipids, necessary to target proteins to LRs [227-234]. 
Identified GPI-anchor proteins such as BST2, SEMA7A, CD58 and PHB, are built on 
phosphatidylinositol that inserts into the exoplasmic leaflet of the membrane. Some of these 
proteins contain alkyl-acyl groups and fatty acylation (myristoylation, palmitoylation, 
prenylation and acetylation) on proteins including LSP1, FLOT2, GNB2 and FMNL1. The 
analysis of acylated proteins suggests that the ribosomal subunits, RPS16, RPS2 and RPS11, 
may be targeted to LRs-enriched membranes through protein acylation. Lipoproteins such as 
GNAI2, LYN, FGR, RPS11, EFNA5 and RFTN1 are post-translationally modified by 
attachment of at least one lipid or fatty acid, e.g., farnesyl, palmitate or myristate [235] that 
may direct these proteins to the LRs [236, 237]. N-glycosylated proteins, such as SPTBN1, 
HLA-DPB1, SEMA7A, ST6GAL1 and HYOU1 are important integral membrane and LRs 
proteins [238-241]. The post-translational modifications listed in Table 3.3 such as 
acetylation, glycoprotein and lipoprotein may attach these proteins to LRs. A number of 
phosphorylated proteins were identified, including CSNK1G3, SHKBP1, CAMK2A and 
LIMA1, that may all be involved in the activation of downstream signaling cascades. 
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The LRs may act as signalling platforms for proteins, serving as organizing centers for 
assembly of complexes, accessible from both sides of the plasma membrane, enabling their 
activation or inhibition [101, 102]. The LRs are the platform for GPSM3 and its substrates of 
G proteins (GNAI2, GNAI3, GNB2, GNB1, GNB2L1 and GNG11) and Neurabin II and its 
interacting proteins PPP1CA, PPM1G, and PPP1R18 (Table 3.3). LRs facilitate reactions 
such as activation of metalloproteinase-2 [206], IFI30 [180, 181] and RAP1A [165], by 
SPARC, RAC2 and SIPA1, respectively. Also LRs facilitate the phosphorylation of BCR 
(IgM) (Ig µ chain C region and Immunoglobulin κ light chain) by Src-family PTKs such as 
LYN kinase [225], and contains ST6GAL1, necessary to prevent IgM endocytosis [221]. In 
addition, LRs provide the flexibility of MHC class II and I endocytosis and surface 
expression. 
3.5 Conclusions 
We have identified 643 proteins from CLL LRs. Proteins (580) were identified after 
fractionation using sucrose density gradient ultracentrifugation, 181 proteins were depleted by 
MβCD treatment and considered to be LRs proteins, and 199 proteins were immuno-
precipitated from LRs as CD20 binding-proteins following CD20 translocation to the LRs 
induced by rituximab. 
The sucrose gradient fractions contained some mitochondrial, ribosomal and nuclear proteins 
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as contaminants. The mitochondrial proteins were not detected after immuno-precipitation, 
but the amounts of ribosomal and nuclear proteins were higher than in the sucrose gradient 
fraction. MβCD depleted only LRs and associated LRs proteins, most proteins that were 
identified by this method are known LRs proteins with post-translational modifications that 
target them to the LRs. We conclude that MβCD treatment identified the most LRs-specific 
proteins and is very useful for validation of proteins localised to LRs. 
Of the proteins identified by these methods, 30 were novel LRs proteins (Table 3.3). Six 
novel LRs proteins (LSP1, HLA-DQB1, HLA-DQA1/DRA, HLA-DRA, RAC2 and Ig kappa 
chain V-IV region B17) were isolated and identified following enrichment by all 3 methods. 
These proteins have roles in cell migration, adhesion, signalling pathways, apoptosis, 
transcription regulation, protein synthesis and degradation in cancer cells. In addition, 21 
proteins were identified by sucrose density gradient and MβCD methods, and 10 proteins 
were identified by MβCD alone. Of these 30 novel proteins, we propose that LSP1, RAC2, 
IFI30, Neurabin II, SIPA1, GPSM3, GNG11, SHKBP1, SPARC, ST6GAL1 and CD74/ROS 
fusion proteins are involved in the immune response, antigen presentation, cell apoptosis and 
survival, and making them a prospect for further investigation to identify potential therapeutic 
targets for CLL as discussed above.  
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Table 3.3: Lipid raft proteins differentially abundant by LC-MS/MS analysis of MEC1 cells treated with MβCD (1 mM, 1 h; p < 0.05). The biological process, sub-
cellular localization and post-translational modifications of identified proteins are indicated. SDG, sucrose density gradient; IP, immuno-precipitation. 
Accession 
number (i) 
Name Novel/ Ref 
assoc. LRs 
ID’s in IP/ 
SDG 
Peptides (95%) 
(ii (% Protein 
coverage (iii)) 
Fold-change 
/p-value (iv) 
Gene name Sub-cellular 
localisation (v) 
Biological process 
(vi) 
Post-translational modification (vii) 
A9YLN4 Tyrosine-protein kinase receptor  Novel -/- 2 (4.8) 0.65 (0.01) CD74/ROS 
fusion 
Plasma membrane Signal transduction Phosphoprotein 
B1AH80 Ras-related C3 botulinum toxin substrate 2  Novel +/+ 1 (6.5) 0.40 (0.04) RAC2 Plasma membrane Signal transduction Lipoprotein/ Acetylation/ 
Prenylation 
P01871 Ig mu chain C region Novel -/+ 8 (19.1) 0.48 (0.05) IGHM Plasma membrane Immune response Glycoprotein 
P01903 HLA class II histocompatibility antigen, DR 
alpha chain 
Novel +/+ 6 (11.4) 0.30 (0.00) HLA-DRA Plasma membrane Signal transduction Glycoprotein 
P01919 HLA class II histocompatibility antigen, 
DQ(W1.1) beta chain  
Novel +/+ 1 (14.9) 0.54 (0.04) HLA-DQB1 Plasma membrane Signal transduction Glycoprotein 
P04440 HLA class II histocompatibility antigen, 
DP(W4) beta chain  
Novel -/- 3 (26.4) 0.29 (0.00) HLA-DPB1 Plasma membrane Immune response Glycoprotein 
P05536 HLA class II histocompatibility antigen, 
DQ(W3) alpha chain  
Novel -/+ 2 (7.9) 0.54 (0.01) HLA-DQA1 Plasma membrane Signal transduction Glycoprotein 
P06314 Ig kappa chain V-IV region B17  Novel +/+ 2 (13.4) 0.69 (0.05)  Plasma membrane Immune response  
P09486 Basement-membrane protein 40 Novel -/- 1 (8.5) 0.50 (0.05) SPARC Plasma membrane Signal transduction Glycosylation 
P13284 Gamma-interferon-inducible lysosomal thiol 
reductase 
Novel -/- 1 (5.2) 0.24 (0.00) IFI30 Plasma membrane Immune response Glycoprotein 
P15907 Beta-galactoside alpha-2,6-sialyltransferase 1, 
B-cell antigen CD75 
Novel -/+ 1 (5.4) 0.46 (0.04) ST6GAL1 Plasma membrane Signal transduction Glycoprotein 
P29144 Tripeptidyl-peptidase 2  Novel -/- 1 (1.4) 0.35 (0.04) TPP2 Plasma membrane Protein metabolism Acetylation 
P33241 Lymphocyte-specific protein 1 Novel +/+ 15(50.4) 0.20 (0.01) LSP1 Plasma membrane Signal transduction Acetylation 
P61952 Guanine nucleotide-binding protein 
G(I)/G(S)/G(O) subunit gamma-11 
Novel -/- 1 (28.8) 0.28 (0.00) GNG11 Plasma membrane Signal transduction Prenylation/ Lipoprotein, lipid 
anchor 
Q01518 Adenylyl cyclase-associated protein 1  Novel -/+ 1 (2.3) 0.51 (0.01) CAP1 Plasma membrane Signal transduction Acetylation 
Q0KKI6 Immunoglobulin kappa light chain Novel -/+ 4 (28.9) 0.61 (0.03) IGKC Plasma membrane Immune response  
Q10567 AP-1 complex subunit beta-1  Novel -/- 1 (4.3) 0.46 (0.00) AP1B1 Plasma membrane Transport Acetylation 
Q6NYC8 Phostensin  Novel -/+ 2 (6.7) 0.43 (0.02) PPP1R18 Plasma membrane Protein metabolism Phosphoprotein 
Q6S8J3 POTE ankyrin domain family member E Novel -/+ 9 (8.6) 0.46 (0.01) POTEE Plasma membrane ATP binding Phosphoprotein 
Q6UW68 Transmembrane protein 205 Novel -/- 1 (9) 0.42 (0.03) TMEM205 Plasma membrane Cisplatin resistance Acetylation 
Q7LGA3 Heparan sulfate 2-O-sulfotransferase 1  Novel -/- 1 (10.4) 0.54 (0.04) HS2ST1 Plasma membrane Signal transduction Glycoprotein 
Q7YPT8 MHC class II antigen  Novel +/+ 6 (11.4) 0.39 (0.00) HLA- Plasma membrane Immune response Glycoprotein 
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DQA1/DRA 
Q8TBC3 SH3KBP1-binding protein 1  Novel -/+ 1 (7.6) 0.40 (0.05) SHKBP1 Plasma membrane Signal transduction Phosphoprotein 
Q8WU40 Calcium/calmodulin-dependent protein 
kinase type II subunit gamma 
Novel -/+ 1 (2.6) 0.30 (0.03) CAMK2G Plasma membrane Signal transduction Phosphoprotein 
Q8WWI1 LIM domain only protein 7  Novel -/+ 3 (4.1) 0.28 (0.01) LMO7 Cytoplasm Protein metabolism Phosphoprotein 
Q92928 Putative Ras-related protein Rab-1C  Novel -/+ 2 (12.4) 0.62 (0.02) RAB1C Plasma membrane Signal transduction Prenylation/ Acetylation/ 
Lipoprotein 
Q96FS4 Signal-induced proliferation-associated 
protein 1  
Novel -/- 1 (2.4) 0.24 (0.01) SIPA1 Cytoplasm Signal transduction Phosphoprotein 
Q96SB3 Neurabin II  Novel -/+ 4 (10.2) 0.52 (0.01) PPP1R9B Plasma membrane Signal transduction Acetylation 
Q9H0X9 Oxysterol-binding protein-related protein 5  Novel -/+ 1 (1.4) 0.30 (0.04) OSBPL5 Cytoplasm Transport Phosphoprotein 
Q9Y4H4 G-protein-signaling modulator 3  Novel -/+ 2 (23.1) 0.50 (0.03) GPSM3 Plasma membrane Signal transduction Phosphoprotein 
A4QPB0 IQ motif containing GTPase activating 
protein 1  
[153]  2 (4.7) 0.36 (0.03) IQGAP1 Plasma membrane Signal transduction Acetylation 
B0I1T2 Myosin-Ig  [242]  29 (31.4) 0.20 (0.05) MYO1G Plasma membrane Signal transduction Phosphoprotein 
B1AP13 CD55 molecule, decay accelerating factor for 
complement (Cromer blood group)  
[153]  4 (14.4) 0.69 (0.03) CD55 Plasma membrane Signal transduction Lipoprotein/ Glycoprotein 
B4DT69 Dihydrolipoyl dehydrogenase [110]  2 (5.2) 0.31 (0.05) DLD Cytoplasm Metabolism energy Acetylation 
B5BUF5 Signal recognition particle 14 kDa protein  [110]  1 (9.6) 0.48 (0.01) SRP14 Cytoplasm Protein targeting Phosphoprotein 
E7EQ40 F-actin-capping protein subunit beta  [243]  1 (2.7) 0.47 (0.01) CAPZB Cytoplasm Cell growth Acetylation 
O00161 Synaptosomal-associated protein 23  [153]  8 (37) 0.58 (0.03) SNAP23 Plasma membrane Transport Acetylation/Palmitate/Lipoprotei
n 
O15144 Actin-related protein 2/3 complex subunit 2  [153]  1 (3.7) 0.50 (0.05) ARPC2 Plasma membrane Cell growth Acetylation 
O15355 Protein phosphatase 1G  [110]  1 (3.3) 0.50 (0.03) PPM1G Cytoplasm Protein metabolism Acetylation 
O43707 Alpha-actinin-4  [242]  9 (15.8) 0.17 (0.00) ACTN4 Plasma membrane Cell growth Acetylation 
O75326 Semaphorin-7A  [244]  8 (17.6) 0.57 (0.02) SEMA7A Plasma membrane Signal transduction Lipoprotein/ Glycoprotein/ GPI- 
Anchored 
O75695 Protein XRP2  [110]  3 (6) 0.40 (0.00) RP2 Plasma membrane Transport Myristate/ Palmitate/ Lipoprotein 
O75955 Flotillin-1  [242]  6 (19.4) 0.40 (0.01) FLOT1 Plasma membrane Cell growth Myristate/ Palmitate 
O95466 Formin-like protein 1  [110]  2 (2.4) 0.62 (0.02) FMNL1 Plasma membrane Cell growth Myristate/ Lipoprotein 
P00558 Phosphoglycerate kinase 1  [110]  27 (48.9) 0.50 (0.00) PGK1 Cytoplasm Metabolism energy Acetylation 
P04233 HLA class II histocompatibility antigen 
gamma chain 
[153]  4 (18.5) 0.54 (0.04) CD74 Plasma membrane Signal transduction Glycoprotein, GPI-Anchored 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  [153]  43 (59.7) 0.54 (0.04) GAPDH Plasma membrane Metabolism energy Acetylation 
P04899 Guanine nucleotide-binding protein G(i), 
alpha-2 subunit 
[153]  8 (24.5) 0.39 (0.04) GNAI2 Plasma membrane Signal transduction Myristate/ Palmitate/ Lipoprotein 
P06733 Alpha-enolase  [110]  46 (58.3) 0.60 (0.05) ENO1 Plasma membrane Metabolism energy Acetylation 
P06734 Low affinity immunoglobulin epsilon Fc 
receptor, CD23 
[245]  2 (15) 0.61 (0.00) FCER2 Plasma membrane Immune response Glycoprotein 
P06748 Nucleophosmin [110]  1 (18) 0.50 (0.01) NPM1 Cytoplasm Protein metabolism Acetylation 
P07195 L-lactate dehydrogenase B chain  [110]  4 (21) 0.53 (0.04) LDHB Cytoplasm Metabolism energy Acetylation 
P07437 Tubulin beta chain  [110]  8 (21.2) 0.53 (0.05) TUBB Plasma membrane Cell growth Acetylation 
P07900 Heat shock protein HSP 90-alpha  [153]  44 (33.1) 0.41 (0.00) HSP90AA1 Plasma membrane Signal transduction Acetylation 
P07948 Tyrosine-protein kinase Lyn  [242]  3 (7) 0.57 (0.01) LYN Plasma membrane Signal transduction Myristate/ Palmitate/ Lipoprotein 
P08133 Annexin A6 [153]  18 (37.1) 0.40 (0.00) ANXA6 Plasma membrane Signal transduction Acetylation 
P08238 Heat shock protein HSP 90-beta [153]  7 (17.4) 0.35 (0.05) HSP90AB1 Plasma membrane Signal transduction Acetylation 
P08631 Tyrosine-protein kinase HCK  [246]  1 (2.3) 0.45 (0.03) HCK Plasma membrane Signal transduction Myristate/Palmitate/Lipoprotein 
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P08670 Vimentin  [242]  4 (18.2) 0.11 (0.02) VIM Plasma membrane Cell 
growth/Apoptosis 
Acetylation 
P08709 Coagulation factor VII [41]  1 (2.5) 0.40 (0.00) F7 Plasma membrane Protein metabolism Glycoprotein 
P08754 Guanine nucleotide-binding protein G(k) 
subunit alpha 
[153] 
 
 6 (21.5) 0.30 (0.01) GNAI3 Plasma membrane Signal transduction Myristate/ Palmitate/ Lipoprotein, 
lipid anchor 
P08758 Annexin A5  [110]  3 (12.5) 0.52 (0.03) ANXA5 Plasma membrane Signal transduction Acetylation 
P09382 Galectin-1  [153]  2 (25.2) 0.54 (0.01) LGALS1 Plasma membrane Signal transduction Acetylation 
P09769 Tyrosine-protein kinase Fgr [247]  4 (9.5) 0.54 (0.02) FGR Plasma membrane Signal transduction Myristate/ Palmitate/ Lipoprotein 
P0C0L5 Complement C4-B  [153]  2 (2) 0.42 (0.03) C4B Extraceluar Immune response Glycoprotein 
P10809 60 kDa heat shock protein [110]  2 (8.9) 0.66 (0.03) HSPD1 Plasma membrane Signal transduction Acetylation 
P11142 Heat shock cognate 71 kDa protein  [153]  27 (37.9) 0.70 (0.02) HSPA8 Plasma membrane Signal transduction Acetylation 
P12268 Inosine-5'-monophosphate dehydrogenase 2 [110]  1 (5.6) 0.46 (0.05) IMPDH2 Cytoplasm metabolism energy Acetylation 
P13639 Elongation factor 2  [110]  20 (19.1) 0.60 (0.05) EEF2 Cytoplasm Protein metabolism Acetylation 
P14317 Hematopoietic lineage cell-specific protein [248]  1 (10.5) 0.30 (0.05) HCLS1 Plasma membrane Signal transduction Acetylation 
P14618 Pyruvate kinase isozymes M1/M2  [153]  21 (40.7) 0.50 (0.02) PKM2 Plasma membrane metabolism energy Acetylation 
P14868 Aspartate-tRNA ligase, cytoplasmic [110]  1 (3.7) 0.44 (0.05) DARS Cytoplasm Metabolism energy Acetylation/ Glycoprotein 
P15880 40S ribosomal protein S2  [110]  1 (13.7) 0.45 (0.02) RPS2 Cytoplasm Protein metabolism Acetylation 
P16189 HLA class I histocompatibility antigen, A-31 
alpha chain 
[249]  4 (11) 0.58 (0.00) HLA-A Plasma membrane Signal transduction Glycoprotein 
P17844 Probable ATP-dependent RNA helicase 
DDX5 
[110]  1 (1.8) 0.44 (0.03) DDX5 Nucleus Nucliec acid 
metabolism 
Acetylation 
P19338 Nucleolin [153]  2 (7.4) 0.65 (0.04) NCL Plasma membrane RNA Binding Acetylation 
P20073 Annexin A7  [245]  2 (10) 0.45 (0.00) ANXA7 Plasma membrane Transport Acetylation 
P20700 Lamin-B1  [250]  6 (11.1) 0.29 (0.02) LMNB1 Plasma membrane Cell growth Prenylation/ Acetylation/ 
Lipoprotein 
P23396 40S ribosomal protein S3  [110]  2 (9.1) 0.55 (0.00) RPS3 Plasma membrane Protein metabolism Acetylation 
P23528 Cofilin-1  [110]  1 (10.2) 0.50 (0.05) CFL1 Plasma membrane Signal transduction Acetylation 
P25705 ATP synthase subunit alpha [110]  17 (32.4) 0.40 (0.00) ATP5A1 Plasma membrane Transport Acetylation 
P26038 Moesin [110]  3 (8.8) 0.63 (0.03) MSN Plasma membrane Cell growth Acetylation 
P26641 Elongation factor 1-gamma [153]  1 (14.6) 0.42 (0.01) EEF1G Cytoplasm Protein metabolism Acetylation 
P27487 Dipeptidyl peptidase 4  [153]  1 (1.3) 0.26 (0.05) DPP4 Plasma membrane Signal transduction Glycoprotein 
P29966 Myristoylated alanine-rich C-kinase substrate [153]  1 (7.8) 0.39 (0.02) MARCKS Plasma membrane Cell growth Myristate/ Lipoprotein 
P31146 Coronin-1A  [110]  1 (6.9) 0.54 (0.00) CORO1A Plasma membrane Immune response Acetylation 
P32119 Peroxiredoxin-2 [110]  1 (4.4) 0.63 (0.04) PRDX2 Plasma membrane metabolism energy Acetylation 
P35579 Myosin-9  [249]  6 (5.8) 0.73 (0.05) MYH9 Plasma membrane Cell growth Acetylation, GPI-Anchored 
P35611 Alpha-adducin  [110]  1 (2) 0.23 (0.00) ADD1 Plasma membrane Signal transduction Acetylation 
P35908 Keratin, type II cytoskeletal 2 epidermal  [110]  9 (19.5) 0.55 (0.05) KRT2 Cytoplasm Cell growth Phosphoprotein 
P36578 60S ribosomal protein L4  [110]  1 (3.7) 0.32 (0.00) RPL4 Ribosome Protein metabolism Acetylation 
P40926 Malate dehydrogenase  [110]  15 (47.2) 0.51 (0.05) MDH2 Plasma membrane metabolism energy Acetylation 
P42766 60S ribosomal protein L35 [110]  1 (13) 0.61 (0.02) RPL35 Ribosome Protein metabolism Acetylation 
P46940 Ras GTPase-activating-like protein IQGAP1  [153]  2 (4.7) 0.34 (0.03) IQGAP1 Plasma membrane Signal transduction Acetylation, lipid anchor 
P50991 T-complex protein 1 subunit delta  [110]  1 (2.4) 0.43 (0.00) CCT4 Cytoplasm Protein metabolism Acetylation 
P51572 B-cell receptor-associated protein 31  [110]  1 (3.7) 0.39 (0.01) BCAP31 Plasma membrane Signal transduction  
P52803 Ephrin-A5  [153]  3 (10.5) 0.49 (0.05) EFNA5 Plasma membrane Signal transduction Lipoprotein/ Glycoprotein/ GPI- 
Anchored 
P52907 F-actin-capping protein subunit alpha-1 [243]  3 (18.5) 0.35 (0.04) CAPZA1 Cytoplasm Protein metabolism Acetylation 
P55084 Trifunctional enzyme subunit beta [153]  1 (1.9) 0.45 (0.01) HADHB Plasma membrane Lipid metabolism Acetylation 
P55884 Eukaryotic translation initiation factor 3 
subunit B  
[251]  1 (1.2) 0.55 (0.02) EIF3B Cytoplasm Protein modification Acetylation 
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P60842 Eukaryotic initiation factor 4A-I [110]  2 (9.4) 0.49 (0.02) EIF4A1 Cytoplasm Signal transduction Acetylation 
P60866 40S ribosomal protein S20  [110]  1 (16.8) 0.46 (0.00) RPS20 Ribosome Protein metabolism Acetylation 
P62070 Ras-related protein R-Ras2  [153]  1 (5.9) 0.17 (0.00) RRAS2 Plasma membrane Signal transduction Prenylation/ Acetylation/ 
Palmitate/ Lipoprotein 
P62136 Serine/threonine-protein phosphatase PP1-
alpha catalytic subunit 
[110]  3 (10) 0.40 (0.04) PPP1CA Cytoplasm Cell proliferation Acetylation 
P62158 Calmodulin [110]  3 (22.5) 0.30 (0.03) CALM3 Plasma membrane Signal transduction Acetylation 
P62241 40S ribosomal protein S8  [153]  1 (6.3) 0.44 (0.00) RPS8 Ribosome Protein modification S-Nitrosylation 
P62249 40S ribosomal protein S16  [153]  2 (21.2) 0.50 (0.02) RPS16 Ribosome Protein metabolism Acetylation 
P62263 40S ribosomal protein S14 [110]  2 (20.5) 0.50 (0.01) RPS14 Ribosome Protein metabolism Phosphoprotein 
P62280 40S ribosomal protein S11  [110]  1 (11.4) 0.36 (0.01) RPS11 Plasma membrane Protein modification Acetylation/ Palmitate/ 
Lipoprotein 
P62701 40S ribosomal protein S4, X isoform  [110]  2 (8) 0.54 (0.02) RPS4X Ribosome Protein metabolism Acetylation 
P62834 Ras-related protein Rap-1A  [243]  2 (13.6) 0.40 (0.00) RAP1A Plasma membrane Signal transduction Prenylation/ Lipoprotein 
P62873 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1  
[153]  3 (10.3) 0.29 (0.05) GNB1 Plasma membrane Signal transduction Acetylation, lipid anchor 
P62879 Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2  
[153]  3 (10.3) 0.20 (0.04) GNB2 Plasma membrane Signal transduction Acetylation, lipid anchor 
P63000 Ras-related C3 botulinum toxin substrate 1  [153]  1 (6.3) 0.51 (0.05) RAC1 Plasma membrane Signal transduction Prenylation/ Lipoprotein 
P63104 14-3-3 protein zeta/delta  [153]  2 (10.2) 0.50 (0.05) YWHAZ Plasma membrane Signal transduction Acetylation 
P63244 Guanine nucleotide-binding protein subunit 
beta-2-like 1  
[110]  1 (5) 0.59 (0.02) GNB2L1 Plasma membrane Signal transduction Acetylation, lipid anchor 
P63261 Actin, cytoplasmic 2 [110]  70 (65.5) 0.18 (0.05) ACTG1 Plasma membrane Cell growth Acetylation 
P69905 Hemoglobin subunit alpha  [110]  2 10.6) 0.34 (0.02) HBA1 Plasma membrane Transport Glycation 
P80723 Brain acid soluble protein 1  [252]  4 (41.9) 0.13 (0.04) BASP1 Plasma membrane Cell growth Myristate/ Lipoprotein 
P82909 28S ribosomal protein S36 [153]  1 (12.6) 0.20 (0.00) MRPS36 Mito Protein metabolism Phosphoprotein 
Q00610 Clathrin heavy chain 1  [242]  1 (1.9) 0.70 (0.05) CLTC Plasma membrane Transport Acetylation 
Q01082 Spectrin beta chain, brain 1  [242]  82 (32.7) 0.13 (0.00) SPTBN1 Plasma membrane Signal transduction Acetylation/ Glycoprotein 
Q01629 Interferon-induced transmembrane protein 2 [253]  3 (12.1) 0.50 (0.05) IFITM2 Plasma membrane Signal transduction Lipoprotein/ Palmitate 
Q06830 Peroxiredoxin-1  [110]  3 (15.1) 0.59 (0.02) PRDX1 Cytoplasm metabolism energy Acetylation 
Q0QEN7 ATP synthase subunit beta  [110]  1 (9.9) 0.48 (0.01) ATP5B Plasma membrane Transport Acetylation 
Q10589 Bone marrow stromal antigen 2 [153]  4 (11.6) 0.70 (0.04) BST2 Plasma membrane Signal transduction Lipoprotein/ Glycoprotein/ GPI- 
Anchored 
Q13442 28 kDa heat- and acid-stable phosphoprotein  [110]  1 (7.7) 0.35 (0.05) PDAP1 Extraceluar Signal transduction Acetylation 
Q13813 Spectrin alpha chain, brain  [242]  92 (34) 0.16 (0.00) SPTAN1 Plasma membrane Cell growth Acetylation 
Q14254 Flotillin-2  [242]  5 (21.4) 0.43 (0.03) FLOT2 Plasma membrane Signal transduction Myristate/ Palmitate 
Q14699 Raftlin  [249]  13 (22.3) 0.38 (0.05) RFTN1 Plasma membrane Cell growth Myristate/ Palmitate/ Lipoprotein 
Q15046 Lysyl-tRNA synthetase  [110]  1 (1.8) 0.45 (0.00) KARS Plasma membrane  Acetylation 
Q15149 Plectin-1 [153]  4 (3.6) 0.14 (0.04) PLEC Plasma membrane Cell growth Acetylation 
Q15286 Ras-related protein Rab-35  [110]  1 (8.5) 0.43 (0.02) RAB35 Plasma membrane Signal transduction Acetylation/ Lipoprotein 
Q15691 Microtubule-associated protein RP/EB family 
member 1  
[110]  1 (6.7) 0.53 (0.02) MAPRE1 Plasma membrane Signal transduction Acetylation 
Q16643 Drebrin  [243]  4 (10.5) 0.23 (0.01) DBN1 Plasma membrane Cell growth Acetylation 
Q32Q12 Nucleoside diphosphate kinase  [110]  1 (17.1) 0.41 (0.01) NME1-
NME2 
Plasma membrane Signal transduction Acetylation 
Q53HC3 Solute carrier family 25 member 3 isoform b 
variant  
[110]  1 (8.5) 0.46 (0.04) SLC25A3 Plasma membrane Transport Acetylation 
Q53HF2 Heat shock 70kDa protein 8 isoform 2 variant  [110]  8 (16.6) 0.62 (0.00) HSPA8 Plasma membrane Signal transduction Acetylation 
Q53HM8 Annexin VII isoform 1 variant  [245]  2 (10.5) 0.45 (0.01) ANXA7 Plasma membrane Signal transduction Acetylation 
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Q53QU3 Septin 2  [110]  1 (3.5) 0.63 (0.05) Sep-02 Plasma membrane Cell cycle Acetylation 
Q53YE8 Proteasome subunit alpha type  [110]  1 (4.2) 0.50 (0.03) PSMA1 Cytoplasm Protein metabolism Acetylation 
Q58I18 Na+/K+ transporting ATPase beta 3 
polypeptide  
[153]  1 (13.1) 0.45 (0.01) ATP1B3 Plasma membrane Transport glycosylation 
Q59EQ2 14-3-3 Beta [153]  1 (11.6) 0.67 (0.03) YWHAB Cytoplasm Signal transduction Acetylation 
Q59FE8 Epithelial protein lost in neoplasm beta 
variant 
[110]  4 (8.3) 0.19 (0.01) LIMA1 Cytoplasm Cell growth Phosphoprotein 
Q5TBN4 Lymphocyte cytosolic protein 1 (L-plastin) [110]  38 (47.2) 0.40 (0.00) LCP1 Plasma membrane Signal transduction Acetylation 
Q5TCU6 Talin 1  [153]  1 (3.1) 0.67 (0.05) TLN1 Plasma membrane Cell growth Acetylation 
Q63HR1 Putative uncharacterized protein 
DKFZp686P17171 
[110]  4 (13.2) 0.59 (0.02) SERBP1 Cytoplasm Protein metabolism Acetylation 
Q6B6N3 Galphai2 protein  [110]  9 (29.8) 0.20 (0.05) GNAI2 Plasma membrane Signal transduction GTP Binding 
Q6IPT9 Elongation factor 1-alpha  [153]  24 (35.5) 0.42 (0.00) EEF1A1 Cytoplasm Protein metabolism Acetylation 
Q6NUR7 Ezrin  [249]  2 (8) 0.47 (0.03) EZR Plasma membrane Cell shape Acetylation 
Q6NZX3 5'-nucleotidase, ecto (CD73)  [153]  8 (21.6) 0.61 (0.03) NT5E Plasma membrane Regulation of 
nucleobase 
N-Glycosylation 
Q6PUJ7 Prohibitin  [243]  7 (28.7) 0.56 (0.02) PHB Plasma membrane Signal transduction Acetylation 
Q6U2E9 Complement C4-B alpha chain [153]  2 (2) 0.40 (0.03) C4B Extracelluar Immune response Glycoprotein 
Q6YJU6 HLA class II histocompatibility antigen, DR 
beta 3 chain 
[254]  13(37.2) 0.51 (0.02) HLA-DRB5 Plasma membrane Signal transduction Glycoprotein 
Q768U4 HLA class II histocompatibility antigen, 
DRB1-12 beta chain 
[254]  6 (53.9) 0.50 (0.03) HLA-DRB5 Plasma membrane Signal transduction Glycoprotein 
Q7Z6A9 B- and T-lymphocyte attenuator, CD272 [255]  1 (3.5) 0.51 (0.03) BTLA Plasma membrane Immune response Glycoprotein 
Q86V81 THO complex subunit 4  [110]  1 (7.4) 0.47 (0.03) THOC4 Cytoplasm Transport Acetylation 
Q8IYB3 Serine/arginine repetitive matrix protein 1 [110]  3 (4.4) 0.25 (0.01) SRRM1 Cytoplasm RNA Binding Acetylation 
Q8N1C8 HSPA9 protein [110]  1 (4.7) 0.54 (0.03) HSPA9 Plasma membrane Signal transduction Acetylation 
Q8N836 Gene_Symbol=LOC349114 cDNA FLJ40085 
fis, clone TESTI2002993 
  1 (4.6) 0.40 (0.03) LOC349114 Plasma membrane Signal transduction  
Q92835 Phosphatidylinositol-3,4,5-trisphosphate 5-
phosphatase 1 
[256]  1 (1.4) 0.40 (0.05) INPP5D Plasma membrane Signal transduction Acetylation 
Q93020 GTP-binding regulatory protein Gi alpha-2 
chain 
[110]  5 (34.5) 0.33 (0.00) WUGSC:H_L
UCA16.1 
Plasma membrane Signal transduction GTP Binding 
Q99623 Prohibitin-2  [110]  6 (23.4) 0.59 (0.01) PHB2 Plasma membrane Signal transduction Acetylation 
Q99720 Sigma 1-type opioid receptor  [153]  1 (5.8) 0.74 (0.01) SIGMAR1 Plasma membrane Signal transduction  
Q99805 Transmembrane 9 superfamily member 2 [249]  1 (2.1) 0.36 (0.02) TM9SF2 Plasma membrane Transport Phosphoprotein 
Q9BRW0 CD58 protein  [153]  2 (4.2) 0.71 (0.05) CD58 Plasma membrane Signal transduction Lipoprotein/ Glycoprotein/ GPI- 
Anchored 
Q9BSQ6 RPL13A protein  [110]  1 (4.5) 0.49 (0.02) RPL13A Ribosome Protein metabolism Acetylation 
Q9BX83 Hemoglobin alpha 1 globin chain  [110]  2 (15) 0.34 (0.02) HBA2 Plasma membrane Transport Glycoprotein, lipid anchor 
Q9GIP0 MHC class I antigen  [110]  4 (14.7) 0.54 (0.02) HLA-A Plasma membrane Immune response Phosphoprotein 
Q9GZY6 Linker for activation of T-cells family 
member 2 
[257]  1 (14.4) 0.43 (0.00) LAT2 Plasma membrane Signal transduction Palmitate/Lipoprotein 
Q9H5A7 CD44 molecule (Indian blood group)  [110]  2 (4.6) 0.66 (0.01) CD44 Plasma membrane Signal transduction Glycoprotein 
Q9HBB3 60S ribosomal protein L6  [110]  3 (24.9) 0.51 (0.01) RPL6 Ribosome Protein metabolism Acetylation 
Q9NYL9 Tropomodulin-3  [153]  2 (8.5) 0.46 (0.00) TMOD3 Cytoplasm Protein metabolism Phosphoprotein 
Q9TQD6 MHC class II antigen HLA-DR12  [254]  7 (32.7) 0.44 (0.03) HLA-DR-
beta1 
Plasma membrane Signal transduction  
Q9UHB6 LIM domain and actin-binding protein 1 [110]  4 (8.7) 0.20 (0.01) LIMA1 Plasma membrane Cell growth Phosphoprotein 
Q9UIP6 Leucocyte antigen B  [110]  3 (15.2) 0.59 (0.02) HLA-B Plasma membrane Signal transduction N-Glycosylation 
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Q9UQM7 Calcium/calmodulin-dependent protein 
kinase type II alpha chain  
[242]  1 (2.5) 0.32 (0.03) CAMK2A Plasma membrane Signal transduction Phosphoprotein 
Q9Y277 Voltage-dependent anion-selective channel 
protein 3  
[110]  1 (7.1) 0.52 (0.05) VDAC3 Plasma membrane Transport Acetylation 
Q9Y2D5 A-kinase anchor protein 2 [110]  11 (13) 0.25 (0.00) AKAP2 Plasma membrane Protein metabolism Phosphoprotein 
Q9Y4L1 Hypoxia up-regulated protein 1  [153]  1 (1.9) 0.70 (0.05) HYOU1 Plasma membrane Signal transduction Glycoprotein 
Q9Y6M4 Casein kinase I isoform gamma-3  [153]  3 (7.6) 0.48 (0.00) CSNK1G3 Cytoplasm Signal transduction Phosphoprotein 
 
i  Accession numbers of proteins were from the UniProtKB/Swiss-Prot database.  
ii
 Number of peptides identified with >95% confidence.  
iii  Protein sequence coverage. 
iv  The fold-change and the p-value of depleted proteins after MβCD treatment. 
v, vi, vii Sub-cellular location, biological process and post-translational modification were obtained from the Human Protein Reference Database (http://www.hprd.org/).
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Chapter 4 
4 Proteome analysis of B-CLL cells treated with rituximab 
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4.1 Introduction 
CD antigens are potential targets for treatment of B-cell lymphoproliferative disorders (B-
LPD) with therapeutic antibodies. For example, antibodies against CD20 (rituximab, 
Mabthera), CD52 (alemtuzumab; Campath-1H) and CD80 (galiximab) are effective for 
treatment of some B-LPD such as B-cell chronic lymphocytic leukaemia (B-CLL) and Non-
Hodgkins lymphoma [22, 23]. Many of the antigens aberrantly expressed on B-CLL cells 
appear to be localized or translocated to LRs, where they may carry out abnormal functions 
[107]. This membrane domain is also an important binding site for therapeutic antibodies 
(e.g., anti-CD20 rituximab) used to treat B-CLL patients [69]. The anti-CD20 mono-
therapeutic antibody rituximab binds CD20 on B-CLL cells resulting in translocation of the 
CD20-rituximab complex into LRs [70]. This movement results in increases of intracellular 
Ca2+ levels and downstream apoptotic signalling [69]. 
Despite its widespread clinical use, the mechanisms by which some tumor cells survive after 
rituximab treatment remain unclear. Identification of differentially abundant proteins in whole 
cell lysates and LRs and cell surface, sub-proteomes of B-CLL cells treated with rituximab 
will improve our understanding of the mechanisms by which rituximab functions. 
Furthermore, this may lead to improvements in B-CLL treatment. 
To identify and quantify proteins in LRs, a previously described (Section 2.3.7) sucrose 
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gradient ultra-centrifugation method was used to isolate LRs from MEC1 cells, a B-CLL cell 
line. Significant changes in protein abundances were identified in the LRs isolated from cells 
before and after rituximab treatment using iTRAQ-labelling coupled to 2DLC-MS/MS. In 
addition we identified and quantified the proteins differentially abundant in whole cell lysates 
before and after rituximab treatment using iTRAQ-labelling coupled to 2DLC-MS/MS. We 
also investigated the changes at the cell surface using DotScan™ microarrays and flow 
cytometry before and after rituximab treatment.  
When rituximab binds to CD20 at the cell surface, CD20 translocates to the LRs, increases 21 
and decreases 10 proteins in the LRs, increases 4 and decreases 14 CD antigens at the cell 
surface, and increases 10 and decreases 5 proteins in whole cell lysates. To identify the 
signalling pathways affected by rituximab, differentially abundant cellular proteins (± 
rituximab) were subjected to the ingenuity pathway analysis (IPA) to identify the biological 
mechanisms, pathways, and functions most relevant to these proteins affected by rituximab. 
Additional proteins from the proposed pathways were examined by immunoblotting to 
investigate their potential differential expression in the two cell lines MEC1 and Raji. MEC1 
cells are resistant to rituximab, whereas, Raji cells are rituximab-responsive. Raji cells were 
used to investigate the rituximab effect in a sensitive B-lymphoid cell line compared to MEC1 
cells. 
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4.2 Methods 
4.2.1 Growth of MEC1 cells and drug treatment 
Human MEC1 CLL cells (American Type Culture Collection 204508/S288c, Manassas, VA, 
USA) were grown at 37oC in RPMI 1640 medium (Hepes modification; Sigma Aldrich, St. 
Louis, MO, USA) supplemented with 10% fetal calf serum and gentamicin in a non-
humidified incubator. Cultures of MEC1 cells were grown in triplicate and treated with 
rituximab at various concentrations (1, 10, 100 µg/mL, Roche, Basel, Switzerland) for 24 h at 
37 oC. Following treatment, cells were harvested by centrifugation (350 xg, 5 min, 22°C) for 
apoptosis assays (described in Section 2.3.6), preparation of whole cell lysates, LRs isolation 
(described in Section 2.3.7), antibody microarray and flowcytometric analyses.   
4.2.2 Lipid rafts proteins collection, digestion and peptide fractionation  
LRs fractions were collected and purified using a 3 kDa cut-off filter (Millipore). The samples 
were digested and the peptides were labelled with iTRAQ 4-plex (Section 2.3.11) as follows: 
untreated sample 1, 114; treated with 1 µg rituximab sample 2, 115; treated with 10 µg 
rituximab sample 3, 116; treated with 100 µg rituximab sample 4, 117 (Table 4.1). The 
resulted peptides were fractioned into 7 fractions then eluted into an connected Agilent 1100 
HPLC system interfaced with a QSTAR Elite mass spectrometer (AB SCIEX, Foster City, 
CA, USA) as described in Section 2.3.13. The data were then analysed as in Section 2.3.14. 
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Table 4.1: iTRAQ labelling plan for samples 
MEC1 
iTRAQ 
Rituximab treatment/ 
isolated lipid raft 
(SET1) 
Rituximab 
treatment/Total cell 
lysate (SET2) 
114 Untreated MEC1 Untreated MEC1 
115 1 µg/ml rituximab 1 µg/ml rituximab 
116 10 µg/ml rituximab 10 µg/ml rituximab 
117 100 µg/ml rituximab 100 µg/ml rituximab 
4.2.3 Preparation of lysates of MEC1 cells for protein identifications  
Cells were lysed in cold MN buffer (25 mM morpho-linoethane sulfonic acid (MES) pH 6.5, 
150 mM NaCl, 1% Na2VO4 and 1% protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, 
Australia) supplemented with 1% Triton X-100 (Sigma-Aldrich). After 30 min on ice, the 
lysate was homogenised for 10 strokes and centrifuged  (800 xg, 10 min, 4 °C). The 
supernatant was transferred to a new tube and the proteins (20 µg) were digested and labelled 
as previously described (Section 2.3.11) with iTRAQ 4-plex as follows: untreated sample 1, 
114; treated with 1 µg rituximab sample 2, 115; treated with 10 µg rituximab sample 3, 116; 
treated with 100 µg rituximab sample 4, 117 (Table 4.1). After labelling, samples were 
combined prior to analysis. Samples were cleaned up using iCAT (AB SCIEX, Foster City, 
CA, USA) and HLB columns (Waters, Rydalmere, Australia) following the manufacturer’s 
instructions. 
Prior to MS analysis, peptides were separated using a strong cation-exchange column 
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(ZORBAX Bio-SCX series II, 3.5 mm, 50 x 0.8 mm, Agilent, Palo Alto, CA, USA) on an 
1100 HPLC system (Agilent, Palo Alto, CA, USA) in off-line mode (Section 2.3.12). The 
SCX fractions were analysed using an Agilent 1100 HPLC system interfaced with a QSTAR 
Elite mass spectrometer (AB SCIEX, Foster City, CA, USA) and the data were analysed as in 
Section 2.3.14. Only proteins identified with at least 95% confidence and an unused Protein 
Score >1.3 were reported. Relative peptide abundances were determined using the MS/MS 
scans of iTRAQ-labelled peptides, where the ratios of peak areas of the iTRAQ reporter ions 
reflect the relative abundances of the peptides and therefore, the proteins in the samples. 
4.2.4 DotScan™ CD antibody microarrays  
MEC1 cells were collected by centrifugation (400 x g, 5 min, RT), washed and re-suspended 
at a density of 1x107 cells/mL in PBS. Cell suspensions (300 µL) were incubated on 
DotScan™ antibody microarrays (Medsaic Pty Ltd, Australia) for 40 min at 37 °C. The 
unbound cells were carefully washed off with fixative solution (4% (v/v) formaldehyde in 
PBS). The microarrays were then fixed for 20 min in the fixative, washed again in PBS before 
scanning. Dot intensities of cells captured on microarrays were quantified and analysed using 
a Medsaic Dot ReaderTM and DotScanTM software (Medsaic Pty Ltd). 
4.2.5 Flow cytometry 
MEC1 cells (4x105) were treated with 10 µg of rituximab for 24 h at 37°C, then washed 3 
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times in PBS and centrifuged (350 x g, 3 min, RT). The MEC1 surface was blocked with 
FACS buffer (0.1% BSA, 0.05% NaN3 in PBS). The cells were then washed and aliquoted in 
100 µL of FACS buffer. Cells (0.5 x 106, 100 µL) were incubated with 20 µL monoclonal 
antibodies conjugated to the fluorochrome phycoerythrin (PE) or fluorescein isothiocyanate 
(FITC) for 30 min at 4°C in the dark. An unstained control and a negative control (with 
isotype antibody) were used with each sample. Labelled cells were washed and resuspended 
in FACS buffer. Samples were analysed using a FACSCalibur flow cytometer (BD 
Biosciences, San Diego, CA, USA) with a 488-nm air-cooled argon-ion laser, running 
CellQuest™ Pro software, Version 5.2 (BD Biosciences, San Diego, CA, USA). 
4.2.6 Immunohistochemistry 
MEC1 cells were treated with rituximab (10 µg, 24 h) and fixed with 3.7% paraformaldehyde 
(PFA) on microscope slide overnight, then washed with water for 5 min at room temperature. 
F actin was labeled with Alexa Fluor 594 phalloidin for 30 min in (0.2% Triton X-100 and 
blocking buffer (1% BSA, 2% FBS in 10 mM MES buffer, 1.5 M NaCL, 50 mM EGTA, 50 
mM MgCL2 and 50 mM glucose, PH 6.1)). Lipid rafts were labeled with Vybrant Alexa Fluor 
488 Lipid Raft Labeling Kit (Invitrogen, Australia) following the manufacturer’s instructions. 
Nuclei were labeled using DAPI in blocking buffer for 1 min at RT. Cells were washed with 
1X PBS and then viewed with an Olympus BX51 fluorescence microscope. 
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4.2.7 Pathway analysis 
A list of differentially abundant proteins (Tables 4.3, 4.4 and 4.5) in MEC1 cells after 
rituximab treatment was uploaded to the Ingenuity Pathway Analysis (IPA) software to 
investigate the biological and canonical functions associated with these proteins 
(http://www.ingenuity.com). This pathway analytical tool uses a database derived from the 
scientific literature to relate genes or proteins based on their interactions and functions. IPA 
generates biological networks, canonical pathways and functions relevant to the uploaded 
dataset. IPA calculated the probability that the genes associated with our data set (identified 
proteins) are involved in particular cellular pathways. Significance values are calculated using 
the right-tailed Fisher’s Exact Test by comparing the number of proteins that occur in a given 
pathway relative to the total number of occurrences of those proteins in all functional 
annotations stored in the Ingenuity Data Base. Each of these pathways is scored and ranked 
for the enrichment of regulated genes/proteins in a particular pathway over competing 
pathways. These scores, derived from p-values, indicate the likelihood that focus genes 
belong to a network versus those obtained by chance. A score >2 indicates a ≥ 99% 
confidence that a focus gene network was not generated by chance alone. 
4.2.8 Western blot analysis 
Cells were treated with rituximab (10 µg/mL, Roche, Basel, Switzerland) for 24 h at 37 oC 
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then were lysed in cold MN buffer (25 mM morpholino ethane sulfonic acid (MES) pH 6.5, 
150 mM NaCl, 1% Na2VO4 and 1% protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, 
Australia) supplemented with 1% Triton X-100 (Sigma-Aldrich). After 30 min on ice, the 
lysate was passed through a 26-gauge needle 10 times and centrifuged (10,000 xg, 10 min, 
4°C). Protein samples were separated by 10% SDS-PAGE, and transferred to a PVDF 
membrane (Immun-Blot™ PVDF Membrane, Bio-Rad Laboratories, Hercules, USA). After 
blocking with 5% skim milk in TBST, the membranes were incubated (4°C, 16 h) with rabbit 
monoclonal antibodies against p-STAT3 (dilution of 1:3,000 in TBST) and YY1 (dilution of 
1:2,000 in TBST) or mouse monoclonal antibody against STAT3 (dilution of 1:2,000 in 2% 
(w/v) BSA in TBST)  (Cell Signalling Technology, Danvers, USA) and actin (dilution of 
1:3,300 in TBST)  (Abcam, Cambridge, USA), followed by incubation (1 h, room 
temperature) with a horse radish peroxidase (HRP)-conjugated secondary antibody: goat-anti-
mouse-HRP (dilution of 1:12,000 in TBST) (Santa Cruz Biotechnology Inc, Santa Cruz, 
USA) or donkey-anti-rabbit-HRP (dilution of 1:6,000 in TBST) (Abcam, Cambridge, USA). 
Proteins were visualized using a Rapid Step ECL Reagent (Merck, Kilsyth, Australia) and 
ECL chemiluminescence film (GE Healthcare, Piscataway, NJ, USA). 
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4.3 Results 
4.3.1 Effects of rituximab on lipid rafts of MEC1 cells 
To gain an insight into the dynamics of LRs induced by rituximab treatment, a comparative 
proteomic analysis was performed of purified LRs from MEC1 cells treated with rituximab 
(1, 10 and 100 µg/mL) with a control. The LRs and associated proteins were isolated from the 
5-30% sucrose interface, purified and quantified after iTRAQ labeling using 2D-LCMS/MS 
and analysed using Protein Pilot V3.0. The changes in protein levels were dose-dependent; at 
100 µg/mL of rituximab 95% of protein changes were significant (p<0.05), compared to 78% 
at 10 µg/mL and 60% at 1 µg/mL. Some of proteins levels were unchanged or even decreased 
at 1 µg/mL treatment, and then their levels were increased at 10 and 100 µg/mL treatments, 
such as, lamin-B1, melanotransferrin, FLOT1 and calmodulin 2. Whereas, other protein levels 
were gradually increased with increased levels of rituximab, For example, spectrin, actin, 
myosin-Ig and vimentin. Overall, 63 differentially abundant proteins (Table 4.2) were 
detected (p<0.05). Of these, 23 proteins had decreased and 40 had increased (Table 4.2). 
Classification using BIOMYN, Uniprot and HPRD, confined proteins were predominantly 
localised proteins to the plasma membrane (58%), cytoplasm (18%) and mitochondria 
(14.5%). They were involved in signal transduction (19.1%), cytoskeleton organization 
(9.5%), apoptosis (7.9%), transport (3.2%), protein metabolism (9.5%), immune/stress 
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response (23.8%), catalysis (7.9%), homeostatic processes (3.2%), protein polymerization 
(4.8%) and transport (3.2%; see Figure 4.1). 
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Table 4.2: The differential abundance of lipid raft proteins in MEC1 cells after treatment with rituximab (1, 10 and 100 µg/mL, 24 h; p < 0.05) as determined by 
LC-MS/MS analysis. In total, 63 proteins were detected and their fold-changes, biological processes, sub-cellular localizations and post-translational modifications, with 
those proteins that translocated to the LRs are indicated. 
Accession 
number (i) 
Name Gene name  Peptides 
(95% (ii)) 
1 µg/mL 
(iii) 
Pval 
(iv) 
10 µg/mL 
(iii) 
PVal 
(iv) 
100 µg/mL 
(iii) 
PVal 
(iv) 
Sub-cellular 
localisation (v) 
Biological process (vi) Post-
translational 
modification (vii) 
Moved 
into 
LR 
B0I1T2 Myosin-Ig MYO1G 33 5.15 0.00 5.97 0.00 14.19 0.00 Plasma membrane Signal transduction Phosphoprotein NO 
O14561 Acyl carrier protein, mitochondrial NDUFAB1 3 0.5 0.04 0.34 0.01 0.24 0.00 Mitochondria Protein lipoylation Acetylation OUT 
O43707 Alpha-actinin-4 ACTN4 9 3.77 0.00 3.44 0.00 6.14 0.00 Plasma membrane Response to stress/ Cytoskeleton Organization 
Acetylation/ Ubl 
conjugation NO 
O43920 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 5 
NDUFS5 5 0.36 0.03 0.36 0.03 0.17 0.01    - 
O75380 
NADH dehydrogenase 
[ubiquinone] iron-sulfur 
protein 6 
NDUFS6 5 0.34 0.03 0.48 0.04 0.20 0.01 Mitochondria Catalysis  - 
O96000 
NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex 
subunit 10 
NDUFB10 9 0.39 0.01 0.30 0.00 0.09 0.00 Mitochondria Catalysis Phosphoprotein - 
P00338 L-lactate dehydrogenase A chain LDHA 3 1.37 0.07 1.57 0.03 1.43 0.05 Cytoplasm Glycolisis Ubl conjugation YES 
P01871 Ig mu chain C region IGHM 6 3.84 0.07 3.84 0.06 7.38 0.03 Plasma membrane Immune response Glycoprotein IN 
P04233 HLA class II histocompatibility antigen gamma chain CD74 10 0.16 0.00 0.25 0.01 0.07 0.00 Plasma membrane Signal transduction 
Glycoprotein, 
GPI-Anchored NO 
P05023 Sodium/potassium-transporting ATPase subunit alpha-1 ATP1A1 8 2.11 0.06 2.91 0.01 4.92 0.00 Plasma membrane Sodium/potassium transport Phosphoprotein YES 
P06748 Nucleophosmin NPM1 3 1.33 0.18 1.36 0.11 1.53 0.06 Cytoplasm Response to Stress/ Cytoskeleton Organization 
Myristate/ 
Acetylation/ Ubl 
conjugation 
IN 
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P08582 Melanotransferrin, CD228 MFI2 4 0.81 0.66 0.97 0.97 2.63 0.05 Plasma membrane Homeostatic Process 
Lipoprotein/ GPI 
anchor/ 
Glycoprotein 
OUT 
P08670 Vimentin VIM 6 7.45 0.02 8.39 0.02 18.71 0.00 Plasma membrane Apoptosis Acetylation NO 
P08754 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 8 2.00 0.05 4.00 0.00 6.66 0.00 Plasma membrane 
Signal transduction/response 
to stress 
Myristate/ 
Palmitate/ 
Lipoprotein, lipid 
anchor 
NO 
P08758 Annexin A5 ANXA5 20 0.42 0.00 0.64 0.00 0.20 0.00 Plasma membrane Response to Stress Acetylation NO 
P0C0L4 Complement C4-A C4A 4 1.98 0.06 1.85 0.21 4.25 0.01 Extracelluar Immune response Glycoprotein YES 
P0CG48 Polyubiquitin-C UBC 5 1.42 0.03 1.78 0.00 1.88 0.00 Cytoplasm Response to Stress  Myristate - 
P11836 B-lymphocyte antigen CD20 MS4A1 19 33.11 0.00 49.66 0.00 47.86 0.00 Plasma membrane Immune response Phosphoprotein YES 
P13639 Elongation factor 2 EEF2 4 3.56 0.01 3.80 0.01 4.88 0.00 Cytoplasm Protein metabolism Acetylation/ Ubl conjugation NO 
P13645 Keratin, type I cytoskeletal 10 KRT10 5 0.70 0.09 0.24 0.00 0.21 0.00 Cytoplasm Keratinocyte differentiation Phosphoprotein - 
P13987 CD59 glycoprotein CD59 11 0.15 0.13 0.27 0.01 0.38 0.02 Plasma membrane Immune response/ Stress response 
Lipoprotein/ GPI 
anchor - 
P14618 Pyruvate kinase isozymes M1/M2 PKM2 5 2.42 0.04 3.40 0.01 3.63 0.01 Plasma membrane Apoptosis 
Acetylation/ Ubl 
conjugation NO 
P19474 E3 ubiquitin-protein ligase TRIM21 TRIM21 3 13.18 0.03 24.66 0.03 20.89 0.03 Cytoplasm Regulation of NF-kappaB Ubl conjugation OUT 
P20700 Lamin-B1 LMNB1 7 0.92 0.81 2.11 0.01 1.89 0.02 Plasma membrane Apoptosis 
Prenylation/ 
Acetylation/ 
Lipoprotein 
NO 
P26641 Elongation factor 1-gamma EEF1G 4 2.63 0.06 2.99 0.05 4.41 0.02 Cytoplasm Protein metabolism Acetylation NO 
P28288 ATP-binding cassette sub-family D member 3 ABCD3 4 1.96 0.34 3.53 0.05 3.60 0.03 Cytoplasm Transport 
Acetylation/Phosp
hoprotein YES 
P28331 NADH-ubiquinone oxidoreductase 75 kDa subunit NDUFS1 7 1.34 0.24 1.87 0.03 1.72 0.04 Mitochondria Apoptosis Acetylation YES 
P33241 Lymphocyte-specific protein 1 LSP1 28 2.8 0.00 2.9 0.00 2.9 0.00 Cell membrane Response to Stress Acetylation - 
P35579 Myosin-9 MYH9 5 5.01 0.00 5.81 0.00 12.25 0.00 Plasma membrane 
Actin cytoskeleton 
reorganization/ Cell 
Morphogenesis 
Acetylation, GPI-
Anchored/ Ubl 
conjugation 
NO 
P35613 Basigin, CD147 BSG 9 0.22 0.00 0.39 0.01 0.24 0.00 Plasma membrane Immune response/ Stress response Glycoprotein OUT 
P36578 60S ribosomal protein L4 RPL4 3 3.40 0.09 3.77 0.08 4.70 0.05 Ribosome Protein metabolism Acetylation IN 
P47756 F-actin-capping protein subunit beta CAPZB 4 2.29 0.13 2.56 0.10 4.09 0.05 Cytoplasm 
Respond to Stress/ 
Cytoskeleton Organization Acetylation IN 
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P47985 Cytochrome b-c1 complex subunit Rieske UQCRFS1 3 0.54 0.02 0.60 0.06 0.43 0.01 Mitochondria Catalysis  - 
P53985 Monocarboxylate transporter 1 SLC16A1 5 2.31 0.02 3.91 0.00 4.92 0.00 Plasma membrane Immune response/ Stress response Phosphoprotein YES 
P54709 Sodium/potassium-transporting ATPase subunit beta-3, CD 298 ATP1B3 9 0.32 0.00 0.46 0.04 0.36 0.01 Plasma membrane 
 Immune response/ Stress 
response Glycosylation IN 
P61421 V-type proton ATPase subunit d 1 ATP6V0D1 4 1.17 0.78 3.47 0.03 3.80 0.02 Plasma membrane 
Response to Stress/ 
Homeostatic Process Phosphoprotein YES 
P62158 calmodulin 2    CALM2 3 1.0 0.95 1.43 0.60 2.18 0.37 Cytoplasm Respond to Stress Acetylation - 
P63261 Actin, cytoplasmic 2 ACTG1 84 5.9 0.00 6.9 0.00 12.7 0.00 Plasma membrane Cytoskeleton Organization Acetylation NO 
Q01082 Spectrin beta chain, brain 1 SPTBN1 61 7.05 0.00 8.95 0.00 17.38 0.00 Plasma membrane 
Cell Morphogenesis / Signal 
transduction/ Cytoskeleton 
Organization 
Acetylation/ 
Glycoprotein NO 
Q07021 Complement component 1 Q subcomponent-binding protein C1QBP 6 0.45 0.02 0.38 0.00 0.03 0.00 
Plasma 
membrane/ 
Extracellular 
Immune response/ Stress 
response Acetylation - 
Q13813 Spectrin alpha chain, brain SPTAN1 61 5.97 0.00 7.45 0.00 14.06 0.00 Plasma membrane 
Cell Morphogenesis / 
Apoptosis/ Cytoskeleton 
Organization 
Acetylation NO 
Q14254 Flotillin-2 FLOT2 6 1.77 0.06 2.63 0.01 3.13 0.00 Plasma membrane Signal transduction/ Cell Adhesion 
Myristate/ 
Palmitate NO 
Q14699 Raftlin RFTN1 5 1.77 0.11 2.01 0.05 3.25 0.01 Plasma membrane 
Cell growth/lipid raft 
integrity and BCR signal 
transduction 
Myristate/ 
Palmitate/ 
Lipoprotein 
NO 
Q15149 Plectin-1 PLEC 5 2.33 0.69 4.83 0.26 11.38 0.02 Plasma membrane Apoptosis Acetylation IN 
Q53GA7 Tubulin alpha 6 variant TUBA1C 2 3.84 0.04 5.55 0.02 6.73 0.01 Cytoplasm Protein polymerization  OUT 
Q53HG1 13kDa differentiation-associated protein variant NDUFA12 5 0.48 0.02 0.55 0.02 0.46 0.01    - 
Q5H9R2 
NADH dehydrogenase 
[ubiquinone] 1 alpha 
subcomplex subunit 5 
NDUFA5 4 0.59 0.03 0.64 0.13 0.47 0.01 Mitochondria Catalysis  - 
Q5JWF2 
Guanine nucleotide-binding 
protein G(s) subunit alpha 
isoforms XLas 
GNAS 4 1.95 0.12 2.99 0.04 4.4 0.01 Cell membrane Signal transduction/ Homeostatic Process  - 
Q6FHM4 COX5B protein COX5B 7 0.40 0.03 0.34 0.01 0.20 0.00 Mitochondria Catalysis  - 
Q6IAA8 Ragulator complex protein LAMTOR1 C11orf59 14 0.55 0.05 0.43 0.01 0.35 0.01 Plasma membrane Homeostatic Process 
Myristate/ 
Lipoprotein - 
Q6IAZ2 CD48 protein CD48 12 0.21 0.00 0.27 0.01 0.35 0.02 Plasma membrane Signal transduction/ T cell activation 
GPI-anchored 
proteins - 
Q6IB58 FLOT1 protein FLOT1 7 1.00 0.70 1.65 0.02 2.10 0.00 Plasma membrane Cell growth Myristate/ Palmitate IN 
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Q6LC01 MRNA encoding beta-tubulin (from clone D-beta-1) TUBB 7 2.36 0.04 2.23 0.05 2.81 0.02 Plasma membrane Protein Polymerisation Acetylation NO 
Q8N5L9 Ribosomal protein S2 RPS2 6 1.43 0.23 1.71 0.10 2.33 0.03 Cytoplasm Protein metabolism Acetylation IN 
Q95IE3 HLA class II histocompatibility antigen, DRB1-12 beta chain HLA-DRB1 10 0.10 0.00 0.25 0.00 0.28 0.00 Plasma membrane Signal transduction 
Myristate/ 
Glycoprotein/ Ubl 
conjugation 
NO 
Q96SB3 Neurabin-2 PPP1R9B 8 2.70 0.00 2.10 0.03 2.55 0.01 Plasma membrane Signal transduction Acetylation IN 
Q9NX63 
Coiled-coil-helix-coiled-coil-
helix domain-containing protein 
3 
CHCHD3 6 0.40 0.01 0.51 0.04 0.3 0.00 Membrane Transcription regulation Acetylation/ Lipoprotein - 
Q9TQD6 
 
MHC class II antigen HLA-
DR12 HLA-DRB5 4 0.71 0.27 0.52 0.08 0.52 0.08 Plasma membrane Immune response  
 
- 
Q9UHA4 Ragulator complex protein LAMTOR3 LAMTOR3 6 0.41 0.04 0.41 0.04 0.29 0.01 
Peripheral 
membrane 
proteins 
MAPK signalling pathway  - 
Q9UJZ1 Stomatin-like protein 2 STOML2 3 0.53 0.20 0.43 0.13 0.09 0.03 Mitochondria Calcium homeostasis and cellular response to stress 
Acetylation/ 
Phosphoprotein OUT 
Q9UNM1 Chaperonin 10-related protein EPFP1 3 0.77 0.52 0.44 0.14 0.20 0.05 Mitochondria Protein folding  OUT 
Q9Y2D5 A-kinase anchor protein 2 AKAP2 7 2.99 0.03 2.49 0.15 4.29 0.01 Plasma membrane Protein metabolism Phosphoprotein NO 
i  Accession numbers of proteins were from the UniProtKB/Swiss-Prot database.  
ii
 Number of peptides identified with >95% confidence.  
iii  The fold-change  
iv the p-value of differentially abundant proteins after rrituximab treatment. 
v, vi, vii Sub-cellular location, biological process and post-translational modification were obtained from the Human Protein Reference Database (http://www.hprd.org/). 
  98 
 
Figure 4.1: The biological process of proteins identified in lipid rafts from MEC1 cells following rituximab 
treatment. The biological processes were annotated from the Human Protein Reference Database, PubMed and 
BioMyn.  
4.3.2 Effects of rituximab on cell surface profiles  
DotScan™ CD antibody microarrays were used to screen for changes of CD antigens on 
MEC1 cells induced by rituximab (10 µg/mL, 24 h). The fold-changes of CD antigens on 
treated cells compare to the control (n = 3) are shown in Table 4.3 (p<0.05). The level of 
CD22 increased 2.1-fold. Other antigen changes included CD19 (0.93-fold), CD20 (0.12-
fold), CD21 (0.84-fold), CD23 (0.8-fold), CD55 (0.74-fold), CD83 (0.3-fold), CD86 (0.81-
fold), CD 80 (0.53-fold), CD 29 (0.6-fold), CD 45RA (0.76-fold), CD 54 (0.73-fold), CD 62L 
(0.21-fold), CD69 (0.11-fold), CD83 (0.32-fold), CD53 (0.16-fold), and CD44 (0.83-fold), 
Kappa immunoglobulin (0.43-fold), and surface immunoglobulin (sIg, 0.59-fold) decreased 
(p<0.05, Table 4.3). Other proteins were increased (CD72, 18.42-fold) or decreased CD32 
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Process, 3.2% 
Protein 
Polymerization, 
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Apoptosis, 7.9% 
Catalysis, 7.9% 
Protein 
Metabolism, 
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(0.25-fold), CD156c (0.45-fold), CD72 (18.42-fold), CD50 (0.4-fold), CD95 (0.72-fold) and 
HLA-DR (0.84-fold) but their expression was insignificant. 
 
Table 4.3: Differentially abundant CD antigens by microarray analysis of MEC1 cells treated with 
rituximab (10 µg/mL, 24 h; p < 0.05). The fold changes of identified proteins are indicated. The p-value was 
calculated using the Student's t test (n = 3). 
CD antigen Fold-change P value CD antigen Fold-change P value 
19 0.93 0.06 kappa 1/2 0.43 6.4E-05 
20 0.12 0.02 sIg 0.59 0.00 
22 2.10 0.01 29 0.60 0.00 
23 0.80 0.02 45RA 0.76 0.02 
55 0.74 0.02 83 0.32 0.01 
72 18.42 0.45 62L 0.21 0.03 
80 0.53 0.02 54 0.73 0.04 
86 0.81 0.05 69 0.11 0.03 
 
4.3.3 Validation of microarray analysis using flow cytometry 
To confirm the differential abundance of CD antigens on MEC1 cells after rituximab 
treatment, cells were again treated with rituximab (10 µg, 24 h) and CD antigens of interest 
were analysed by flow cytometry. CD antigens levels on the surface of MEC1 cells were 
determined using CellQuest Pro software (Becton Dickinson, San Jose, USA); median 
fluorescence intensities were used for calculation of fold-changes of CD antigen levels (drug 
treated)/(control). These results show that rituximab induces significant increases in CD72 
(11.5-fold), CD22 (1.12-fold), CD79a (1.2-fold) and CD181 (1.34-fold). Rituximab induces 
decreased levels of CD19 (0.52-fold), CD20 (0.25-fold), CD21 (0.58-fold), CD23 (0.55-fold), 
CD32 (0.11-fold), CD50 (0.79-fold), CD55 (0.9-fold), CD86 (0.93-fold), CD95 (0.79-fold), 
CD80 (0.81-fold) and CD156c (0.76-fold). In addition, rituximab significantly decreases 
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CD205 (0.67-fold), CD46 (0.85-fold) and CD120b (0.86-fold) (Table 4.4 and Figure 4.2). 
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Figure 4.2: Flow cytometry of CD antigens on MEC1 cells affected by rituximab. The results of DotScan analysis were confirmed for selected CD antigens by 
flow cytometry. The gray area represents untreated cells; the black line cells exposed to rituximab. The Figures are representative of 3 independent experiments.
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Table 4.4: Differentially abundant CD antigens on MEC1 cells after treatment with 10 µg rituximab 
assessed by flow cytometry. 
CD antigens FOLD-
CHANGE a 
P VALUE b CD 
antigens 
FOLD 
CHANGE a 
P VALUE b 
CD22 1.12 8.90E-05 CD120b 0.86 1.40E-05 
CD181 1.34 3.40E-04 CD205 0.67 2.30E-05 
CD80 0.81 1.40E-07 CD79a 1.20 0.05 
CD20 0.25 3.40E-07 CD32 0.11 1.42E-08 
CD19 0.52 6.10E-07 CD 21 0.58 0.00500 
CD72 11.54 1.10E-08 CD23 0.55 9.18E-06 
CD86 0.93 0.01 CD55 0.90 4.50E-05 
CD46 0.85 1.50E-06 CD95 0.79 0.014 
CD156c 
(ADAM10) 
0.76 1.29E-08 
CD50 0.79 6.70E-05 
 
a Fold-change calculated by dividing the median fluorescence intensity for the drug-treated sample by that for the control 
(Figure 4.2).  
b The p-value was calculated using the Student's t test (n = 3).  
4.3.4 Effects of rituximab at a cellular level 
2DLC-MS/MS analyses of MEC1 cells treated with rituximab (1, 10 and 100 µg/mL, 24 h), 
identified 1033 proteins, 15 differentially abundant proteins were identified in rituximab 
treated cells (Table 4.5, p<0.05). The changes in proteins levels were dose-dependent; at 100 
µg/mL of rituximab 80% of protein changes were significant (p<0.05) compare to a 73% at 10 
µg/mL and 80% at 1 µg/mL. Protein levels were gradually increased or decreased with 
increased rituximab concentrations, except for triosephosphate isomerase and alpha-enolase, 
their levels were increased between 1 and 10 µg/mL, and decrease at 100 µg/mL rituximab. 
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Of these, 10 proteins were increased and localized to specific cell compartments. Proteins 
from the plasma membrane are CLTC (2.4-fold), ENO1 (2.05-fold), RAC1 (2.6-fold), HLA-
DRB5 (20-fold) and F7 (6.1-fold), to the cytoplasm GAPDH (1.97-fold), MYH9 (2.12-fold) 
and TPI (9.8-fold), to the nucleus CSTP (3.19-fold) and to the ribosomes RPL10 (1.7-fold). 
These proteins function in signal transduction, stress response and cell death.  The other 5 
proteins were depleted and localized to the cytoplasm including, HSPA8 (0.81-fold) and 
PABPC1 (0.48-fold) or to nucleus, such as PARP1 (0.5-fold), NPM1 (0.5-fold) and SS-B 
(0.57-fold) and function in stress response, translation and tRNA modification. 
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Table 4.5: The differential abundance of total cell proteins from lysates of MEC1 cells after treatment with rituximab (1, 10 and 100 µg/mL, 24 h; p < 0.05) as 
determined by LC-MS/MS analysis. In total, 15 proteins were detected and their fold-changes, biological processes and sub-cellular localizations are shown. 
Accession 
no (i) 
Name Gene Name Peptides (95% (ii)) 
1 
µg/mL 
(iii) 
PVal 
115:114 
(iv) 
10 
µg/mL 
(iii) 
PVal 
116:114 
(iv) 
100 
µg/mL 
(iii) 
PVal 
117:114 
(iv) 
Sub-cellular localisation  
(v) 
Biological process 
(vi)  
P04080 Cystatin-B  CSTB 8 2.86 0.35 3.19 0.12 3.73 0.05 Cytoplasm/ Nucleus Regulation of apoptosis process 
P04406 Glyceraldehyde-3-phosphate dehydrogenase  GAPDH 69 2.33 0.01 1.97 0.03 3.10 0.00 Cytoplasm/ Nucleus Cell death 
P05455 Sjoegren syndrome type B antigen SSB 9 0.35 0.00 0.57 0.01 0.45 0.05 Nucleus tRNA modification 
P06733 Alpha-enolase  ENO1 42 1.80 0.00 2.05 0.00 1.31 0.22 Plasma membrane/    Cytoplasm 
P06748 Nucleophosmin 1 isoform 1  NPM1 23 0.42 0.00 0.50 0.00 0.61 0.05 Cytoplasm/ Nucleus 
Response to stress/ 
Signal transduction/ 
Aging 
P08709 Coagulation factor VII F7 4 5.80 0.03 6.10 0.03 5.70 0.33 Secreted Response to stress 
P09874 Poly (ADP-ribose) polymerase 1  PARP1 25 0.86 0.45 0.97 0.80 0.50 0.00 Nucleus Response to stress 
P11142 Heat shock cognate 71 kDa protein  HSPA8 89 0.52 0.01 0.81 0.29 0.64 0.03 Cytoplasm Response to stress 
P11940 Polyadenylate-binding protein 1 PABPC1 12 0.52 0.00 0.48 0.00 0.53 0.04 Cytoplasm/ Nucleus Translation 
P27635 60S ribosomal protein L10 RPL10 4 3.31 0.07 1.70 0.27 3.53 0.04 Ribosome Translation 
P35579 Myosin-9  MYH9 20 2.17 0.05 2.12 0.09 3.19 0.01 Cytoplasm 
Cell death /Signal 
transduction/ Immune 
response 
P60174 Triosephosphate isomerase  TPI 18 6.85 0.02 9.81 0.00 2.14 0.98 Cytoplasm Gluconeogenesis 
P63000 
Ras-related C3 botulinum toxin substrate 1 (Rho 
family, small GTP binding protein Rac1) (Ras-
related C3 botulinum toxin  
RAC1 4 1.5 0.03 2.6 0.02 2.0 0.03 Plasma membrane 
Cell death/ Response to 
stress/ Signal 
transduction 
Q00610 Clathrin heavy chain 1  CLTC 16 2.6 0.01 2.4 0.04 4.2 0.00 Plasma membrane Signal transduction 
Q9TQD6 MHC class II antigen HLA-DR12  HLA-DRB5 25 12.18 0.05 20.00 0.03 19.50 0.04 Plasma membrane Immune response 
i  Accession numbers of proteins were from the UniProtKB/Swiss-Prot database.  
ii
 Number of peptides identified with >95% confidence.  
iii  The fold-change  
iv the p-value of differentially abundant proteins after rrituximab treatment. 
v, vi Sub-cellular location and biological process were obtained from the Human Protein Reference Database (http://www.hprd.org/).
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4.3.5 Effects of rituximab on Raji cell 
To analyze the in vitro effects of rituximab on the cell density of raji cells, a dose-response 
study was conducted (Figure 4.3). Rituximab decreased cell density. Concentration (10 
µg/mL, 24 h) was chosen for subsequent studies. At this concentration, rituximab efficiently 
arrested growth of Raji cells (Figure 4.3).  
 
Figure 4.3: Effect of rituximab on Raji cells. Raji cells were treated with 0, 1, 10 and 100 µg/mL of rituximab 
for 24 h at 37°C. Cells density was determined using a hemocytometer with trypan blue. The figures are 
representative of three independent experiments.  
4.3.6 Networks induced by rituximab treatment 
IPA software was used to investigate the signaling pathways affected by rituximab treatment 
based on the differentially abundant proteins from LRs, the cell surface and total cell lysate 
with fold-changes of at least 1.25 (p < 0.05). The IPA Database was restricted to human 
immune, leukemia and lymphoma cells. The two top scoring networks showed overlap of 
transcriptional regulation or binding to Signal transducer and activator of transcription 3 
(STAT3). These networks had independent scores of 89 and 30, with 56 and 27 focus 
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molecules, and are involved in “cell death, necrosis, apoptosis and cell activation and 
proliferation” and “cell death and proliferation”, respectively. Of the 237 proteins in the 
merged network, 180 are involved in cell death, 95 in proliferation of blood cells, 94 in the 
cell activation, 155 in apoptosis and 152 in necrosis. A simplified merged network showing a 
focus on STAT3, c-Myc, cyclin D1 (CCND1), NFKB, PAX5, BCL2 and YY1 (Figure 4.4A 
and B). To simplify the IPA generated network in Figure 4.4 and to show proteins that change 
after rituximab treatment, a summary pathway was generated (Figure 6.1).  
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Figure 4.4: Ingenuity Pathway Analysis network of differentially abundant proteins induced by rituximab 
treatment of MEC1 cells. Networks based on proteins differentially abundant between MEC1 rituximab-treated 
versus MEC1 control A. (Table 4.4 and 4.5) with rituximab related and B. (Table 4.3, 4.3 and 4.5). Proteins in 
red represent increased abundance, and green decreased abundance. This merged protein functional network was 
generated by IPA software. Proteins with color shaded icons were detected in this study, other interacting 
proteins were identified in the IPA database. Protein−protein interactions are indicated by edges with single 
lines, proteins that affect another protein (by controlling expression) are indicated by arrows. Proteins are 
denoted by their gene names.  
 
 
B 
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4.3.7 Validation of differentially abundant proteins 
The relative abundances of key proteins identified by LC−MS/MS and predicted by IPA 
software were confirmed by Western blotting of whole cell extract from MEC1 and Raji 
(Figure 4.5). In the whole cell lysate, Western blotting for MEC1 confirmed increases in p-
STAT3 (1.67-fold, p < 0.05) and STAT3 (1.4-fold, p < 0.05) as well as YY1 (1.46-fold, p < 
0.05) following rituximab (10 µg, 24 h). Whereas, in Raji (a rituximab sensitive cell line 
[258], Figure 4.3) these proteins were down regulated p-STAT3 (-2.1-fold, p < 0.05) and 
STAT3 (-3.1-fold, p < 0.05) as well as YY1 (-1.45-fold, p < 0.05; Figure 4.5). 
 
Figure 4.5: Validation of differentially abundant proteins in MEC1 and Raji cell lines. Levels of MEC1 and 
Raji proteins affected by rituximab (10 µg, 24 h). (A) Western blots of the indicated proteins in MEC1 and Raji 
with actin as an internal control (n = 3), control (C) and treated (T). (B) Relative levels of differentially abundant 
proteins after rituximab. Relative band intensities were detected using ImageJ software. The density of each 
band was normalized against that of β-actin. Results are shown as ratios of biological triplicates relative to controls 
(actin), error bars represent mean ± standard deviation (n = 3). 
4.4 Discussion 
Rituximab is a valuable drug for treating B-cell malignancies, but it is not effective for all 
patients. Development of resistance to therapy is common. Therefore, understanding the 
mechanisms of action would improve its use with patients. Changes in the protein content of 
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the LRs after rituximab treatment have been determined for the cell line MEC1. When 
rituximab binds to CD20 the resulting complex translocates to LRs within the cell membrane. 
Therefore, the LRs contents were analysed before and after rituximab treatment. We also 
determined the levels of CD antigens, analyzed the whole cell proteome, and investigated 
apical shape formation at the LRs after rituximab treatment. 
4.4.1 Rituximab forms an apical LRs at B-cells  
Multiple signal transduction pathways converge to induce rearrangements of the actin 
cytoskeleton to mediate motility, shape, and attachment to substrate. Rho family small 
GTPases play important regulatory roles in actin cytoskeletal reorganization [259, 260]. There 
are at least 20 Rho family GTPase proteins in the human genome with RhoA, RAC1, and 
Cdc42 the most extensively studied and characterized. RAC1 stimulates actin polymerization 
and induces broad plasma membrane extensions known as lamellipodia and membrane ruffles 
[261, 262].  
RAC1 and Cdc42 are activated by the G-protein alpha-s that activates adenylate cyclases. 
Upon stimulation, adenylate cyclases increase the level of cyclic adenosine 3',5'-
monophosphate  (cAMP) in cells resulting in PKA activation [263]. Activated PKA requires 
A-kinase anchor proteins (AKAPs) to position it in proximity to its substrates [264]. 
Stimulation of PKA by cAMP results in Rho guanine nucleotide exchange factor 7 
phosphorylation, which in turn controls RAC1 and CDC42 activation [265]. As a result of the 
movement of CD20 with rituximab bound into LRs, some proteins accumulate and form an 
apical lipid raft (Figure 4.6, Table 4.2). Rituximab signaling increased G-proteins [(guanine 
nucleotide-binding protein G(s) subunit alpha isoforms XLas (GNAS, 4.4-fold) and guanine 
nucleotide-binding protein G(k) subunit alpha (GNAI3, 6.6-fold)] and AKAP 4.3-fold in LRs 
(Table 4.2), These 3 proteins are modulators or transducers of several transmembrane 
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signaling systems. In addition, the RAC1 protein in the cytoplasm was increased 2-fold 
(Table 4.5). Increased RAC1 levels may be induced by increased GNAS, GNAI3 and AKAP 
as discussed at above. This may have resulted in the accumulation and polymerization of actin 
in LRs (Figure 4.6).  
 
Figure 4.6: Redistribution of lipid rafts after rituximab treatment. MEC1 cells were fixed on a slide and 
labeled with Vybrant® Alexa Fluor® 594 Lipid Raft Labeling Kit (Red) then with DAPI (nuclear marker, Blue), 
A: Untreated MEC1 cells, B: Treated with 100 µg/ mL rituximab, c: MEC1 cells treated with 100 µg/ mL 
rituximab and label with Phalloidin and DAPI. 
The cytoplasmic domain of tissue factor (TF) may also activate RAC1, once TF binds Factor 
VII (FVII) [266]. The main role of FVII is to initiate the process of coagulation by binding 
with TF that activates FVII (FVIIa). The TF/FVIIa complex converts Factor X (FX) to Factor 
Xa (FXa), and FXa in turn activates prothrombin leading to formation of thrombin (Factor 
IIa). Thrombin subsequently activates platelets and converts fibrinogen into fibrin. Mutations 
a b 
c 
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in p53 up-regulate TF, consistent with MEC1 cells that have truncated p53 [267]. Binding of 
FVIIa to TF initiates a series of signaling events that regulate a range of cellular responses, 
such as: (1) gene transcription, (2) cell survival, and (3) cytoskeletal changes. The TF/FVIIa 
complex may directly signal via the TF cytoplasmic tail through RAC1 and p38 by 
stimulating cytoplasmic tail recruitment of the actin-binding protein 280 and potentially 
resulting in cytoskeletal remodeling [266]. Signaling of TF/FVIIa via PAR2 elicits calcium 
transients and activation of major members of the MAPK family, p44/42, p38, and JNK. In 
addition, Src-like kinases, PI3 kinase, the Jak/STAT pathway, and the Rho GTPases RAC1 
and Cdc42 are activated, culminating in cell survival and cytoskeletal rearrangements [268]. 
Thus, increased FVII (6.1-fold, p<0.05) in whole cell lysates (Table 4.5) after rituximab 
treatment may induce RAC1 activation, cytoskeletal changes and cell survival. 
Also rituximab signaling increased LSP1 (F-actin binding protein) and the spectrins 
(SPTAN1 and SPTBN1) in LRs (Table 4.2). High levels of LSP1 induces F-actin bundles and 
inhibits motility in neutrophils and melanoma cells [269]. Spectrins are a family of widely 
distributed filamentous cytoskeletal proteins whose functions include regulation of receptor 
binding and actin cross-linking. The SH3 domain of spectrin plays an essential role in RAC1 
activation, initiation of actin network formation, adhesion, lamellipodia extension, cell 
spreading and DNA repair [270]. Also SPTAN1 interacts with vimentin, plectin and 
SPTBN1. 
Translocation of the rituximab-CD20 complex to LRs resulted in accumulation of increased 
levels of cytoskeletal proteins such as actin, F-actin cross-linking protein (ACTN4), SPTAN1, 
SPTBN1, actin-based motor molecules ((MYO1G and MYH9 (Table 4.2)), EEF1G, 
intermediate filament binding protein (PLEC) and intermediate filaments vimentin, as well as 
increasing levels of LRs specific proteins such as FLOT1, FLOT2 and RFTN1 in LRs (Table 
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4.2). Aggregation of these proteins in LRs facilitated actin polymerization that results in 
formation of an apical shape at the LRs (Figure 4.6). The polarization of B-cells induced by 
rituximab is one of its therapeutic functions by triggering NK-cell-mediated antibody 
dependent cellular cytotoxicity (ADCC) [271].  
4.4.2 Proteins that move into LRs after rituximab treatment 
Eleven of the increased proteins were not detected in LRs fractions of untreated cells, 
indicating that these proteins moved into LRs upon rituximab treatment (Table 4.2). These 
proteins include CD20, SLC16A1, LDHA, CD228, TRIM21, C4A, ATP1A1, ABCD3, 
ATP6V0D1 and TUBA1C. The movement of these proteins to LRs may be attributed to an 
effect of rituximab or as CD20 binding partners, leading to down-stream signaling or cell 
apoptosis. 
Proliferating cancer cells often use glycolysis rather than oxidative phosphorylation to supply 
energy, called the Warburg effect. Lactate, one of the major waste products of cellular 
fermentation, can inhibit cell growth and affect cellular metabolism at high concentrations. 
Glucose is oxidized to pyruvate by the pyruvate kinase isozymes M1/M2 (PKM2) and finally 
converted to lactate by lactate dehydrogenase A (LDHA), which causes acidification of the 
culture medium, and thus inhibition of cell growth [272]. Monocarboxylate transporter 1 
(MCT1, SLC16A1) facilitates unidirectional proton-linked transport of L-lactate across the 
plasma membrane. In the cancer context, MCT1 should be expressed at the plasma membrane 
for proper efflux of the accumulating lactate resultant from high glycolytic rates [273]. There 
is evidence that up-regulation of MCTs occurs in many tumors, such as colorectal carcinomas 
[274], breast cancer [275] uterine cervix [276] and lung cancer [277], among others. There is 
also an association between lactate derived from tumor cells and cancer progression [278]. 
Importantly, co-expression of MCT1 and its chaperone CD147 (basigin) is associated with 
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poor patient survival [273].  Therefore, silencing of MCT1 via inducible shRNA, or silencing 
of CD147/basigin alone, significantly reduces glycolytic flux and tumor growth [279]. 
Analysis of the LRs fraction of rituximab treated cells showed increased levels of PKM2 
(3.40-fold), LDHA (1.57-fold), MCT1 (3.91-fold), ABCD3 (3.53-fold), ATP6V0D1 (3.47-
fold) and decreased basigin (0.39-fold) (Table 4.2). The increase of lactate inside the cells 
require high levels of MCT1 to efflux lactate, but the levels of basigin required to activate 
MCT1 decrease in LRs due to rituximab treatment. Translocation of MCT1 to the LRs may 
result in efflux of lactate but rituximab reduces basigin in the LRs that would reduce MCT1 
activation with an increase in acidity inside the cells that could inhibit cell growth. 
The calcium-channel activity of CD20 is stimulated by the CD20-Ab treatment [64, 280]. 
Rituximab induces translocation of CD20 (50-fold) into the LRs with depletion of 
intracellular calcium stores that result in activation of store-operated calcium channels at the 
plasma membrane with influx of extracellular calcium [69]. The increase in intracellular free 
calcium with a 1.43-fold increase in calmodulin, a calcium binding messenger protein, 
stimulates Ca2+ signaling. Calmodulin is a Ca2+-binding protein that functions as a ubiquitous 
secondary messenger in several Ca2+ signaling pathways to dynamically regulate the 
functions of hundreds of proteins. For example, the cardiac and neuronal voltage-gated ion 
channels, such as sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) [281, 
282] is increased in the LRs by 2.91-fold. Increased surface expression of functional ATP1A1 
is activated by cyclic AMP [283]. 
Activation of ATP1A1 could result from high levels of intracellular Ca2+. Ca2+ removed by 
the sodium/calcium exchanger membrane protein, which uses a Na gradient generated by 
ATP1A1 channel to remove the elevated Ca2+ [284]. Rituximab increased ATP1A1 (2.91-
fold), which interacts directly with Src, a non-receptor tyrosine kinase, to form a signaling 
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receptor complex. Src kinase is inhibited by this interaction. The free Src kinase domain can 
be activated which then subsequently phosphorylates various effectors, resulting in the 
assembly and activation of different pathways including the Ras/Raf/ERK1/2 cascade and 
mitochondrial ROS production [285]. Thus, inhibition of Src by ATP1A1 interaction could 
result in the inhibition of Ras/Raf/ERK1/2 signaling cascade and cell growth.  
A principal function of A-kinase anchor proteins (AKAPs) is to position PKA and other 
cAMP-responsive enzymes in proximity to their substrates, and to function as a link for 
cytoskeletal signaling complexes [264]. AKAP2 is targeted to the inner apical surface of 
plasma membrane with tight association with the actin cytoskeleton. AKAP2 interacts with 
and modulates the structure of the actin cytoskeleton, establishing polarity in signalling 
systems, regulating the function of ion channels, and targeting the AKAP2-PKA signalling 
complex near the junction of the cytoskeleton and apical membrane and may facilitate cAMP-
signal transduction [286]. Thus the increase of AKAP2 (4.3-fold) in apical LRs is induced by 
rituximab may elevated cAMP and reorganize actin in the LRs (Figure 4.6). The increase of 
complement C4-A (C4A, 4.3-fold) probably is due to the decrease of CD46 and CD55 at the 
cell surface after rituximab treatment, will be further discussed in Section 4.4.4. The extreme 
up-regulation of TRIM21 (21-fold) will be discussed in Chapter 5. 
4.4.3 Proteins involved in the cell apoptosis, survival and proliferation 
after rituximab treatment 
Cystatin-B (CSTB) is increased 3.7-fold after rituximab treatment. CSTB is an endogenous 
cysteine cathepsin inhibitor (33) that protects melanoma cells against tumor necrosis factor 
(TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. CSTB prevents 
degradation of FLICE-like inhibitory protein (FLIP) by E3 ligase Itch. As a structural 
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homologue of caspase-8, FLIP competes with caspase-8 for binding to Fas-associated death 
domain (FADD), thereby inhibiting recruitment of caspase-8 to the death-inducing signaling 
complex (DISC) [287, 288], inhibiting downstream effector caspases and cell apoptosis. 
There is increasing evidence that CSTB is elevated in cancer cells [289-291]. FLIP also acts 
as inhibitor for Fas receptor (CD95) [292].  Thus, increasing of CSTB by rituximab (3.7-fold, 
p<0.05, Table. 4.5) will stabilize FLIP and inhibit CD95 mediated apoptosis by preventing 
FADD and caspase 8 interactions. Rituximab also down-regulates CD95 at the cell surface 
(0.79-fold, p<0.05, Table 4.4). These differentially abundant proteins could be responsible for 
MEC1 survival and proliferation after rituximab treatment. 
SS-B protein is an RNA-binding protein involved in initiation and termination of RNA 
polymerase III transcription. SS-B stimulates the translation of terminal oligopyrimidine 
(TOP) mRNAs, that include ribosomal proteins and eEF1α [293]. SS-B is highly abundant 
and over-expressed at both the mRNA and protein levels in human cancer cell lines [294, 
295] and primary human cancers [295-297]. SS-B over-expression led to increased MDM2 
and enhanced resistance to apoptosis [296] SS-B over-expression is correlated with 
proliferation, migration and invasion of lymph nodes hypopharyngeal SCC cells [297]. Thus 
its down-regulation by rituximab may decrease cell proliferation and survival. 
NPM1 is involved in transcriptional regulation by interaction with NFκB, YY1, ARF and 
IRF1 [298-302]. NPM1 can act as coactivator of NFκB [300] and alter the transcriptional 
activity of IRF1 and p53 [298, 299]. NPM1 interacts with YY1 blocking its transcriptional 
repressive function [301]. Over-expression NPM1 promotes cell growth and proliferation, 
particularly through enhancing ribosome biogenesis [303, 304], Knock-down of NPM1 by 
siRNA inhibits cells proliferation and induces apoptosis in the leukemia cell line [305]. 
Down-regulation of NPM1 is a key element for induction of cellular apoptosis or 
  117 
differentiation. Decreased NPM1 in the MEC1 CLL cell line by -2.0-fold by rituximab could 
halt cell proliferation or trigger apoptosis. 
Alternatively, increased levels of proteins such as, clathrin heavy chain (CLT), alpha-enolase 
(ENO1) and triosephosphate isomerase (TPI), and decreased levels of Sjoegren syndrome 
type B antigen (SS-B) and Nucleophosmin 1 isoform 1 (NPM1) in whole cell lysates by 
rituximab (Table 4.5) may inhibit cell survival and proliferation.  
Rituximab binding to CD20 resulted in up-regulation of CLT in whole cell lysates. CLT is 
mainly known as a structural component of clathrin and for its role in clathrin-mediated 
endocytosis (CME) [306, 307]. The association of 3 CLTs and up to 3 clathrin light chains 
forms a clathrin triskelion structure that self-polymerizes to form a curved lattice around 
invaginated pits. Through this mechanism, CLT is involved in the uptake of nutrients, the 
internalization of pathogens, the down-regulation of certain ligand-induced receptors and in 
protein sorting at the trans-Golgi network (TGN) during protein secretion [306, 308, 309]. 
Like other endocytic proteins [310], CLT appears to perform multiple functions in cells. It has 
been reported that CLT is involved in chromosome segregation during mitosis [311]. In 
addition, a fraction of CLT proteins localizes to the nucleus and binds to p53-responsive 
promoters and favours p53-mediated transcription [312]. CLT prevents constitutive IKK-
mediated phosphorylation, degradation of IκBα in unstimulated epithelial cells, and 
constitutive NF-κB p65 nuclear localization. Therefore, CLT controls basal NF-κB activation 
and terminates constitutive IL-8 secretion. By showing that CLT prevents constitutive 
expression of the pro-inflammatory and tumorigenic factor IL-8, Kim and collegues 
suggested that alterations in CLT expression might be associated with chronic inflammation 
disorder or cancer [313]. Therefore, up-regulation of CLTC (4.2-fold, p<0.05) after rituximab 
treatment could be one mechanism of rituximab action that inhibits NF-κB transcription 
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activity and thus induces apoptosis.  
In addition, ENO1 over-expression (2.05-fold) after rituximab treatment could suppress 
MEC1 growth. ENO1 is a negative regulator of the c-Myc proto-oncogene, that regulates 
expression of many genes, some of which are involved in cell proliferation, also mutation in 
c-Myc may promote formation of cancer [314, 315]. 
Polyadenylate-binding protein 1 (PABPC1) is an RNA-binding protein with important roles 
in post-translational control and metabolism of mRNA [316]. PABPC1 binds to the poly (A) 
tail of mRNA. In esophageal cancer, reduced expression of PABPC1 correlated with tumor 
progression and poor prognosis after surgery [317]. Thus, down-regulation of PABPC1 by 
rituximab may increase the progression of MEC1 cells after rituximab treatment.  
Poly (ADP-Ribose) polymerase 1 (PARP1) was initially identified as a central component of 
the DNA repair pathway for single-strand breaks. PARP1 is a molecular switch, that affects 
cell homeostasis and determines cell death pathways. It is a well-known apoptotic marker 
[318]. PARP1 hyperactivity depletes the energy-donor molecules NAD+ and ATP, that induce 
necrotic pathways. Low levels of PARP1 may lead to reduced pro-inflammatory mediators, 
tissue damage and reperfusion injury [319-321]. Thus, down-regulation of PARP1 by 
rituximab should increase the resistance to apoptosis in MEC1 cells. 
4.4.4 Levels of CD antigens on MEC1 cells treated with rituximab 
Rituximab (10 µg/mL, 24 h) changed the levels of some CD antigens on the human leukemia 
B-cell line MEC1. Changes in the surface proteins were identified using DotScan Cluster of 
Differentiation (CD) antibody microarrays that capture live cells, results were confirmed by 
flow cytometry. 
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The B-cell receptor (BCR) is a hetero-oligomeric complex composed of membrane Ig (mIg), 
CD79a and CD79b. Aggregation of BCR by antigen results in tyrosyl phosphorylation and/or 
activation of many proteins, including CD79a and CD79b [322, 323] and protein tyrosine 
kinases (PTKs) of the Src, Syk, and Tec families [324-326]. Activation of PTKs leads to 
phosphorylation of other proteins [327-329]. These effector molecules mediate downstream 
signaling leading to cell proliferation, differentiation, and/or apoptosis. 
Rituximab treatment resulted in up-regulation of CD79A (1.2-fold, p < 0.05) at the cell 
surface (Figure 4.2 and Table 4.4). It has been shown that rituximab induces signals 
resembling B-cell receptor (BCR) stimulation [330], perhaps due to a functional association 
of CD20 with the BCR [330, 331]. Thus, rituximab may cause B-cell polarization involving 
the BCR. Consistent with this hypothesis, clustering of proteins in LRs such as IGHM, a 
membrane-bound IgM, induces phosphorylation of CD79a and CD79b by the Src family of 
protein tyrosine kinases, thus inducing BCR down-stream signaling.  
CD22, a regulator of BCR, was increased 2.0-fold by DotScan analysis (Table 4.3) and 1.1-
fold by flow cytometery (Table 4.4). CD22 is a B-cell-specific sialo-glycoprotein of the 
immunoglobulin super-family commonly expressed on Non-Hodgkins lymphoma [332] 
involved with cellular adhesion, homing and regulation of B-cell activation. CD22 enables 
recruitment of proteins that inhibit BCR signaling [333], thus, up-regulation of CD22 may 
increase the threshold for BCR activation and may increase CD22 signaling, proliferation, 
and inhibit apoptosis. 
CD80 and CD86 are decreased by -2.0- and -1.25-fold respectively in MEC1 cells as 
determined by DotScan (Table 4.3) and 0.8- and 0.93-fold by flow cytometry (Table 4.4) after 
rituximab treatment. These co-regulators of T-cell activation induce proliferation, cytokine 
production, and effector functions. Down-regulation of CD80 and CD86 by rituximab may 
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suppress a T-cell response to CLL and lymphoma [334]. CD95 is a cell death receptor that, 
when bound to its ligand (CD95L), initiates the assembly of a signaling complex that includes 
the FAS-associated death domain and then apoptosis [335]. The Fas (CD95)/Fas ligand 
system has a potential role in cytotoxic killing of some leukemias [336]. CD95 is down-
regulated 0.79-fold on MEC1 cells after rituximab treatment (Table 4.4). Thus rituximab 
inhibits the apoptosis pathway that could be initiated by CD95 on MEC1 cells. However, this 
pathway could be activated by combination treatment of rituximab with fludarabine, which is 
known to induce Fas and Fas-L mRNAs [337]. 
Because the strength of BCR signaling can generate many outcomes including cell death, 
survival, proliferation and differentiation, the threshold of BCR response is controlled by both 
stimulatory and inhibitory factors. The stimulatory receptors such as the CD19/CD21/CD81 
complex, an essential B-cell co-receptor that functions synergistically to enhance signaling 
through the B-cell Ag receptor in response to T cell-dependent, complement-tagged Ags 
[338]. This complex brings the LYN kinase close to the BCR, which results in 
phosphorylation of BCR at immune-receptor tyrosine-based activation motifs (ITAMs), that 
leads to the activation of downstream signaling pathways [339, 340] 
Inhibitory receptors such as FcγRIIB (CD32), CD22 and CD72, that are negative regulators of 
B-cell responses, have immunoreceptor tyrosine-based inhibitory motifs (ITIMs); the tyrosine 
phosphatase SHP-1 binds at these sites [341-345]. In the absence of antibodies or natural 
ligands to these regulators, BCR signals are suppressed due to binding of SHP-1 with 
inhibitory receptors, resulting in B-cell hypo-responsiveness. Here we show that rituximab 
increases the inhibitory receptors CD72 and CD22, and decreases the stimulatory receptors 
CD19 and CD21. These surface proteins could minimize or prevent rituximab signaling 
through the BCR. Depleted CD32 levels following rituximab treatment likely reflects the 
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ability of CD32 to bind the Fc region of rituximab, thereby blocking CD32 and impeding its 
quantitation by DotScan or flow cytometry.  
CD23 plays a role in modulating the production of IgE by B-cells [346] and promotes the 
survival of germinal center B-cells [347]. CD23 can undergo proteolytic cleavage between the 
extracellular lectin-binding domain and the transmembrane region, releasing soluble CD23 
from the cell surface [348]. The expression of CD23 is increased in activated follicular B-
cells and in CLL B-cells [2, 349, 350]. 
A prominent feature of B-CLL cells is the high expression of CD23, which is closely related 
to cell survival and is regulated by Notch2. Down-regulation of CD23 and loss of Notch2 
activity are early steps in proteasome inhibitors-induced apoptosis of B-CLL lymphocytes 
[351, 352]. CD23a, which is increased by IL-4 and IFN-gamma, has been implicated in the 
anti-apoptotic state of B-CLL lymphocytes [351, 353]. The protein kinase C (PKC) activator, 
phorbol 12-myristate 13-acetate (PMA), for instance, is a strong inducer of FCER2 (CD23a) 
transcription in CLL cells, but has only a minor effect on surface CD23 expression in normal 
B-cells [353-355]. PMA not only induces CD23a but also inhibits spontaneous and 
chemotherapy induced apoptosis in cultured CLL cells [356]. Engagement of CD72 by the 
IgG monoclonal antibody BU40 potentiates the capacity of IL-4 to promote CD23 production 
in B-cells [357]. Therefore, decreased CD23 (-1.8-fold) by rituximab is likely a result of IL-4 
down-regulation and thus initiation of cell apoptosis. 
ADAM 10 is essential for Notch signaling, Notch signaling requires a series of proteolytic 
cleavage events to release the Notch intracellular domain (NICD) that functions directly in 
signal transduction. ADAM10 and ADAM17 have been reported to cleave Notch to facilitate 
NICD release by γ-secretase [358, 359]. ADAM10 cleaves notch, which travels to the nucleus 
and activates the transcription of CD21 and CD23. Thus down-regulation of ADAM10 
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inhibits the metastasis and invasiveness in hepatocellular carcinoma [360] and in mantle cell 
lymphoma induced growth inhibition and cell cycle arrest [361]. Therefore, down-regulation 
of ADAM10 to 0.76-fold at MEC1 cell surface after rituximab treatment could explain CD21 
and CD23 down-regulation. In addition, reduction of ADAM10 and CD23 in MEC1 cells by 
rituximab may inhibit proliferation and survival. 
Hypoxia-inducible factor (HIF-1) and nuclear factor-kappaB (NF-kappaB) mediate the up-
regulation of C-X-C chemokine receptor type 1 (CD181, CXCR1, IL-8 receptor type 1). IL-8 
signaling potentiates NF-κB-mediated transcription of anti-apoptotic genes [362, 363] and 
activates the phosphoinositide-3 kinase (PI3K)/Akt, the mitogen-activated protein kinase 
(MAPK) signaling cascades, and increases cyclin D1 expression [364]. Therefore, inhibition 
of the IL-8 receptor reduces cell proliferation in colorectal cancer. We have shown that the 
IL-8 receptor type 1 is up-regulated at the surface of MEC1 cells after rituximab treatment 
(Figure 4.2 and Table 4.4). Increase expression of IL-8 receptor type 1 may enhance MEC1 
cell survival and avoid rituximab induced apoptosis. 
The increase of complement C4-A (4.3-fold) in LRs indicates the initiation of complement 
system after rituximab treatment. The complement system is triggered by activation of the 
C1-complex. The C1-complex is composed of 1 molecule of C1q, 2 molecules of C1r and 2 
molecules of C1s, or C1qr2s2. The C1r2s2 component now splits C4 and then C2, producing 
C4a, C4b, C2a, and C2b. C4b and C2a bind to form the classical pathway C3-convertase 
(C4b2a complex), which promotes cleavage of C3 into C3a and C3b; C3b later joins with 
C4b2a (the C3 convertase) to make C5 convertase (C4b2a3b complex). This enzyme then 
cleaves C5 to C5a and C5b. The C5b then recruits and assembles C6, C7, C8 and multiple C9 
molecules to assemble the membrane attack complex [365]. This creates a hole or pore in the 
membrane that can kill or damage the cell. Membrane-bound complement regulatory proteins 
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(mCRPs) CD55, CD46 and CD59, are often detected at elevated levels on tumor cells [366, 
367]. CD59 restricts formation of the membrane attack complex by preventing C9 protein 
polymerization through binding to C8 and C9 [368]. CD55 inactivates the C3 and C5 
convertases by accelerating the decay of these proteases [369], whereas CD46 acts as a 
cofactor for inactivation of cell-bound C4b and C3b by serum factor I [370]. Therefore the 
down-regulation of mCRPs contributes to the sensitivity of CLL cells to rituximab and 
initiates the complement system. After rituximab treatment, CD46 and CD55 levels are 
slightly reduced (Figure 4.2 and Table 4.4), whereas, CD59 increases (data not shown). These 
changes in CD46 and CD55 would not be enough to sensitize the cells to complement attack, 
as CD59 prevents complement activation by binding to C9 and therefore inhibits complement 
dependent cytotoxicity (CDC). 
Intercellular adhesion molecule 3 (ICAM-3, CD50), is a ligand for leukocyte function-
associated antigen-1 (LFA-1) and a potent signaling molecule. Myeloma cells may down-
regulate CD50 to escape immune-surveillance. MEC1 cells may down-regulate CD50 
(ICAM-3) to 0.79-fold (Table 4.4 and Figure 4.2) after rituximab treatment to avoid NK cells. 
4.4.5 A signalling pathway for rituximab in MEC1 and Raji cell lines 
IPA software was used to map a network of interacting proteins whose levels changed 
following rituximab treatment of MEC1 cells (Figure 4.4). The interaction network converged 
on 5 key proteins, CCND1, STAT3, c-Myc, PAX5 and YY1. STAT3, p-STAT3 and YY1 
displayed significant differential abundance in whole cell lysates of MEC1 (1.4, 1.67, and 
1.46-fold, respectively) and Raji (-3.1, -2.1, and -1.45-fold, respectively). Changes in these 
protein levels might be direct effects of rituximab or a result of changing activity of 
transcription factors or kinases. IPA analysis of these differentially abundant proteins 
suggests several interesting mechanisms (Figures 4.4, and 6.1) such as activation of the 
  124 
PI3K/RAC1 pathway and induction of STAT3, YY1, Bcl2, c-Myc and CCND1 in MEC1 
(Figures 4.4, 4.5 and 6.1). Conversely in Raji a rituximab sensitive cell line (Figure 4.3) 
[258], inhibition of the PI3K/RAC1 pathway induces suppression of STAT3, YY1, BcL2, c-
Myc and CCND1 (Figure 4.5).  
Western blotting (Figure 4.5) showed that rituximab treatment of MEC1 cells results in up-
regulation of some key proteins such as, STAT3, p-STAT3 and YY1. Whereas, in Raji cells 
there was down-regulation of these proteins. The PI3K/RAC1 pathway is activated in MEC1 
cells and inhibited in Raji after rituximab treatment. Additional key proteins from the IPA 
analysis need to be validated. 
In MEC1 cells rituximab inhibits p-LYN [46] and modulates the activity of Syk by engaging 
CD20 and BCR in lipid rafts [49, 330]. Syk is phosphorylated at Tyr 323, which is required 
for Syk to associate with PI3K [371, 372] inducing activation of Akt and RAC1 [373-376]. 
Activated RAC1 and Akt enhance NF-kB activation [377-379]. The activity of RAC1 leads to 
STAT3 activation by phosphorylation on residue Y705, that induces homodimerization or 
heterodimerization with other STAT proteins that results in nuclear translocation and 
activation of the STAT3 transcriptional regulatory function [380, 381]. STAT3 also activates 
NF-κB in CLL [382]. Constitutive activation of NF-κB and STAT3 depends on upstream 
signaling through PI3K, this activation is important for cell survival and proliferation, as well 
as for maintaining the level of c-Myc [383], that leads to increased expression of ENO1 [384-
386], MYH9, GAPDH, CSTB and TPI1 (Figure 4.4B and 6.1, Table 4.5). In addition, 
activated NF-kB stimulates YY1 transcription, that is negatively regulates CD95 [387] and 
PARP1 [388], with inhibition of Fas mediated apoptosis. STAT3 activates several genes 
involved in cell cycle progression such as CCND1, c-Myc and up-regulates anti-apoptotic 
genes such as Bcl-2 and Bcl-XL [389-392]. STAT3 also suppresses Fas [391] and PAX5 
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[393, 394] transcription. Down-regulation of PAX5 leads to decreases in the stimulatory 
receptors CD21, CD23 and CD19, thus inhibiting BCR signaling.  
4.5 Conclusion 
Aggregation of cytoskeletal proteins in LRs induced by rituximab facilitated actin 
polymerization that results in formation of an apical shape of the LRs (Figure 4.6). Increased 
FVII and spectrin levels in whole cell lysates and GNAS, GNAI3 and AKAP in the lipid rafts 
after rituximab treatment may induce RAC1 activation. RAC1 stimulates actin polymerization 
and induces broad plasma membrane extensions known as lamellipodia and membrane 
ruffles. The polarization of B-cells by rituximab may stimulate its therapeutic functions by 
triggering NK-cell-mediated antibody dependent cellular cytotoxicity (ADCC).  
Some of the proteins that move into the LRs from the cell membrane or cytoplasm because 
they are a CD20 binding partners, they may assist rituximab to induce apoptosis. Down-
regulation of Basigin could result in high acidity that may kill the cell. CD20 increases the 
intracellular calcium concentration, ATP1A1 inhibits Src kinase and AKAP is necessary for 
actin polymerization.  
Changes in proteins that may assist rituximab to induce apoptosis, include increased levels of 
CLT, ENO1 and TPI and decreased levels of SS-B, CD23, ADAM10, CD55 and CD46. 
Whereas, increases in CSTB, FVII, RAC1, CD72, CD22 and IL-8 and decreased CD95, 
PABPC1, PARP1, CD80, CD86, CD19, CD21 and CD50 may provide resistance to 
apoptosis. 
Data presented in this chapter demonstrate that rituximab treatment activates the PI3K/RAC1 
pathway in the CLL cell line, MEC1, and inhibits this pathway in rituximab-sensitive Raji. In 
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MEC1, activating this pathway may induce the expression of STAT3, YY1, Bcl2, c-Myc, 
CCND1 and NF-κB and inhibits the expression of PAX5, resulting in resistance to apoptosis. 
Further immunoblotting is needed to investigate the potential differential expression of Bcl2, 
c-Myc, CCND1 and PAX5. 
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Chapter 5 
5 TRIM21 KNOCK-DOWN 
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5.1 Introduction 
The tripartite motif-containing 21 (TRIM21, Ro52) gene is located on chromosome 11 [395], 
its protein can be detected in the cytoplasm and nucleus [396] and its expression may be 
ubiquitous in cells [397]. TRIM21 is capable of binding to an invariant region of antibody 
molecules via its PRYSPRY domain [398]. TRIM21 possesses a cytosolic IgG receptor 
activity, that binds antibodies with a higher affinity than any other IgG receptor. The 
appearance of antibodies in the cytosol of cells is detected by the Fc receptor TRIM21 [398-
400]. Detection triggers the E3 ligase activity of TRIM21, that catalyses the synthesis of K48 
and K63 ubiquitin chains [399, 401]. TRIM21 binds to incoming antibody-bound virus and 
targets the complex to proteasomes via its E3 ubiquitin ligase activity. Proteasomal targeting 
leads to rapid degradation of virions in the cytosol before translation of virally encoded genes 
[399]. Meanwhile, production of K63 chains by TRIM21 activates innate immunity by 
signaling via the NFκB, AP-1 and IRF3/5/7 transcription pathways [401]. This leads to potent 
cytokine and chemokine expression, up-regulation of NKG2D ligands and MHC Class I, and 
induction of an antiviral state [401]. On the other hand, TRIM21 induces the Lys48 (K48)-
linked ubiquitination and degradation of DDX41 and negatively regulates the innate immune 
response to intracellular dsDNA [402].  
In our study we found that TRIM21 concentrated in LRs in proximity to rituximab. Therefore, 
TRIM21 has been knocked down with siRNA in MEC1, IM9 and Raji cell lines to investigate 
its contribution to rituximab signaling.  
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5.2 Methods 
5.2.1 TRIM21 Knock-down 
MEC1, IM9 and Raji cells (2x105 /mL) were cultured in 6-well plates in RPMI medium 
without gentamicin the day prior to transfection. The transient siRNA knock-down of 
TRIM21 was carried out on MEC1, IM9 and Raji cells using 300-600 pmol of TRIM21 
siRNA (3 mixed oligonucleotides) (Invitrogen, Australia). The siRNA and 2 µL of 1 mg/mL 
Lipofectamine RNAiMAX (Invitrogen, Australia) were separately diluted in 50 µL OPTI-
MEM1 medium and incubated at RT for 5 min before they were mixed and re-incubated for 
25 min at RT. The mixture containing siRNA/Lipofectamine complex was then added to the 
cells. The cells were incubated for 24 h or 48 h at 37°C. A negative control with a random 
sequence siRNA was used following the manufacturer’s instructions. MEC1 cells were 
collected and lysed for Western blotting. MEC1, IM9 and Raji cells were transfected with 200 
pmol of each oligonucleotide (3 mixed oligonucleotides) of TRIM21 siRNA for 24 h and 48 h 
then treated with rituximab (10 µg, 24 h or 48 h), with a negative control. The target 
sequences for the human TRIM21 siRNA were GAAAGGAGUGAGUCCUGGAACCUGA, 
GACAAUUUGGUUGUGGAACAAACAA and CCACCUUCAGGUGCCUCCAUGCCAA. 
5.2.2 Western blot analysis 
Cells were lysed in cold MN buffer (25 mM morpholino ethane sulfonic acid (MES) pH 6.5, 
150 mM NaCl, 1% Na2VO4 and 1% protease inhibitor cocktail (Sigma-Aldrich, Castle Hill, 
Australia) supplemented with 1% Triton X-100 (Sigma-Aldrich). After 30 min on ice, the 
lysate was homogenised for 10 strokes and centrifuged (800 xg, 10 min, 4°C). Protein 
samples were separated by 8% SDS-PAGE, and transferred to a PVDF membrane (Immun-
Blot™ PVDF Membrane, Bio-Rad Laboratories, Hercules, USA). After blocking with 5% 
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skim milk in TBST, the membranes were incubated (4°C, 16 h) with primary antibodies: 
purified anti TRIM21 monoclonal antibody (dilution of 1:3,500 in TBST) (Abnova, Taipei 
City, Taiwan), mouse anti actin monoclonal antibody (Abcam, Cambridge, USA), followed 
by incubation (1 h, room temperature) with a horse radish peroxidase (HRP)-conjugated 
secondary antibody: goat-anti-mouse-HRP (dilution of 1:10,000 in TBST) (Santa Cruz 
Biotechnology Inc, Santa Cruz, USA). Proteins were visualized using a Rapid Step ECL 
Reagent (Merck, Kilsyth, Australia) and ECL chemiluminescence film (GE Healthcare, 
Piscataway, NJ, USA). 
5.3 Results 
5.3.1 TRIM21 knock-down inhibits cell apoptosis and initiates 
proliferation 
After 24 h and 48 h of TRIM21 knock-down, cell viability was assessed using Annexin V-PE 
and 7-ADD (Annexin V-PE Apoptosis Detection Kit I, BD Biosciences, San Diego, CA, 
USA) with flow cytometry as described in Section 2.3.6. The viability for MEC1, IM9 and 
Raji cultures was 80-90%. MEC1 cells were lysed and subjected to Western blotting to assess 
the TRIM21 knock-down efficiency (Figure 5.1). There was 60% knock-down of TRIM21 
after 48 h when MEC1 cells were transfected with 100 pmol siRNA of each oligonucleotide 
(3 mixed oligonucleotides) and 40% and 96.3% knock-down of TRIM21 with transfection of 
200 pmol of each oligonucleotide (3 mixed oligonucleotides) siRNA after 24 h and 48 h 
respectively (Figure 5.2). MEC1 and IM9 cells transfected with 200 pmol siRNA for 48 h and 
treated with rituximab for 24 h showed increased density of ~ 40% and 50%, respectively, 
compared to the negative control, whereas Raji cell numbers didn’t change (Figure 5.3). 
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5.4 Discussion 
TRIM21 knock-down resulted in increases in MEC1 and IM9 cells. By contrast, the Raji cell 
number didn’t change, the cell line may be responsive to rituximab or the level of TRIM21 in 
Raji cells may be higher than in MEC1 and IM9. The following mechanism for the role of 
TRIM21 in the response to rituximab is proposed. 
TRIM21 down-regulates NF-κB signalling by mono-ubiquitylating IκB kinase β (IKKβ) and 
translocating IKKβ to autophagosomes, in addition, when the murine TRIM21 gene disrupted 
the production of NF-κB-dependent cytokines, such as IL-1β, TNFα, and IL-6 in fibroblast 
cells were increased [403-405]. The NF-κB gene family consists of five related proteins, all of 
which bind the common sequence motif κB. The proteins are tightly regulated and in the 
steady-state are bound to the Inhibitor of NF-κB (IκB) proteins [406], and inactivated. Upon 
inflammatory stimuli, the IKK complex, consisting of IKKα, β and γ, will be activated, 
whereby IκB will be phosphorylated and subsequently degraded in the proteasome, the NF-
κB is released and enters the nucleus to initiate transcription [406]. 
In addition, TRIM21 ubiquitylates IRF8 to enhance cytokine expression in macrophages [403, 
407]. IRF-8 is a transcription factor that plays a critical role in the expression of 
proinflammatory cytokines including IL-12p40 and type I IFN genes [408-410]. IRF-8 is 
induced by IFN-γ in macrophages in synergy with TLR signaling [411]. Ro52 interacts with 
IRF-8 in IFN-γ/TLR-stimulated macrophages, causing IRF-8 ubiquitination. Rather than 
prompting its degradation, Ro52 enhanced the ability of IRF-8 to stimulate IL-12p40 
expression. By facilitating transcriptional activity of IRF-8, Ro52 may play a significant role 
in regulating host defense responses in macrophages [407]. Several factors involved in 
apoptosis are regulated by TRIM21, such as BCL2 protein levels (regulated by TRIM21-
mediated ubiquitination [412]). The proteins FLASH and Daxx, responsible for recruitment of 
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pro-Caspase-8 to Fas, are also regulated by TRIM21 [413]. Furthermore, TRIM21 negatively 
regulates expression of c-FLIP (cellular FADD-like IL1 beta-converting enzyme-inhibitory 
protein), a protein that binds FADD and/ or caspase-8 and inhibits apoptosis [414]. IRF8, a 
substrate of TRIM21 [403, 407, 415], regulates the transcription of several apoptosis related 
genes, such as Bcl-2, c-FLIP and Bax [416-418]. IRF8 deficient cells exhibit increased 
resistance to apoptosis [419, 420]. 
Consistent with these literature reports, IPA analysis (Figure 5.4) suggests that TRIM21 may 
degrades IKBKB (IKK-B) and thus may inhibit NF-κB2 and STAT3 transcription resulting in 
Bcl2 inhibition or down-regulation. TRIM21 ubiquitinate IRF8, that would activate PAX5, 
CIITA and BCL6, and deactivate c-Myc and Bcl2. These proteins that were mapped by IPA 
need to be validated.  
5.5 Conclusions 
TRIM21 knock-down resulted in increases in MEC1 and IM9 cell numbers. By contrast, the 
Raji cell number didn’t change, the cell line may be responsive to rituximab or the level of 
TRIM21 in Raji cells may be higher than in MEC1 and IM9. TRIM21 knock-down in MEC1 
and IM9 cells may up-regulate Bcl2, NF-κB2 and STAT3, resulting in apoptotic resistance 
and cell proliferation after rituximab treatment. TRIM21 could have an essential role in 
turning off NF-κB signalling, avoiding prolonged over-production of proinflammatory 
cytokines, chemokines, and adhesion molecules, subsequently decreasing cellular resistance 
to apoptosis. Therefore, a strategy for increasing E3 activity of TRIM21 in synergy with 
rituximab treatment may be useful for the treatment of CLL. 
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Figure 5.1: siRNA TRIM21 knock-down. (A) TRIM21 RNA sequence for open reading frame encoding 
protein. The boxed regions show respective areas where the three different siRNA bind. (B) Western blots for 
TRIM21 and actin, performed using TRIM21 antibody. The PVDF membrane was then stripped and blotted with 
antibody against actin. MEC1 cells were treated with negative control siRNA or 100 pmol, or 200 pmol of each 
oligonucleotide (3 mixed oligonucleotides) siRNA for 24 and 48 h. 
       C            100 pmol      200 pmol                  C           100 pmol        200 pmol     
TRIM21 
Actin 
24 h 48 h 
B 
A 
GCUUCUGAGCGGAAACUGAAAGUGAAAUAGGGAGCUGGCUACCAGCGUUGAGU
CCCCUGUAAAGCCAAACCCCCUAAAGGUCUCCACACUGCUGUUUAACGGCACA
CUUGACAAUGGCUUCAGCAGCACGCUUGACAAUGAUGUGGGAGGAGGUCACAU
GCCCUAUCUGCCUGGACCCCUUCGUGGAGCCUGUGAGCAUCGAGUGUGGCCAC
AGCUUCUGCCAGGAAUGCAUCUCUCAGGUUGGGAAAGGUGGGGGCAGCGUCUG
UCCUGUGUGCCGGCAGCGCUUUCUGCUCAAGAAUCUCCGGCCCAAUCGACAGC
UAGCCAACAUGGUGAACAACCUUAAAGAAAUCAGCCAGGAGGCCAGAGAGGGC
ACACAGGGGGAACGGUGUGCAGUGCAUGGAGAGAGACUUCACCUGUUCUGUGA
GAAAGAUGGGAAGGCCCUUUGCUGGGUAUGUGCCCAGUCUCGGAAACACCGUG
ACCACGCCAUGGUCCCUCUUGAGGAGGCUGCACAGGAGUACCAGGAGAAGCUC
CAGGUGGCAUUAGGGGAACUGAGAAGAAAGCAGGAGUUGGCUGAGAAGUUGGA
AGUGGAAAUUGCAAUAAAGAGAGCAGACUGGAAGAAAACAGUGGAAACACAGA
AAUCUAGGAUUCACGCAGAGUUUGUGCAGCAAAAAAACUUCCUGGUUGAAGAA
GAACAGAGGCAGCUGCAGGAGCUGGAGAAGGAUGAGAGGGAGCAGCUGAGAAU
CCUGGGGGAGAAAGAGGCCAAGCUGGCCCAGCAGAGCCAGGCCCUACAGGAGC
UCAUCUCAGAGCUAGAUCGAAGGUGCCACAGCUCAGCACUGGAACUGCUGCAG
GAGGUGAUAAUUGUCCUGGAAAGGAGUGAGUCCUGGAACCUGAAGGACCUGG
AUAUUACCUCUCCAGAACUCAGGAGUGUGUGCCAUGUGCCAGGGCUGAAGAAG
AUGCUGAGGACAUGUGCAGUCCACAUCACUCUGGAUCCAGACACAGCCAAUCC
GUGGCUGAUACUUUCAGAAGAUCGGAGACAAGUGAGGCUUGGAGACACCCAGC
AGAGCAUACCUGGAAAUGAAGAGAGAUUUGAUAGUUAUCCUAUGGUCCUGGGU
GCCCAGCACUUUCACUCUGGAAAACAUUACUGGGAGGUAGAUGUGACAGGAAA
GGAGGCCUGGGACCUGGGUGUCUGCAGAGACUCUGUGCGCAGGAAGGGGCACU
UUUUGCUUAGUUCCAAGAGUGGCUUCUGGACAAUUUGGUUGUGGAACAAACA
AAAAUAUGAGGCUGGCACCUACCCCCAGACUCCCCU CCACCUUCAGGUGCC
UCCAUGCCAA GUUGGGAUUUUCCUGGACUAUGAGGCUGGCAUGGUCUCCUUC
UACAACAUCACUGACCAUGGCUCCCUCAUCUACUCCUUCUCUGAAUGUGCCUU
UACAGGACCUCUGCGGCCCUUCUUCAGUCCUGGUUUCAAUGAUGGAGGAAAAA
ACACAGCCCCUCUAACCCUCUGUCCACUGAAUAUUGGAUCACAAGGAUCCACU
GACUAUUGAUGGCUUUCUCUGGACACUGCCACUCUCCCCAUUGGCACCGCUUC
UCAGCCACAAACCCUGCCUCUUUUCCCCAUGAACUCUGAACCACCUUUGUCUC
UGCAGAGGCAUCCGGAUCCCAGCAAGCGAGCUUUAGCAGGGAAGUCACUUCAC
CAUCAACAUUCCUGCCCCAGAUGGCUUUGUGAUUCCCUCCAGUGAAGCAGCCU
CCUUAUAUUUGGCCCAAACUCAUCUUGAUCAACCAAAAACAUGUUUCUGCCUU
CUUUAUGGGACUUAAGUUUUUUUUUUCUCCUCUCCAUCUCUAGGAUGUCGUCU
UUGGUGAGAUCUCUAUUAUAUCUUGUAUGGUUUGCAAAAGGGCUUCCUAAAAA
UAAAAAAUAAAAUUUAAAAAACUGUGAAAAAAAAAAAAAAAAA 
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Figure 5.2: TRIM21 knock-down levels in MEC1 cells. After 48 h of TRIM21 knock-down using 100 pmol of 
each oligonucleotide (3 mixed oligonucleotides) siRNA, TRIM21 levels were down-regulated to 40%. Knock-
down of TRIM21 using 200 pmol of each oligonucleotide (3 mixed oligonucleotides) siRNA resulted in down-
regulation of TRIM21 by 40% and 96.3% in 24 h and 48 h respectively. Relative band intensities were detected 
using ImageJ software. The density of each band was normalized against that of β-actin. Results are shown as 
ratios of biological triplicates relative to controls (actin), error bars represent mean ± standard deviation (n = 3), 
significant changes (p < 0.05) are indicated by (*) relative to the control (n = 3). 
 
Figure 5.3: TRIM21 deficiency results in proliferation of B-lymphoid cells. MEC1 and IM9 cells increased ~ 
40% and 50%, respectively, compare to the negative control siRNA following TRIM21 knock-down and 
rituximab treatment for 24 h. Raji cell remained the same as the control. Results are shown as ratios of biological 
triplicates relative to controls (actin), error bars represent mean ± standard deviation (n = 3), significant changes 
(p < 0.05) are indicated by (*) relative to the control (n = 3). 
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
110 
120 
 Vector Control !100 pmol !200 pmol 
T
R
IM
21
 K
no
ck
do
w
n 
Pe
rc
en
ta
ge
 
24 h 
48 h 
!"
!"
!" !" !"
!"
!"
#"
$"
%"
&"
MEC1 IM9 Raji 
C
el
l n
um
be
r 
(X
 1
05
) 
Vector Control 
TRIM21 Knockdown 
!"
!"
!"
!"
!" !"
  135 
 
Figure 5.4: TRIM21 functional and interacting proteins network. Ingenuity Pathway Analysis indicated that 
TRIM21 regulated genes belong to the categories of cell proliferation, anti-apoptotic and drug resistance.  
TRIM21 directly or indirectly inhibits NFKB2, STAT3, Bcl2 and MYC transcription and activates IRF8. 
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Chapter 6 
6 Conclusions and future directions 
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6.1 Identifying novel proteins in the LRs 
Three different methods have been used to identify the LRs proteome from the human CLL 
cell line, MEC1. Firstly, LRs proteins were enriched using sucrose gradient ultra-
centrifugation and identified with 2DLC-MS/MS. To confirm protein localization to LRs, 
proteomes were compared before and after cholesterol depletion by MβCD using iTRAQ-
labelling coupled to 2DLC-MS/MS. LRs proteins were also identified by immuno-
precipitation using rituximab cross-linked to CD20. In total, 643 proteins were found in LRs 
of CLL cells (580 from sucrose gradient method, 181 depleted by MβCD and 199 isolated by 
immuno-precipitation), 64 proteins were identified by all 3 methods.  To our knowledge, the 
sub-proteome described here represents the first data set for the LRs proteome in CLL cells. 
The comprehensive lists of 643 LRs proteins provided, includes 30 proteins with no previous 
association to the LRs. Of these 30 novel proteins, we propose that LSP1, RAC2, IFI30, 
Neurabin II, SIPA1, GPSM3, GNG11, SHKBP1, SPARC, ST6GAL1 and CD74/ROS fusion 
proteins are potential therapeutic targets for CLL. 
6.2 Effect of rituximab on LRs, the cell surface and whole cells  
Rituximab induces accumulation of cytoskeletal proteins (actin, spectrins, myosin, vimentin 
and tubulin) in LRs, LRs specific proteins (RFTN1, FLOT2, FLOT1) and the actin structure 
modulator AKAP2 (Table 4.2). Aggregation of these proteins in LRs facilitates actin 
polymerization [269, 270] that results in formation of an apical shape at the LRs (Figure 4.6). 
The polarization of B-cells induced by rituximab triggers NK-cell-mediated antibody 
dependent cellular cytotoxicity [271]. Other proteins that moved into the LRs after rituximab 
treatment include CD20, LDHA, CD228, TRIM21, C4A, ATP1A1, ABCD3, ATP6V0D1, 
TUBA1C and SLC16A1. The movement of these proteins to LRs may be attributed to direct 
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effect of rituximab or as CD20 binding partners. Some of these proteins may be involved with 
down-stream signaling or cell apoptosis. SLC16A1 facilitates unidirectional proton-linked 
transport of L-lactate through the LRs [273]. However, SLC16A1 activity is reduced due to 
down-regulation of basigin by rituximab as discussed in Section 4.4.2 that may result in 
increasing the acidity inside the cells, resulting in apoptosis [273, 279]. In addition, up-
regulation of CD20 in LRs activates calmodulin and ATP1A1, that may interact with Src to 
form a functional signaling complex that results in inhibition of cell growth [285]. The 
increase of complement C4-A (4.3-fold) in LRs indicates the initiation of complement system 
after rituximab treatment. The complement system is triggered by activation of the C1-
complex, resulting in C1r2s2 components, which splits C4 and then C2, producing C4a, C4b, 
C2a, and C2b. C4b and C2a bind to form the classical pathway C3-convertase, which 
promotes cleavage of C3 into C3a and C3b; C3b later joins with C4b2a (the C3 convertase) to 
make C5 convertase (C4b2a3b complex). This enzyme then cleaves C5 to C5a and C5b. The 
C5b then recruits and assembles C6, C7, C8 and multiple C9 molecules to assemble the 
membrane attack complex [365]. This creates a hole or pore in the membrane that can kill or 
damage the cell. In addition, rituximab decreases CD46 and CD55 levels at the cell surface 
after rituximab treatment. CD55 inactivates the C3 and C5 convertases of complement by 
accelerating the decay of these proteases [369], whereas CD46 acts as a cofactor for 
inactivation of cell-bound C4b and C3b by serum factor I [370]. Therefore the down-
regulation of membrane-bound complement regulatory proteins (CD46 and CD55) 
contributes to the sensitivity of CLL cells to rituximab and initiates complement system. 
Up-regulation of CSTB and down-regulation of PABPC1 and PARP1 as seen in whole cell 
lysates may result in cellular proliferation. CSTB inhibits downstream effector caspases [287, 
288] and thus cell apoptosis. In addition, low levels of PARP1 may lead to reduce pro-
inflammatory mediators, tissue damage and reperfusion injury [319-321], and reduced 
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expression of PABPC1 correlated with tumor progression and poor prognosis [317]. On the 
other hand, up-regulation of other proteins such as, CLT, ENO1 and TPI and down-regulation 
of NPM1 and SS-B and in whole cell lysates (Table 4.5) may activate the mechanism of 
action of rituximab by inhibiting cell survival and proliferation and increasing sensitivity to 
the chemotherapy. CLT prevents constitutive expression of the pro-inflammatory and 
tumorigenic factor IL-8 [313], ENO1 is a negative regulator of the c-Myc proto-oncogene 
[314, 315], that regulates expression of many genes, some of which are involved in cell 
proliferation, TPI1 protein is known to increase the sensitivity of cells toward chemotherapy, 
SS-B over-expression led to increased MDM2 and enhanced resistance to apoptosis [296] and 
is correlated with proliferation, migration and invasion [297] and NPM1 can act as coactivator 
of NFκB [300] and its over-expression promotes cell growth and proliferation [303, 304].  
However, some of CD antigens that changed at the cell surface could help rituximab induce 
apoptosis, e.g., down-regulation of CD23, ADAM10, CD55 and CD46. Whereas, other 
differentially abundant CD antigens may make the cells resistant to apoptosis, e.g., up-
regulation of CD72, CD22 and IL-8 and down-regulation of CD95, CD80, CD86, CD19, 
CD21 and CD50.  
The strength of BCR signaling can generate many outcomes including cell death, survival, 
proliferation and differentiation; the threshold of BCR response is controlled by both 
stimulatory and inhibitory factors. The stimulatory receptors such as the CD19/CD21/CD81 
complex, an essential B-cell co-receptor that functions synergistically to enhance signaling 
through the B-cell antigen receptor in response to T-cell-dependent, complement-tagged 
antigens [338]. The inhibitory receptors such as, FcγRIIB, CD22 and CD72, that are negative 
regulators of B-cell responses. Rituximab increased CD22 and CD72 and decreased CD19 
and CD21 at the cell surface, thus inhibits BCR signaling that may induce cell proliferation. 
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A prominent feature of B-CLL cells is the high expression of CD23, which is closely related 
to cell survival and is regulated by Notch2. Down-regulation of CD23 and loss of Notch2 
activity are early steps in proteasome inhibitor-induced apoptosis of B-CLL cells [351, 352]. 
ADAM10 cleaves notch, which travels to the nucleus and activates the transcription of CD21 
and CD23. Thus down-regulation of ADAM10 inhibits the metastasis and invasiveness in 
hepatocellular carcinoma [360] and in mantle cell lymphoma induced growth inhibition and 
cell cycle arrest [361]. Therefore, down-regulation of ADAM10 to 0.76-fold at the surface of 
MEC1 cells after rituximab treatment could explain CD21 and CD23 down-regulation. In 
addition, reduction of ADAM10 and CD23 in MEC1 cells by rituximab may inhibit 
proliferation and survival. 
Rituximab decreased CD80 and CD86 at the cell surface that may suppress a T-cell response 
to CLL and lymphoma [334]. In addition, rituximab inhibited the apoptosis pathway that 
could be initiated by CD95 on MEC1 cells, as rituximab decreases CD95 levels at the cell 
surface. However, this pathway could be activated by combination of rituximab with 
fludarabine, that is known to induce Fas and Fas-L mRNAs [337]. CD50 is a ligand for 
leukocyte function-associated antigen-1 (LFA-1) and a potent signaling molecule. Myeloma 
cells may down-regulate CD50 to escape immune-surveillance. MEC1 cells may down-
regulate CD50 to 0.79-fold (Table 4.4 and Figure 4.2) after rituximab treatment to avoid NK 
cells. 
PARP1 is a molecular switch, that affects cell homeostasis and determines cell death 
pathways. It is a well-known apoptotic marker [318]. PARP1 hyperactivity depletes the 
energy-donor molecules NAD+ and ATP, that induce necrotic pathways. Low levels of 
PARP1 may lead to reduced pro-inflammatory mediators, tissue damage and reperfusion 
injury [319-321]. PABPC1 is RNA-binding protein with important roles in post-translational 
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control and metabolism of mRNA. Reduced expression of PABPC1 correlated with tumor 
progression and poor prognosis after surgery [317]. Thus, down-regulation of PARP1 and 
PABPC1 by rituximab should increase the progression of MEC1 cells after rituximab 
treatment.  
6.3 Rituximab activates the PI3K/ RAC1 pathway in MEC1 cells 
In MEC1 cells, rituximab increased GNAS, GNAI3, AKAP, spectrins (SPTAN1 and 
SPTBN1) in LRs that would activate RAC1 (Figure 6.1). In addition, rituximab inhibits p-
LYN [46] and modulates the activity of Syk by engaging CD20 and BCR in lipid rafts [49, 
330]. Syk is phosphorylated at Tyr 323, that is required for Syk to associate with PI3K [371, 
372] inducing activation of Akt and RAC1 [373-376]. Activated RAC1 and Akt enhance NF-
kB activation [377-379]. The activity of RAC1 leads to STAT3 activation by phosphorylation 
on residue Y705, inducing homo-dimerization or hetero-dimerization with other STAT 
proteins that result in nuclear translocation and activation of the STAT3 transcriptional 
regulatory function [380, 381]. STAT3 also activates NF-κB in CLL [382]. Constitutive 
activation of NF-κB and STAT3 depends on upstream signaling through PI3K, this activation 
is important for cell survival and proliferation, as well as for maintaining the level of c-Myc 
[383], that leads to increased expression of ENO1 [384-386], MYH9, GAPDH, CSTB and 
TPI1 (Figures 4.4 and 6.1, Table 4.5). In addition, activated NF-kB stimulates YY1 
transcription, that is negatively regulates CD95 [387] and PARP1 [388], with inhibition of 
Fas-mediated apoptosis. STAT3 activates several genes involved in cell cycle progression 
such as CCND1, c-Myc and up-regulates anti-apoptotic genes such as Bcl-2 and Bcl-XL 
[389-392]. STAT3 also suppresses Fas [391] and PAX5 [393, 394] transcription. Down-
regulation of PAX5 leads to decreases in the stimulatory receptors CD21, CD23 and CD19, 
thus inhibiting BCR signaling.  
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Figure 6.1: Proposed molecular signaling from rituximab in CD20+ B-lymphoid cell lines. Based on the 
findings reported in this study including the time-dependent effects of rituximab, we propose that rituximab 
activates the anti-apoptotic gene products Bcl-2, through activation of Syk, STAT3, PI3K and RAC1 pathways. 
In addition, RAC1 activates NF-κB, that activates YY1, SP1, IL6 and then STAT3 thus down-regulating CD95 
(Fas), PARP1 and NPM1. The activation of STAT3 results in down-regulation of HLADRB1, CD46, CD120b, 
CD80, and PAX5, that inhibits CD23, CD21 and CD19 expression. On the other hand, STAT3 activates NF-κB, 
CCND1 and c-Myc, that activate ENO1, MYH9, GAPDH, CSTB and TPI1. Overall, the expression of these 
proteins after rituximab treatment leads to resistance to apoptosis. GNAS, GNAI3, AKAP, spectrins and CD20 
were detected in increased levels in LRs fractions. CD72 and CD22 were detected increasing at the cell surface. 
CD19, CD21, CD23, CD95, CD46, CD120b, CD80 and CD205 were detected decreasing. Parp1 and NPM1 
were detected at low levels in whole cell lysates. Whereas, YY1, RAC1, STAT3, p-STAT3, ENO1, MYH9, 
GAPDH, CSTB and TPI1 were detected at high levels. þ  Proteins detected and quantified here. Proteins 
highlighted in white were not detected but predicted by IPA analysis. Proteins highlighted in yellow were down-
regulated and those in orange are up-regulated. 
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6.4 TRIM21 is necessary for rituximab signaling pathway 
TRIM21 was up-regulated (20-fold, p<0.05) in LRs after rituximab treatment and is known to 
bind human IgG [398-400]. Activation or up-regulation of TRIM21 may have an essential 
role in turning off NF-κB signaling. NF-κB proteins are tightly regulated and are bound to the 
Inhibitor of NF-κB (IκB) proteins [406]. TRIM21 prevents constitutive IKBKB (IKK-B) 
mediated phosphorylation, degradation of IκB, and constitutive NF-κB nuclear localization, 
thus reducing NF-κB transcription activity [406]. 
 TRIM21 inhibits NF-κB2 and STAT3 transcription (Figure 5.4) that would result in Bcl2 
inhibition or down-regulation. TRIM21 ubiquitinate IRF8 [403, 407], that would activate 
PAX5, CIITA and BCL6, and deactivate c-Myc and Bcl2 (Figure 5.4). Avoiding prolonged 
over-production of pro-inflammatory cytokines, chemokines, and adhesion molecules, 
subsequently decreasing cellular resistance to apoptosis by down-regulation of Bcl2, NF-κB2 
and STAT3. Therefore, a strategy for increasing the E3 activity of TRIM21 in synergy with 
rituximab treatment may be useful for the treatment of CLL. 
6.5 Future directions 
A mechanism of action of rituximab against the MEC1 cell line has been proposed with 
proteins involved in survival and apoptosis in CLL. One approach to further validate the 
scheme of Figure 6.1 would be to selectively inhibit the proteins identified using 
commercially-available inhibitors or siRNA knock-downs. It might be possible to identify the 
influence of these proteins on the sensitivity of the cells to rituximab. For example, by 
knocking down the TPI1 protein, that increases the sensitivity of cells toward chemotherapy. 
TPI1 was highly up-regulated (9.8-fold) after rituximab treatment in whole cell lysates. 
Knocking down TPI1 should increase the cell’s resistance to rituximab. In addition, inhibition 
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or knock-down of RAC1, Syk, or CSTB with rituximab treatment may result in cell apoptosis. 
Decreasing CSTB would increase the degradation of FLIP E3 ligase Itch allowing caspase-8 
to bind to Fas-associated death domain (FADD), thus activating downstream effector 
caspases and cell apoptosis, as explained in Section 4.4.3. In addition, knock-down of RAC1 
or Syk would deactivate NF-κB and STAT3, resulting in up-regulation of CD95, PARP1, 
NPM1, CD21 and CD19, and down-regulation of Bcl2, c-Myc and CCND1, resulting in cell 
apoptosis (Figure 6.1). We have proposed that activation of TRIM21 also results in apoptosis. 
TRIM21 can be activated by increasing its gene expression in MEC1 cells using an 
engineered plasmid, then test for cell apoptosis using the Apoptosis kit described in Section 
2.3.6. 
CD72 was up-regulated (11.5-fold) after rituximab treatment in MEC1 cells. Phosphorylation 
of CD72 by Syk results in binding of SHP-1 to the CD72 immunoreceptor tyrosine-based 
inhibitory motifs (as discussed in Section 4.4.4), resulting in inhibition of BCR [344]. In the 
absence of antibodies or natural ligands to these regulators, BCR signals are suppressed due 
to binding of SHP-1 with inhibitory receptors (CD72), resulting in B-cell hypo-
responsiveness. The natural ligand of CD72, CD100/Sema4D, belonging to the semaphorin 
family, induces dissociation of SHP-1 from CD72 [421, 422], and prevents association of 
CD72 with BCR, switching off the negative signals from CD72 [423]. In addition, CD72 
signalling enhances PAX5 expression [424]. Thus stimulation of CD72 with an anti-CD72 
antibody in synergy with rituximab may activate PAX5 and thus up-regulate CD21 and CD19 
resulting in BCR activation and initiation of cell apoptosis. Using recombinant protein 
CD100, the natural ligand for CD72, along with rituximab may enhance BCR activation and 
cell apoptosis. 
Further validation or detection and quantification are needed for some proteins (Figure 6.1) 
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such as CCND1, PAX5, c-Myc and Bcl2 after rituximab treatment. In addition, measurement 
of caveolin-1 (CAV1) protein as its increase is associated with apoptosis [425]. In Figure 4.4 
the IPA analysis predicted that CAV1 inhibits RAC1 activation, thus activation or up-
regulation of surface CAV1 in synergy with rituximab treatment may result in cellular 
apoptosis. 
A number of proteins have been found over-expressed in both B-cell lines (Raji and MEC1) 
suggesting a role in rituximab action. However, due to a small set of cell lines used in this 
study, the involvement of these proteins in rituximab action needs to be further investigated. 
In addition, we identified protein changes in Raji and MEC1 cancer cell lines. These cell lines are 
commonly used as models for malignancies. However, it is important that the findings generated 
here with cell lines are translated to leukaemia cells from patients. 
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Table 1: Lipid raft proteins identified by sucrose density gradient method of MEC1 cells. 
No Accession number (i) 
Name Gene Name No 
Accession 
number (i) 
Name Gene Name 
1 A2ALJ3 Major histocompatibility complex, class II, DP alpha 1 HLA-
DPA1 
292 Q15149 Plectin-1 PLEC 
2 A4UCS3 NADH:ubiquinone oxidoreductase SDAP subunit NDUFAB
1 
293 Q15181 Inorganic pyrophosphatase PPA1 
3 A6NI79 Coiled-coil domain-containing protein 69 CCDC69 294 Q15286 Ras-related protein Rab-35 RAB35 
4 A6NJG9 Putative uncharacterized protein PSME1 PSME1 295 Q15300 RET tyrosine kinase/cAMP protein kinase A subunit RI NULL 
5 A6NN80 Annexin A6, isoform CRA_c ANXA6 296 Q15691 Microtubule-associated protein RP/EB family member 1 MAPRE1 
6 A8MUH2 ATP synthase-coupling factor 6, mitochondrial ATP5J 297 Q9BU65 Syntaxin-binding protein 2 STXBP2 
7 B0I1T2 Myosin-Ig [Cleaved into: Minor histocompatibility antigen HA-2 MYO1G 298 Q15904 V-type proton ATPase subunit S1 ATP6AP1 
8 B1AH80 Ras-related C3 botulinum toxin substrate 2 RAC2 299 Q16577 Elongation factor 1-alpha EEF1A1 
9 B2R4D8 60S ribosomal protein L27 RPL27 300 Q16643 Drebrin DBN1 
10 B2R886 Dendritic cell-derived ubiquitin-like protein, isoform CRA_a UBTD2 301 Q16864 V-type proton ATPase subunit F ATP6V1F 
11 B2RD27 cDNA, FLJ96428, highly similar to Homo sapiens proteasome PSMD7 302 Q16891 Mitochondrial inner membrane protein IMMT 
12 B3KPC7 Actin-related protein 2/3 complex subunit 5 ARPC5L 303 Q1RMG2 AHCY protein AHCY 
13 B3KXV7 Chromosome 10 open reading frame 42, isoform CRA_b CCDC109
A 
304 Q1RMY8 GNB1 protein GNB1 
14 B4DE32 cDNA FLJ53970, highly similar to ATP-dependent DNA helicase 2 
subunit 1 
XRCC6 305 Q2LE71 Actin related protein 2/3 complex ARPC3 
15 B4DMU8 cDNA FLJ53063, highly similar to Tubulin beta-7 chain NULL 306 Q2VYF0 Mitochondrial NADH oxidoreductase-like protein NDUFV3 
16 B4DNY3 Adenylyl cyclase-associated protein CAP1 307 Q2YDC2 HCG1985580, isoform CRA_f AHRR 
17 B4DT69 Dihydrolipoyl dehydrogenase DLD 308 Q30097 MHC class II HLA-DQ-beta-1 HLA-
DQB1 
18 B4DUU6 Pyruvate kinase PKM2 309 Q32Q12 Nucleoside diphosphate kinase NME1-
NME2 
19 B4DVJ0 Glucose-6-phosphate isomerase GPI 310 Q3KNR6 ST13 protein ST13 
20 B4DY56 ATP synthase subunit alpha ATP5A1 311 Q3LAB9 MHC class II antigen HLA-
DRB5 
21 B4DYB2 cDNA FLJ52802, highly similar to Eukaryotic translation initiation 
factor 3subunit 6-interacting protein 
NULL 312 Q3MHU6 NDUFB1 protein NDUFB1 
22 B4E1H9 Phosphoglycerate kinase PGK1 313 Q496I0 COX7A2 protein COX7A2 
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23 B4E1K7 cDNA FLJ61039, highly similar to Stomatin-like protein 2 STOML2 314 Q4EXW4 NADH-ubiquinone oxidoreductase chain 5 ND5 
24 B4E2A4 cDNA FLJ53275, highly similar to Homo sapiens spectrin domain 
with coiled-coils 1 
CYTSB 315 Q4VB24 Histone cluster 1, H1e HIST1H1E 
25 B4E2S3 cDNA FLJ56561 RFTN1 316 Q53F35 Acidic ANP32B 
26 B4E2W0 cDNA FLJ56214, highly similar to Trifunctional enzyme subunit 
beta, mitochondrial 
HADHB 317 Q53FC7 Heat shock 70kDa protein 6 HSPA6 
27 B4E2Z3 cDNA FLJ54090, highly similar to 4F2 cell-surface antigen heavy 
chain 
SLC3A2 318 Q53FG3 Interleukin enhancer binding factor 2 variant ILF2 
28 B4E3C2 cDNA FLJ52184, highly similar to 60S ribosomal protein L17 RPL17 319 Q53FS4 Lectin, mannose-binding, 1 variant LMAN1 
29 B5BU24 14-3-3 protein beta/alpha YWHAB 320 Q53FT5 Proteasome 26S non-ATPase subunit 11 variant PSMD11 
30 B5MDF5 Putative uncharacterized protein RAN RAN 321 Q53FT8 Proteasome beta 1 subunit variant PSMB1 
31 B7WNL4 Oxysterol-binding protein OSBP 322 Q53FX5 Lin-7 homolog C variant LIN7C 
32 B7Z1R5 cDNA FLJ51804, highly similar to Vacuolar ATP synthase catalytic 
subunit A, ubiquitous isoform 
ATP6V1
A 
323 Q53G17 NADH dehydrogenase NDUFS8 
33 B7Z2B0 cDNA FLJ53470, highly similar to Calcium/calmodulin-dependent 
protein kinase type II delta chain 
CAMK2D 324 Q53G70 NADH dehydrogenase NDUFV1 
34 B7Z2T5 cDNA FLJ55427, highly similar to Sodium/potassium-transporting 
ATPase alpha-1 chain 
ATP1A1 325 Q53G71 Calreticulin variant CALR 
35 B7Z478 Proteasome PSMB2 326 Q53G83 Ribosomal protein S3 variant RPS3 
36 B7Z4U5 Nuclear factor 1 NFIC 327 Q53G91 Solute carrier family 16, member 3 variant SLC16A3 
37 B7Z4V2 cDNA FLJ51907, highly similar to Stress-70 protein, mitochondrial HSPA9 328 Q53GA7 Tubulin alpha 6 variant TUBA1C 
38 B7Z4Z4 cDNA FLJ51918, highly similar to Peroxisomal membrane protein 
PEX14 
PEX14 329 Q53GB0 Mitochondrial import receptor Tom22 variant TOMM22 
39 B7Z593 cDNA FLJ52191, highly similar to Vacuolar ATP synthase subunit 
C 
ATP6V1C
1 
330 Q53GD8 FK506-binding protein 3 variant FKBP3 
40 B7Z5A2 cDNA FLJ57759, moderately similar to Transgelin-2 NULL 331 Q53GF9 Full-length cDNA 5-PRIME end of clone 
CS0DF013YM24 of Fetal brain of Homo sapiens 
TMED10 
41 B7Z5E3 L-lactate dehydrogenase LDHA 332 Q53GK6 Beta actin variant ACTB 
42 B7Z5E7 cDNA FLJ51046, highly similar to 60 kDa heat shock protein, 
mitochondrial 
HSPD1 333 Q53GR3 Translin variant TSN 
43 B7Z6U1 cDNA FLJ54173, highly similar to Ran-specific GTPase-activating 
protein 
RANBP1 334 Q53HC2 Peroxiredoxin 3 isoform a variant PRDX3 
44 B7Z6W7 cDNA FLJ55662, highly similar to Proto-oncogene tyrosine-protein 
kinase FGR 
FGR 335 Q53HD3 Ribosomal protein L18a variant RPL18A 
45 B7Z792 cDNA FLJ53932, highly similar to NADH-ubiquinone 
oxidoreductase 49 kDa subunit, mitochondrial 
NDUFS2 336 Q53HE2 Triosephosphate isomerase TPI1P1 
46 B7Z7H6 cDNA FLJ52173, highly similar to Ras-related protein R-Ras2 RRAS2 337 Q53HG1 13kDa differentiation-associated protein variant NDUFA12 
47 B7Z7N1 cDNA FLJ50915, highly similar to NADH dehydrogenase NDUFB9 338 Q53HH2 ATP synthase ATP5O 
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48 B7Z9C2 cDNA FLJ58569, highly similar to Nucleosome assembly protein 1-
like 1 
NAP1L1 339 Q53HM6 Splicing factor 3a, subunit 3 variant SF3A3 
49 B7Z9I3 cDNA, FLJ78847, highly similar to Renin receptor NULL 340 Q53HM8 Annexin VII isoform 1 variant ANXA7 
50 B7Z9L0 T-complex protein 1 subunit delta ILK-2 341 Q53HT6 B-cell receptor-associated protein 31 variant BCAP31 
51 B7ZAT2 Chaperonin containing TCP1, subunit 2 CCT2 342 Q53HU7 Eukaryotic translation initiation factor 3, subunit 2 beta, 
36kDa variant 
EIF3I 
52 B7ZAV6 cDNA, FLJ79320, highly similar to Importin beta-1 subunit KPNB1 343 Q53HV1 Ribosomal protein S4, X-linked X isoform variant RPS4X 
53 B7ZL00 SEC31A protein SEC31A 344 Q53T09 Putative uncharacterized protein XRCC5 XRCC5 
54 B7ZLJ4 Peroxiredoxin 5 PRDX5 345 Q53T69 Putative uncharacterized protein HADHA HADHA 
55 B8ZWD7 Diazepam binding inhibitor, splice form 1A(1)-G DBI 346 Q53X12 Vacuolar-type H(+)-ATPase ATP6V0A
1 
56 B8ZZS0 Putative uncharacterized protein BET1L BET1L 347 Q53XZ0 Interferon induced transmembrane protein 1 IFITM1 
57 B8ZZU8 Putative uncharacterized protein TCEB2 TCEB2 348 Q562M3 Actin-like protein ACTB 
58 O00151 PDZ and LIM domain protein 1 PDLIM1 349 Q567R0 UQCRH protein UQCRH 
59 Q4LE56 Myosin-Ic MYO1C 350 Q567R6 Single-stranded DNA binding protein 1 SSBP1 
60 O00161 Synaptosomal-associated protein 23 SNAP23 351 Q573B4 Proto-oncogene tyrosine-protein kinase LCK LCK 
61 O00425 Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 352 Q59EJ3 Heat shock 70kDa protein 1A variant HSPA1B 
62 O00461 Golgi integral membrane protein 4 GOLIM4 353 Q59ET3 Chaperonin containing TCP1, subunit 6A isoform a 
variant 
CCT6A 
63 O00483 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 NDUFA4 354 Q59F44 Cytochrome b-5 isoform 1 variant CYB5A 
64 B7ZLN2 Syntenin-1 SDCBP 355 Q59FA2 Splicing factor, arginine/serine-rich 1 SFRS1 
65 O14548 Cytochrome c oxidase subunit 7A-related protein, mitochondrial COX7A2
L 
356 Q59FE8 Epithelial protein lost in neoplasm beta variant LIMA1 
66 O14949 Cytochrome b-c1 complex subunit 8 UQCRQ 357 Q59FI9 Ribosomal protein L12 variant RPL12 
67 O14957 Cytochrome b-c1 complex subunit 10 UQCR11 358 Q59FV6 ARP3 actin-related protein 3 homolog variant ACTR3 
68 O14974 Protein phosphatase 1 regulatory subunit 12A PPP1R12
A 
359 Q59G12 Lamina-associated polypeptide 2, isoforms beta/gamma 
variant 
TMPO 
69 O15121 Sphingolipid delta(4)-desaturase DES1 DEGS1 360 Q59G24 Activated RNA polymerase II transcription cofactor 4 
variant 
SUB1 
70 O15144 Actin-related protein 2/3 complex subunit 2 ARPC2 361 Q59G88 Putative uncharacterized protein CORO1A 
71 O15355 Protein phosphatase 1G PPM1G 362 Q59GL1 Synaptotagmin binding, cytoplasmic RNA interacting 
protein variant 
SYNCRIP 
72 O15371 Eukaryotic translation initiation factor 3 subunit D EIF3D 363 Q59GN2 Putative 60S ribosomal protein L39-like 5 RPL39P5 
73 O43166 Signal-induced proliferation-associated 1-like protein 1 SIPA1L1 364 Q59GX2 Solute carrier family 2 SLC2A1 
74 O43181 NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, NDUFS4 365 Q59GX9 Ribosomal protein L5 variant RPL5 
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mitochondrial 
75 O43242 26S proteasome non-ATPase regulatory subunit 3 PSMD3 366 Q59GY2 Ribosomal protein L4 variant RPL4 
76 Q9BV64 Heterogeneous nuclear ribonucleoprotein R HNRNPR 367 Q59HF3 ATPase, H+ transporting, lysosomal 56/58kD, V1 
subunit B, isoform 2 variant 
ATP6V1B
2 
77 O43491 Band 4.1-like protein 2 EPB41L2 368 Q5CAQ5 Tumor rejection antigen HSP90B1 
78 O43504 Hepatitis B virus X-interacting protein HBXIP 369 Q5FWY2 GNAS complex locus GNAS 
79 O43633 Charged multivesicular body protein 2a CHMP2A 370 Q5H9R2 Putative uncharacterized protein DKFZp781K1356 NDUFA5 
80 O43665 Regulator of G-protein signaling 10 RGS10 371 Q5HY50 Ribosomal protein L10 RPL10 
81 O43670 Zinc finger protein 207 ZNF207 372 Q5HYL6 Putative uncharacterized protein DKFZp686E1899 TMOD3 
82 O43676 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 3 NDUFB3 373 Q5JNX2 Complement component 4A C4A 
83 O43678 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 2 NDUFA2 374 Q5JR08 Ras homolog gene family, member C RHOC 
84 O43707 Alpha-actinin-4 ACTN4 375 Q5JR95 Ribosomal protein S8 RPS8 
85 O43920 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 NDUFS5 376 Q5JWF2 Guanine nucleotide-binding protein G(s) subunit alpha 
isoforms XLas 
GNAS 
86 O60744 Thioredoxin delta 3 TXN 377 Q5SV24 ATPase family, AAA domain containing 3A ATAD3A 
87 O75326 Semaphorin-7A SEMA7A 378 Q5SZ08 Hepatoma-derived growth factor HDGF 
88 O75348 V-type proton ATPase subunit G 1 ATP6V1
G1 
379 Q5T4B6 HCG1780554 NULL 
89 O75380 NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, 
mitochondrial 
NDUFS6 380 Q5T4L4 Putative uncharacterized protein RPS27 RPS27 
90 O75477 Erlin-1 ERLIN1 381 Q5T7C6 High-mobility group box 1 HMGB1 
91 O75489 NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial 
NDUFS3 382 Q5TEC6 Histone H3 NULL 
92 O75531 Barrier-to-autointegration factor BANF1 383 Q5U071 High-mobility group box 2 HMGB2 
93 O75695 Protein XRP2 RP2 384 Q5U0A0 Proteasome subunit alpha type PSMA5 
94 O75822 Eukaryotic translation initiation factor 3 subunit J EIF3J 385 Q5U0B3 Proteasome PSMD8 
95 O75947 ATP synthase subunit d, mitochondrial ATP5H 386 Q5U0C3 RAP1A, member of RAS oncogene family RAP1A 
96 O75964 ATP synthase subunit g, mitochondrial ATP5L 387 Q5VSN0 SH3-domain kinase binding protein 1 SH3KBP1 
97 O94832 Myosin-Id MYO1D 388 Q5VU59 Tropomyosin 3 TPM3 
98 O94905 Erlin-2 ERLIN2 389 Q5W0S5 RAD23 homolog B RAD23B 
99 O95139 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 6 NDUFB6 390 Q64F87 T-cell immune regulator 1 transcript variant 4 TCIRG1 
100 O95168 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 4 NDUFB4 391 Q67AC8 MHC class II antigen HLA-
DQA1 
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101 O95298 NADH dehydrogenase [ubiquinone] 1 subunit C2 NDUFC2 392 Q67AU1 MHC class II antigen HLA-
DPA1 
102 O96000 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 NDUFB1
0 
393 Q68DG4 Putative uncharacterized protein DKFZp686A15170 HNRNPH
1 
103 O96008 Mitochondrial import receptor subunit TOM40 homolog TOMM40 394 Q68DQ4 Putative uncharacterized protein DKFZp779L0468 PRKAR1A 
104 P00387 NADH-cytochrome b5 reductase 3 CYB5R3 395 Q6FHJ9 COX5B protein COX5B 
105 P00813 Adenosine deaminase ADA 396 Q6FHU0 PSMB8 protein PSMB8 
106 P01903 HLA class II histocompatibility antigen, DR alpha chain HLA-
DRA 
397 Q6FI35 Proliferating cell nuclear antigen PCNA 
107 P01911 HLA class II histocompatibility antigen, DRB1-15 beta chain HLA-
DRB5 
398 Q6FI42 RAB11B protein RAB11B 
108 P02538 Keratin, type II cytoskeletal 6A KRT6A 399 Q6GMX6 IGH@ protein IGHG1 
109 P04075 Fructose-bisphosphate aldolase A ALDOA 400 Q6IAA8 RhoA activator C11orf59 C11orf59 
110 P04233 HLA class II histocompatibility antigen gamma chain CD74 401 Q6IAS8 RAB27A protein RAB27A 
111 P04264 Keratin, type II cytoskeletal 1 KRT1 402 Q6IAZ2 CD48 protein CD48 
112 P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH 403 Q6IAZ9 NDUFC1 protein NDUFC1 
113 P05387 60S acidic ribosomal protein P2 RPLP2 404 Q6IB58 FLOT1 protein FLOT1 
114 P06313 Ig kappa chain V-IV region JI NULL 405 Q6IB89 NDUFA7 protein NDUFA7 
115 P06314 Ig kappa chain V-IV region B17 NULL 406 Q6IBG5 MYL6 protein MYL6 
116 P06576 ATP synthase subunit beta, mitochondrial ATP5B 407 Q6IBH6 RPL26 protein RPL26 
117 P06733 Alpha-enolase ENO1 408 Q6IBK3 SCAMP2 protein SCAMP2 
118 P06734 Low affinity immunoglobulin epsilon Fc receptor FCER2 409 Q6IBS5 DLST protein DLSTP1 
119 B5BU00 Nucleophosmin NPM1 410 Q6ICN0 GRB2 protein GRB2 
120 P07195 L-lactate dehydrogenase B chain LDHB 411 Q6ICS0 ANXA11 protein ANXA11 
121 P07237 Protein disulfide-isomerase P4HB 412 Q6IN67 HYOU1 protein HYOU1 
122 Q8TBV2 Annexin A2 ANXA2 413 Q6IPH7 RPL14 protein RPL14 
123 P07477 Trypsin-1 PRSS1 414 Q6IPI1 Ribosomal protein L29 RPL29 
124 P07737 Profilin-1 PFN1 415 Q6IPT9 Elongation factor 1-alpha EEF1A1 
125 P07900 Heat shock protein HSP 90-alpha HSP90AA
1 
416 Q6IRZ0 RPL31 protein RPL31 
126 P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC 417 Q6IS14 Eukaryotic translation initiation factor 5A-1-like EIF5A 
127 P07948 Tyrosine-protein kinase LYN LYN 418 Q6LC01 MRNA encoding beta-tubulin. TUBB 
128 P08133 Annexin A6 ANXA6 419 Q6LCP6 Photoreceptor transducin gamma subunit GNGT1 
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129 P08238 Heat shock protein HSP 90-beta HSP90AB
1 
420 Q6LES8 TFAM protein TFAM 
130 P08574 Cytochrome c1, heme protein, mitochondrial CYC1 421 Q6LEU2 ATP1B1 protein ATP1B1 
131 P08582 Melanotransferrin MFI2 422 Q6N077 Putative uncharacterized protein DKFZp686L19154 TNIP1 
132 P08670 Vimentin VIM 423 Q6N097 Putative uncharacterized protein DKFZp686H20196 IGHG1 
133 P08754 Guanine nucleotide-binding protein G(k) subunit alpha GNAI3 424 Q6NSF2 RPLP0 protein RPLP0 
134 P08865 40S ribosomal protein SA RPSA 425 Q6NUM7 AGPAT5 protein AGPAT5 
135 P09211 Glutathione S-transferase P GSTP1 426 Q6NUR7 Ezrin EZR 
136 P09382 Galectin-1 LGALS1 427 Q6NVC0 SLC25A5 protein SLC25A5 
137 P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA
1 
428 Q6NW36 Proteasome PSMC1 
138 P09669 Cytochrome c oxidase subunit 6C COX6C 429 Q6NXR8 Ribosomal protein S3A RPS3A 
139 P10176 Cytochrome c oxidase subunit 8A, mitochondrial COX8A 430 B7ZCV7 Phostensin KIAA1949 
140 P11142 Heat shock cognate 71 kDa protein HSPA8 431 Q6NZ44 Ferritin FTH1 
141 P11233 Ras-related protein Ral-A RALA 432 Q6NZX3 5'-nucleotidase, ecto NT5E 
142 P11940 Polyadenylate-binding protein 1 PABPC1 433 Q6P2H9 CD40 protein CD40 
143 P12259 Coagulation factor V F5 434 Q6P452 ANXA4 protein ANXA4 
144 Q6P666 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial COX4I1 435 Q6P4E4 RPL37A protein RPL37A 
145 P13639 Elongation factor 2 EEF2 436 Q6P6D7 Phosphoglycerate mutase PGAM1 
146 P13645 Keratin, type I cytoskeletal 10 KRT10 437 Q6PIN5 PA2G4 protein PA2G4 
147 Q5TBN4 Plastin-2 LCP1 438 Q6PJT4 MSN protein MSN 
148 P13987 CD59 glycoprotein CD59 439 Q6PKD3 RDX protein RDX 
149 P14314 Glucosidase 2 subunit beta PRKCSH 440 Q6PUJ7 Prohibitin PHB 
150 Q6IBK9 Hematopoietic lineage cell-specific protein HCLS1 441 Q6QE17 IMP dehydrogenase 2 IMPDH2 
151 P14854 Cytochrome c oxidase subunit 6B1 COX6B1 442 Q6S8J3 POTE ankyrin domain family member E POTEE 
152 P14868 Aspartyl-tRNA synthetase, cytoplasmic DARS 443 Q6U2E9 C4B1 C4B 
153 P14927 Cytochrome b-c1 complex subunit 7 UQCRB 444 Q6UV22 KIAA0107 isoform PSMD6 
154 P15531 Nucleoside diphosphate kinase A NME1-
NME2 
445 Q6UXV4 Apolipoprotein O-like APOOL 
155 P15907 Beta-galactoside alpha-2,6-sialyltransferase 1 ST6GAL1 446 Q6W3F3 SMAC3 DIABLO 
156 P15954 Cytochrome c oxidase subunit 7C, mitochondrial COX7C 447 Q71V99 Peptidyl-prolyl cis-trans isomerase PPIA 
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157 P17568 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 7 NDUFB7 448 Q75MT9 Malate dehydrogenase MDH2 
158 P19338 Nucleolin NCL 449 Q7KZ24 Nuclease sensitive element binding protein-1 YBX1 
159 P20674 Cytochrome c oxidase subunit 5A, mitochondrial COX5A 450 Q7Z427 Putative MAPK activating protein TFG 
160 P20700 Lamin-B1 LMNB1 451 Q7Z4F3 Caveolin CAV1 
161 P21281 V-type proton ATPase subunit B, brain isoform ATP6V1B
2 
452 Q7Z4R8 UPF0669 protein C6orf120 C6orf120 
162 P21283 V-type proton ATPase subunit C 1 ATP6V1C
1 
453 Q7Z4X2 Neuronal protein NDUFB11 
163 P21796 Voltage-dependent anion-selective channel protein 1 VDAC1 454 Q7Z518 NADH dehydrogenase NDUFA10 
164 Q68CQ5 Multifunctional protein ADE2 [Includes: 
Phosphoribosylaminoimidazole-succinocarboxamide synthase 
PAICS 455 Q7Z5A3 Small nuclear ribonucleoprotein Sm D1 SNRPD1 
165 P22695 Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 456 Q7Z612 Acidic ribosomal phosphoprotein P1 RPLP1 
166 P23284 Peptidyl-prolyl cis-trans isomerase B PPIB 457 Q3HS85 B- and T-lymphocyte attenuator BTLA 
167 A6NGN1 Tryptophanyl-tRNA synthetase, cytoplasmic WARS 458 Q86TW7 Dihydrolipoamide S-succinyltransferase DLSTP1 
168 P23528 Cofilin-1 CFL1 459 Q86XM2 ADD1 protein ADD1 
169 P24534 Elongation factor 1-beta EEF1B2 460 Q86Y39 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 11 
NDUFA11 
170 P24539 ATP synthase subunit b, mitochondrial ATP5F1 461 Q86YK2 Similar to small nuclear ribonucleoprotein polypeptide B'' SNRPB2 
171 P25398 40S ribosomal protein S12 RPS12 462 Q8IWR8 Ribosomal protein L19 RPL19 
172 P26641 Elongation factor 1-gamma TUT1 463 Q8N183 Mimitin, mitochondrial NDUFAF2 
173 P27348 14-3-3 protein theta YWHAQ 464 Q8N4H5 Mitochondrial import receptor subunit TOM5 homolog TOMM5 
174 P27449 V-type proton ATPase 16 kDa proteolipid subunit ATP6V0C 465 Q8N5K1 CDGSH iron sulfur domain-containing protein 2 CISD2 
175 P27824 Calnexin CANX 466 Q8N5L9 Ribosomal protein S2 RPS2 
176 B2RB77 Tropomodulin-1 TMOD1 467 Q8N5M0 DDX39 protein DDX39 
177 P28331 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial NDUFS1 468 Q8N6F7 Germinal center B-cell-expressed transcript 2 protein GCET2 
178 P29692 Elongation factor 1-delta EEF1D 469 Q8NC51 Plasminogen activator inhibitor 1 RNA-binding protein SERBP1 
179 P29966 Myristoylated alanine-rich C-kinase substrate MARCKS 470 Q8ND76 Cyclin-Y CCNY 
180 P30050 60S ribosomal protein L12 RPL12 471 Q8NHM4 Putative trypsin-6 PRSS1 
181 P30101 Protein disulfide-isomerase A3 PDIA3 472 Q8TAS0 ATP synthase gamma chain ATP5C1 
182 P30626 Sorcin SRI 473 Q8TBK5 60S ribosomal protein L6 RPL6 
183 P31930 Cytochrome b-c1 complex subunit 1, mitochondrial UQCRC1 474 Q8TC62 Septin 7 Sep-07 
184 P32119 Peroxiredoxin-2 PRDX2 475 Q8WLS2 MHC class I antigen MICA 
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185 P32322 Pyrroline-5-carboxylate reductase 1, mitochondrial PYCR1 476 Q8WU40 Calcium/calmodulin-dependent protein kinase type II 
subunit gamma 
CAMK2G 
186 P32969 60S ribosomal protein L9 RPL9 477 Q8WV92 MIT domain-containing protein 1 MITD1 
187 P32970 CD70 antigen CD70 478 Q8WVV2 Oxysterol-binding protein OSBPL5 
188 P33241 Lymphocyte-specific protein 1 LSP1 479 Q8WVX7 Ribosomal protein S19 RPS19 
189 A8K650 Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial DUT 480 Q8WWI1 LIM domain only protein 7 LMO7 
190 P35527 Keratin, type I cytoskeletal 9 KRT9 481 Q92544 Transmembrane 9 superfamily member 4 TM9SF4 
191 P35579 Myosin-9 MYH9 482 Q92835 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 LOC64674
3 
192 P35610 Sterol O-acyltransferase 1 SOAT1 483 Q92928 Putative Ras-related protein Rab-1C RAB1C 
193 P35613 Basigin BSG 484 Q92930 Ras-related protein Rab-8B RAB8B 
194 P35908 Keratin, type II cytoskeletal 2 epidermal KRT2 485 B0LUZ6 HLA class II histocompatibility antigen, DRB1-12 beta 
chain 
HLA-
DRB5 
195 P36543 V-type proton ATPase subunit E 1 ATP6V1E
1 
486 Q96A26 Protein FAM162A FAM162A 
196 B5BUF5 Signal recognition particle 14 kDa protein SRP14 487 Q96AG4 Leucine-rich repeat-containing protein 59 LRRC59 
197 P38159 Heterogeneous nuclear ribonucleoprotein G RBMX 488 Q96C71 GNAI2 protein GNAI2 
198 P38919 Eukaryotic initiation factor 4A-III EIF4A3 489 Q96DI8 Heme oxygenase HMOX1 
199 P42766 60S ribosomal protein L35 RPL35 490 Q96DV6 Ribosomal protein S6 RPS6 
200 P43686 26S protease regulatory subunit 6B PSMC4 491 Q96GD7 CSDA protein CSDA 
201 P46778 60S ribosomal protein L21 RPL21P1
9 
492 Q96HS1 Serine/threonine-protein phosphatase PGAM5, 
mitochondrial 
PXMP2 
202 P46781 40S ribosomal protein S9 RPS9 493 Q96HX3 Similar to ribophorin I RPN1 
203 P46783 40S ribosomal protein S10 RPS10 494 Q96MX4 Ewing sarcoma breakpoint region 1, isoform CRA_h EWSR1 
204 P46977 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 
subunit STT3A 
STT3A 495 Q96NT0 Coiled-coil domain-containing protein 115 CCDC115 
205 P47756 F-actin-capping protein subunit beta CAPZB 496 Q96Q74 Mitochondrial ribosomal protein L7/L12 MRPL12 
206 P47985 Cytochrome b-c1 complex subunit Rieske, mitochondrial UQCRFS
1 
497 Q96RS2 Laminin receptor-like protein LAMRL5 RPSA 
207 P49207 60S ribosomal protein L34 RPL34 498 Q96SB3 Neurabin-2 PPP1R9B 
208 Q8WTW0 Signal recognition particle 9 kDa protein SRP9 499 Q96T49 Protein phosphatase 1 regulatory inhibitor subunit 16B PPP1R16B 
209 P50151 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-
10 
GNG10 500 Q99623 Prohibitin-2 PHB2 
210 P50995 Annexin A11 ANXA11 501 Q99720 Sigma non-opioid intracellular receptor 1 SIGMAR1 
211 P51149 Ras-related protein Rab-7a RAB7A 502 Q99805 Transmembrane 9 superfamily member 2 TM9SF2 
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212 P51665 26S proteasome non-ATPase regulatory subunit 7 PSMD7 503 Q99816 Tumor susceptibility gene 101 protein TSG101 
213 P51970 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 NDUFA8 504 Q99828 Calcium and integrin-binding protein 1 CIB1 
214 P51991 Heterogeneous nuclear ribonucleoprotein A3 HNRNPA
3 
505 Q9B1A3 ATP synthase protein 8 NULL 
215 P52272 Heterogeneous nuclear ribonucleoprotein M HNRNPM 506 Q9B2U8 Cytochrome c oxidase subunit 2 COX2 
216 P52566 Rho GDP-dissociation inhibitor 2 ARHGDI
B 
507 Q9B2X5 NADH-ubiquinone oxidoreductase chain 1 ND1 
217 P52803 Ephrin-A5 EFNA5 508 Q9BRJ6 Uncharacterized protein C7orf50 C7orf50 
218 P53985 Monocarboxylate transporter 1 SLC16A1 509 Q9BRW0 CD58 protein CD58 
219 P53990 IST1 homolog KIAA017
4 
510 Q9BS26 Endoplasmic reticulum resident protein 44 ERP44 
220 P54709 Sodium/potassium-transporting ATPase subunit beta-3 ATP1B3 511 Q9BSQ6 RPL13A protein RPL13A 
221 P54819 Adenylate kinase 2, mitochondrial AK2 512 Q9BSV4 SFPQ protein SFPQ 
222 Q0V924 Transitional endoplasmic reticulum ATPase VCP 513 Q9BTT5 Similar to NADH dehydrogenase NDUFA9 
223 P56181 NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial NDUFV3 514 Q9BTV4 Transmembrane protein 43 TMEM43 
224 B2RE54 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 NDUFA6 515 Q9BUF9 Myosin, light chain 9, regulatory MYL9 
225 P57105 Synaptojanin-2-binding protein SYNJ2BP 516 Q9BUJ2 Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPU
L1 
226 P60842 Eukaryotic initiation factor 4A-I EIF4A1 517 Q9BUL8 Programmed cell death protein 10 PDCD10 
227 P60866 40S ribosomal protein S20 RPS20 518 Q9BUQ0 Polypyrimidine tract binding protein 1 PTBP1 
228 P60900 Proteasome subunit alpha type-6 PSMA6 519 Q9BVK6 Transmembrane emp24 domain-containing protein 9 TMED9 
229 P61009 Signal peptidase complex subunit 3 SPCS3 520 Q9BX83 Hemoglobin alpha 1 globin chain HBA2 
230 P61160 Actin-related protein 2 ACTR2 521 Q9BXV4 PNAS-140 RAP1B 
231 P61221 ATP-binding cassette sub-family E member 1 ABCE1 522 Q9BZK3 Putative nascent polypeptide-associated complex subunit 
alpha-like protein 
NACAP1 
232 P61353 60S ribosomal protein L27 RPL27 523 Q9GIP0 MHC class I antigen HLA-A 
233 P61970 Nuclear transport factor 2 NUTF2 524 A8K209 Linker for activation of T-cells family member 2 LAT2 
234 P61981 14-3-3 protein gamma YWHAG 525 Q6ZSI4 Protein FAM107B FAM107B 
235 P62158 Calmodulin CALM3 526 Q9H246 Uncharacterized protein C1orf21 C1orf21 
236 P62249 40S ribosomal protein S16 RPS16 527 Q9H2R7 NPD011 NUDC 
237 Q4VJB6 14-3-3 protein epsilon YWHAE 528 Q9H3H0 Vacuolar ATP synthase subunit D homolog ATP6V1D 
238 P62263 40S ribosomal protein S14 RPS14 529 Q9H444 Charged multivesicular body protein 4b CHMP4B 
239 P62266 40S ribosomal protein S23 RPS23 530 Q9H4I9 UPF0466 protein C22orf32, mitochondrial C22orf32 
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240 P62269 40S ribosomal protein S18 RPS18P9 531 Q9H5A7 CD44 molecule CD44 
241 P62277 40S ribosomal protein S13 RPS13 532 Q9HBL7 Transmembrane protein C9orf46 C9orf46 
242 P62280 40S ribosomal protein S11 RPS11 533 Q9HCP0 Casein kinase I isoform gamma-1 CSNK1G1 
243 P62424 60S ribosomal protein L7a RPL7A 534 Q9MY51 Leucocyte antigen A HLA-A 
244 P62750 60S ribosomal protein L23a RPL23A 535 Q9NPA0 UPF0480 protein C15orf24 C15orf24 
245 Q9UDC2 40S ribosomal protein S15 RPS15 536 Q96B16 Reticulon-4 RTN4 
246 Q7Z3D1 40S ribosomal protein S24 RPS24 537 Q9NQL2 Ras-related GTP-binding protein D RRAGD 
247 P62851 40S ribosomal protein S25 RPS25 538 Q9NV96 Cell cycle control protein 50A TMEM30
A 
248 P62861 40S ribosomal protein S30 FAU 539 Q9NVT9 Armadillo repeat-containing protein 1 ARMC1 
249 P62879 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 GNB2 540 Q9NX63 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 3, mitochondrial 
CHCHD3 
250 P62906 60S ribosomal protein L10a RPL10A 541 Q9NXZ8 HDJ2 protein DNAJA1 
251 P62910 60S ribosomal protein L32 RPL32 542 Q9NY65 Tubulin alpha-8 chain TUBA8 
252 P62917 60S ribosomal protein L8 RPL8 543 Q9NY85 Ribosomal protein L3 LOC65388
1 
253 P63104 14-3-3 protein zeta/delta YWHAZ 544 Q9NZ01 Trans-2,3-enoyl-CoA reductase TECR 
254 P63173 60S ribosomal protein L38 RPL38 545 Q9P0J0 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 
NDUFA13 
255 P63208 S-phase kinase-associated protein 1 SKP1 546 Q9P0L0 Vesicle-associated membrane protein-associated protein 
A 
VAPA 
256 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 547 Q9BXC3 Serine/threonine-protein kinase MST4 MST4 
257 P67936 Tropomyosin alpha-4 chain TPM4 548 Q9T3Q5 NADH-ubiquinone oxidoreductase chain 2 ND2 
258 P68133 Actin, alpha skeletal muscle ACTA1 549 Q9UDW1 Cytochrome b-c1 complex subunit 9 UQCR10 
259 P78548 G18 GPSM3 550 Q9UEG9 Cytochrome c oxidase polypeptide VIa COX6A1 
260 Q6YJU6 HLA class II histocompatibility antigen, DR beta 3 chain HLA-
DRB5 
551 Q9UEH5 24-kDa subunit of complex I NDUFV2 
261 P79547 MHC class II antigen HLA-
DRB5 
552 Q9UHA4 Mitogen-activated protein kinase scaffold protein 1 MAPKSP1 
262 P80723 Brain acid soluble protein 1 BASP1 553 B4DTL9 Septin-9 NULL 
263 P83731 60S ribosomal protein L24 RPL24 554 Q9UI12 V-type proton ATPase subunit H ATP6V1H 
264 P99999 Cytochrome c CYCS 555 Q9UKY7 Protein CDV3 homolog CDV3 
265 Q00325 Phosphate carrier protein, mitochondrial SLC25A3 556 Q86SZ7 Proteasome activator complex subunit 2 PSME2 
266 Q00610 Clathrin heavy chain 1 CLTC 557 Q9ULD0 2-oxoglutarate dehydrogenase-like, mitochondrial OGDHL 
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267 Q00839 Heterogeneous nuclear ribonucleoprotein U HNRNPU 558 Q9UNM1 Chaperonin 10-related protein HSPE1 
268 Q01082 Spectrin beta chain, brain 1 SPTBN1 559 Q9UPN1 Serine/threonine-protein phosphatase PPP1CC 
269 Q01105 Protein SET SET 560 Q9Y277 Voltage-dependent anion-selective channel protein 3 VDAC3 
270 Q03252 Lamin-B2 LMNB2 561 B2RTU4 A-kinase anchor protein 2 NULL 
271 Q06830 Peroxiredoxin-1 PRDX1 562 Q9Y2Q5 Mitogen-activated protein-binding protein-interacting 
protein 
ROBLD3 
272 Q07021 Complement component 1 Q subcomponent-binding protein, 
mitochondrial 
C1QBP 563 Q9Y3D9 28S ribosomal protein S23, mitochondrial MRPS23 
273 Q08722 Leukocyte surface antigen CD47 CD47 564 Q9Y487 V-type proton ATPase 116 kDa subunit a isoform 2 ATP6V0A
2 
274 Q0D2M2 HIST1H2BC protein HIST1H2
BC 
565 Q53HC4 Sorting and assembly machinery component 50 homolog SAMM50 
275 Q0P5U7 TMSB4X protein TMSB4X 566 Q9Y6A9 Signal peptidase complex subunit 1 SPCS1 
276 Q0QEN7 ATP synthase subunit beta ATP5B 567 Q9Y6E3 HSPC027 PSMD13 
277 Q0VAS5 Histone H4 HIST2H4
A 
568 Q9Y6H1 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 2, mitochondrial 
CHCHD2 
278 Q0VGL1 UPF0539 protein C7orf59 C7orf59 569 Q9Y6M4 Casein kinase I isoform gamma-3 CSNK1G3 
279 Q10589 Bone marrow stromal antigen 2 BST2 570 O00237 RING finger protein 103 RNF103 
280 Q12771 P37 AUF1 HNRNPD 571 O95167 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 3 
NDUFA3 
281 Q12907 Vesicular integral-membrane protein VIP36 LMAN2 572 P08758 Annexin A5 ANXA5 
282 Q13151 Heterogeneous nuclear ribonucleoprotein A0 HNRNPA
0 
573 P11021 78 kDa glucose-regulated protein HSPA5 
283 Q13442 28 kDa heat- and acid-stable phosphoprotein PDAP1 574 P22626 Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA
2B1 
284 Q13502 Phosphotyrosine independent ligand p62B for the Lck SH2 domain 
B-cell isoform 
SQSTM1 575 P52907 F-actin-capping protein subunit alpha-1 CAPZA1 
285 Q13813 Spectrin alpha chain, brain SPTAN1 576 P61313 60S ribosomal protein L15 RPL15 
286 Q14240 Eukaryotic initiation factor 4A-II EIF4A2 577 Q12846 Syntaxin-4 STX4 
287 Q14254 Flotillin-2 FLOT2 578 Q9Y266 Nuclear migration protein nudC NUDC 
288 Q14739 Lamin-B receptor LBR 579 P01871 Ig mu chain C region IGHM 
289 Q14UF6 Decay-accelerating factor splicing variant 1 CD55 580 Q0KKI6 Immunoglobulin kappa light chain IGKC 
290 Q15005 Signal peptidase complex subunit 2 SPCS2     
291 Q53QU3 Septin-2 Sep-02     
 
i  Accession numbers of proteins were from the UniProtKB/Swiss-Prot database. 
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Table 2: Lipid raft proteins immuno-precipitated of MEC1 cells by rituximab (10 µg/mL). The biological process and sub-cellular localization of identified proteins 
are indicated. 
No Accession number (i) 
Name Gene Name Sub cellular localization (ii) 
Biological process (iii) 
1 A2N7P4 Immunoglobulin mu-chain D-J4-region  Plasma Membrane Immune Response 
2 A6NG51 Putative uncharacterized protein SPTAN1 SPTAN1 Plasma Membrane Cell Growth 
3 A8MXA8 Putative uncharacterized protein RPL23A RPL23A Cytoplasm Protein Metabolism 
4 B1AH80 Ras-related C3 botulinum toxin substrate 2 RAC2 Plasma Membrane Signal Transduction 
5 B2R4D8 60S ribosomal protein L27 RPL27 Cytoplasm Protein Metabolism 
6 Q06830 cDNA, FLJ92164, highly similar to Homo sapiens peroxiredoxin 1 PRDX1 Cytoplasm Protein Metabolism 
7 Q59GL1 cDNA, FLJ94136, highly similar to Homo sapiens synaptotagmin binding, cytoplasmic RNA 
interacting protein 
SYNCRIP Cytoplasm RNA binding 
8 Q9NZ01 cDNA FLJ10554 fis, clone NT2RP2002385, highly similar to Synaptic glycoprotein SC2 TECR ER Lipid Biosynthesis 
9 P33241 cDNA FLJ34752 fis, clone NESOP2000452, highly similar to Lymphocyte-specific protein 1 LSP1 Plasma Membrane Signal Transduction 
10 P19338 cDNA FLJ38578 fis, clone HCHON2007674, highly similar to NUCLEOLIN NCL Plasma Membrane RNA binding 
11 B3KV44 Nucleosome assembly protein 1-like 1, isoform CRA_c NAP1L1 Cytoplasm RNA binding 
12 B4DTG2 cDNA FLJ56389, highly similar to Elongation factor 1-gamma TUT1 Cytoplasm Protein Metabolism 
13 B4DVJ0 Glucose-6-phosphate isomerase GPI Cytoplasm Protein Metabolism 
14 P60866 cDNA FLJ58953, highly similar to 40S ribosomal protein S20 RPS20 Ribosome Protein Metabolism 
15 O15371 cDNA FLJ58383, highly similar to Eukaryotic translation initiation factor 3 subunit 7 EIF3D Cytoplasm Protein Metabolism 
16 P51991 cDNA FLJ58832, highly similar to Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 Cytoplasm RNA binding 
17 B5MDF5 Putative uncharacterized protein RAN RAN Cytoplasm Signal Transduction 
18 P02786 cDNA FLJ57106, highly similar to Transferrin receptor protein 1 TFRC Plasma Membrane Signal Transduction 
19 B7Z4B8 cDNA FLJ56481, highly similar to Heterogeneous nuclear ribonucleoprotein U-like protein 1 HNRNPUL1 Cytoplasm Protein Metabolism 
20 B7Z5E3 L-lactate dehydrogenase LDHA Cytoplasm Metabolism Energy 
21 O00425 Insulin-like growth factor 2 mRNA-binding protein 3 IGF2BP3 Cytoplasm Protein Metabolism 
22 O00483 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 4 NDUFA4 Plasma Membrane Metabolism Energy 
23 Q9BV64 Heterogeneous nuclear ribonucleoprotein R HNRNPR Nucleus RNA binding 
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24 O75964 ATP synthase subunit g, mitochondrial ATP5L Plasma Membrane Transport 
25 P01903 HLA class II histocompatibility antigen, DR alpha chain HLA-DRA Plasma Membrane Immune Response 
26 P04075 Fructose-bisphosphate aldolase A ALDOA Cytoplasm Metabolism Energy 
27 P04264 Keratin, type II cytoskeletal 1 KRT1 Plasma Membrane Immune Response 
28 P04406 Glyceraldehyde-3-phosphate dehydrogenase GAPDH Plasma Membrane Metabolism Energy 
29 P05387 60S acidic ribosomal protein P2 RPLP2 Cytoplasm Protein Metabolism 
30 P06314 Ig kappa chain V-IV region B17 NULL Plasma Membrane Signal Transduction 
31 P06748 Nucleophosmin NPM1 Cytoplasm Protein Metabolism 
32 P07195 L-lactate dehydrogenase B chain LDHB Cytoplasm Metabolism Energy 
33 P07477 Trypsin-1 PRSS1 Extracellular Protein Metabolism 
34 P07900 Heat shock protein HSP 90-alpha HSP90AA1 Plasma Membrane Signal Transduction 
35 P07910 Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC Cytoplasm Rna binding 
36 P08195 4F2 cell-surface antigen heavy chain SLC3A2 Plasma Membrane Transport 
37 P08238 Heat shock protein HSP 90-beta HSP90AB1 Plasma Membrane Signal Transduction 
38 P09651 Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 Cytoplasm RNA binding 
39 P11142 Heat shock cognate 71 kDa protein HSPA8 Plasma Membrane Signal Transduction 
40 P11836 B-lymphocyte antigen CD20 MS4A1 Plasma Membrane Signal Transduction 
41 P11940 Polyadenylate-binding protein 1 PABPC1 Cytoplasm RNA binding 
42 P13639 Elongation factor 2 EEF2 Cytoplasm Protein Metabolism 
43 P13645 Keratin, type I cytoskeletal 10 KRT10 Cytoplasm Cell Growth 
44 Q5TBN4 Plastin-2 LCP1 Plasma Membrane Signal Transduction 
45 P13987 CD59 glycoprotein CD59 Plasma Membrane Signal Transduction 
46 B3KRY0 Pyruvate kinase isozymes M1/M2 PKM2 Plasma Membrane Metabolism Energy 
47 P18621 60S ribosomal protein L17 RPL17 Ribosome Protein Metabolism 
48 Q5XPV5 52 kDa Ro protein TRIM21 Plasma Membrane Ubiquitation 
49 P20700 Lamin-B1 LMNB1 Plasma Membrane Cell Growth 
50 P21796 Voltage-dependent anion-selective channel protein 1 VDAC1 Plasma Membrane Transport 
51 P22695 Cytochrome b-c1 complex subunit 2, mitochondrial UQCRC2 Mitochondria Metabolism Energy 
52 P23528 Cofilin-1 CFL1 Plasma Membrane Signal Transduction 
53 P25705 ATP synthase subunit alpha, mitochondrial ATP5A1 Plasma Membrane Signal Transduction 
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54 P29692 Elongation factor 1-delta EEF1D Cytoplasm Signal Transduction 
55 P30050 60S ribosomal protein L12 RPL12 Cytoplasm Protein Metabolism 
56 P32969 60S ribosomal protein L9 RPL9 Ribosome Protein Metabolism 
57 P35527 Keratin, type I cytoskeletal 9 KRT9 Cytoplasm Cell Growth 
58 P35579 Myosin-9 MYH9 Plasma Membrane Signal Transduction 
59 P35613 Basigin BSG Plasma Membrane Signal Transduction 
60 P35908 Keratin, type II cytoskeletal 2 epidermal KRT2 Cytoplasm Cell growth 
61 P36873 Serine/threonine-protein phosphatase PP1-gamma catalytic subunit PPP1CC Cytoplasm Signal Transduction 
62 B5BUF5 Signal recognition particle 14 kDa protein SRP14 Cytoplasm Protein Metabolism 
63 P38919 Eukaryotic initiation factor 4A-III EIF4A3 Cytoplasm Signal Transduction 
64 P42167 Lamina-associated polypeptide 2, isoforms beta/gamma TMPO Cytoplasm Nuclear Organization 
65 P42766 60S ribosomal protein L35 RPL35 Ribosome Protein Metabolism 
66 P46778 60S ribosomal protein L21 RPL21P19 Ribosome Protein Metabolism 
67 P46781 40S ribosomal protein S9 RPS9 Ribosome Protein Metabolism 
68 P48047 ATP synthase subunit O, mitochondrial ATP5O Plasma Membrane Transport 
69 P49207 60S ribosomal protein L34 RPL34 Ribosome Protein Metabolism 
70 P52272 Heterogeneous nuclear ribonucleoprotein M HNRNPM Plasma Membrane Protein Metabolism 
71 Q0V924 Transitional endoplasmic reticulum ATPase VCP Cytoplasm Signal Transduction 
72 P60842 Eukaryotic initiation factor 4A-I EIF4A1 Cytoplasm Signal Transduction 
73 P62249 40S ribosomal protein S16 RPS16 Ribosome Protein Metabolism 
74 P62263 40S ribosomal protein S14 RPS14 Ribosome Protein Metabolism 
75 P62266 40S ribosomal protein S23 RPS23 Ribosome Protein Metabolism 
76 P62269 40S ribosomal protein S18 RPS18P9 Ribosome Protein Metabolism 
77 P62277 40S ribosomal protein S13 RPS13 Ribosome Protein Metabolism 
78 P62280 40S ribosomal protein S11 RPS11 Ribosome Protein Metabolism 
79 P62424 60S ribosomal protein L7a RPL7A Ribosome Protein Metabolism 
80 Q9UDC2 40S ribosomal protein S15 RPS15 Ribosome Protein Metabolism 
81 Q7Z3D1 40S ribosomal protein S24 RPS24 Ribosome Protein Metabolism 
82 P62851 40S ribosomal protein S25 RPS25 Ribosome Protein Metabolism 
83 P62861 40S ribosomal protein S30 FAU Ribosome Protein Metabolism 
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84 P62906 60S ribosomal protein L10a RPL10A Ribosome Protein Metabolism 
85 P62910 60S ribosomal protein L32 RPL32 Ribosome Protein Metabolism 
86 P62917 60S ribosomal protein L8 RPL8 Ribosome Protein Metabolism 
87 P63173 60S ribosomal protein L38 RPL38 Ribosome Protein Metabolism 
88 P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 Plasma Membrane Signal Transduction 
89 Q6YJU6 HLA class II histocompatibility antigen, DR beta 3 chain HLA-DRB5 Plasma Membrane Immune Response 
90 P83731 60S ribosomal protein L24 RPL24 Ribosome Protein Metabolism 
91 Q00325 Phosphate carrier protein, mitochondrial SLC25A3 Plasma Membrane Transport 
92 Q00610 Clathrin heavy chain 1 CLTC Plasma Membrane Lipid Biosynthesis 
93 Q07021 Complement component 1 Q subcomponent-binding protein, mitochondrial C1QBP Plasma Membrane Immune Response 
94 Q0D2M2 HIST1H2BC protein HIST1H2BC Nucleus DNA binding 
95 Q0QEN7 ATP synthase subunit beta ATP5B Plasma Membrane Transport 
96 Q0VAS5 Histone H4 HIST2H4A Nucleus DNA binding 
97 Q10589 Bone marrow stromal antigen 2 BST2 Plasma Membrane Signal Transduction 
98 Q1RMG2 AHCY protein AHCY Cytoplasm Metabolism Energy 
99 Q2LIR1 MHC class II antigen HLA-DQA1 Plasma Membrane Immune Response 
100 Q32Q12 Nucleoside diphosphate kinase NME1-NME2 Cytoplasm Signal Transduction 
101 Q32XH3 Ribosomal protein L18a-like protein RPL18A Ribosome Protein Metabolism 
102 Q3KQT6 Ribosomal protein S2 RPS2 Cytoplasm Protein Metabolism 
103 Q4VB24 Histone cluster 1, H1e HIST1H1E Nucleus DNA binding 
104 Q53FG3 Interleukin enhancer binding factor 2 variant ILF2 Cytoplasm Transcrpition 
105 Q53G83 Ribosomal protein S3 variant RPS3 Plasma Membrane Protein Metabolism 
106 Q53GK6 Beta actin variant ACTB Plasma Membrane Cell Growth 
107 Q53HC2 Peroxiredoxin 3 isoform a variant PRDX3 Endosome Metabolism Energy 
108 Q53T09 Putative uncharacterized protein XRCC5 XRCC5 Nucleus DNA Repaire 
109 Q53T69 Putative uncharacterized protein HADHA HADHA Mitochondria Metabolism Energy 
110 Q59FA2 Splicing factor, arginine/serine-rich 1 SFRS1 Cytoplasm Protein Metabolism 
111 Q59GN2 Putative 60S ribosomal protein L39-like 5 RPL39P5 Ribosome Protein Metabolism 
112 Q59GX9 Ribosomal protein L5 variant RPL5 Ribosome Protein Metabolism 
113 Q59GY2 Ribosomal protein L4 variant RPL4 Ribosome Protein Metabolism 
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114 Q5CAQ5 Tumor rejection antigen HSP90B1 Plasma Membrane Signal Transduction 
115 Q5HY50 Ribosomal protein L10 RPL10 Ribosome Protein Metabolism 
116 Q5JR95 Ribosomal protein S8 RPS8 Ribosome Protein Metabolism 
117 Q8NC51 Putative uncharacterized protein DKFZp686P17171 SERBP1 Cytoplasm RNA binding 
118 P14868 Putative uncharacterized protein DKFZp781B11202 DARS Cytoplasm Metabolism Energy 
119 Q6IAZ2 CD48 protein CD48 Plasma Membrane Signal Transduction 
120 Q6IBH6 RPL26 protein RPL26 Ribosome Protein Metabolism 
121 Q6IPH7 RPL14 protein RPL14 Ribosome Protein Metabolism 
122 Q6IPI1 Ribosomal protein L29 RPL29 Ribosome Protein Metabolism 
123 Q6IQ15 Elongation factor 1-alpha EEF1A1 Cytoplasm Protein Metabolism 
124 Q6IRZ0 RPL31 protein RPL31 Ribosome Protein Metabolism 
125 Q6LC01 MRNA encoding beta-tubulin. TUBB Plasma Membrane Cell Growth 
126 Q6NSF2 RPLP0 protein RPLP0 Cytoplasm Protein Metabolism 
127 Q6NVC0 SLC25A5 protein SLC25A5 Cytoplasm Protein Metabolism 
128 Q6NXR8 Ribosomal protein S3A RPS3A Cytoplasm Protein Metabolism 
129 Q6NZ55 60S ribosomal protein L13 RPL13 Ribosome Protein Metabolism 
130 Q6P2H9 CD40 protein CD40 Plasma Membrane Signal Transduction 
131 Q6PUJ7 Prohibitin PHB Plasma Membrane Signal Transduction 
132 Q6U2E9 C4B1 C4B Plasma Membrane Immune Response 
133 Q6ZNK5 Myosin-IG MYO1G Plasma Membrane Signal Transduction 
134 Q71V99 Peptidyl-prolyl cis-trans isomerase PPIA Cytoplasm Protein Metabolism 
135 Q7KZ24 Nuclease sensitive element binding protein-1 YBX1 Nucleus DNA binding 
136 Q7YQ27 MHC class II antigen HLA-DRB5 Plasma Membrane Immune Response 
137 Q7Z5A3 Small nuclear ribonucleoprotein Sm D1 SNRPD1 Cytoplasm RNA binding 
138 Q7Z612 Acidic ribosomal phosphoprotein P1 RPLP1 Ribosome Protein Metabolism 
139 Q8IWR8 Ribosomal protein L19 RPL19 Ribosome Protein Metabolism 
140 Q8TAS0 ATP synthase gamma chain ATP5C1 Mitochondria Transport 
141 Q8WVX7 Ribosomal protein S19 RPS19 Ribosome Protein Metabolism 
142 Q95466 Major histocompatibility complex class II beta chain HLA-DQB1 Plasma Membrane Immune Response 
143 Q95HB9 HLA-DPA1 protein HLA-DPA1 Plasma Membrane Signal Transduction 
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144 Q7YP04 HLA class II histocompatibility antigen, DRB1-12 beta chain HLA-DRB5 Plasma Membrane Immune Response 
145 Q96AG4 Leucine-rich repeat-containing protein 59 LRRC59 ER  
146 Q96DV6 Ribosomal protein S6 RPS6 Ribosome Protein Metabolism 
147 Q96GD7 CSDA protein CSDA Nucleus DNA binding 
148 Q96HS1 Serine/threonine-protein phosphatase PGAM5, mitochondrial PXMP2 peroxisome Transport 
149 Q96HX3 Similar to ribophorin I RPN1 Cytoplasm Protein Metabolism 
150 Q96IR1 RPS4X protein RPS4X Ribosome Protein Metabolism 
151 Q96MX4 Ewing sarcoma breakpoint region 1, isoform CRA_h EWSR1 Plasma Membrane RNA binding 
152 Q96QL0 Ribosomal protein L3 LOC653881 Ribosome Protein Metabolism 
153 Q96RS2 Laminin receptor-like protein LAMRL5 RPSA Plasma Membrane Signal Transduction 
154 Q99623 Prohibitin-2 PHB2 Plasma Membrane Signal Transduction 
155 Q9B2U8 Cytochrome c oxidase subunit 2 COX2 Mitochondria Metabolism Energy 
156 Q9BRW0 CD58 protein CD58 Plasma Membrane Signal Transduction 
157 Q9BSV4 SFPQ protein SFPQ Cytoplasm RNA binding 
158 Q9GJ38 MHC class I antigen MICA Plasma Membrane Signal Transduction 
159 Q9HBB3 60S ribosomal protein L6 RPL6 Ribosome Metabolism Energy 
160 Q9NVI7 ATPase family AAA domain-containing protein 3A ATAD3A Plasma Membrane Cell Growth 
161 Q9TQ74 MHC class I antigen heavy chain HLA-A Plasma Membrane Immune Response 
162 Q4GX01 MHC class I antigen HLA-B Plasma Membrane Signal Transduction 
163 F5H6I0 Beta-2-microglobulin B2M Plasma Membrane Signal Transduction 
164 Q30154 HLA class II histocompatibility antigen, DR beta 5 chain HLA-DRB5 Plasma Membrane Immune Response 
165 Q12906 cDNA FLJ77456, highly similar to Homo sapiens interleukin enhancer binding factor 3, 
90kDa 
ILF3 Cytoplasm RNA binding 
166 B1ALS3 Protein tyrosine phosphatase, receptor type, C PTPRC Plasma Membrane Signal Transduction 
167 Q13263 cDNA, FLJ94025, highly similar to Homo sapiens tripartite motif-containing 28 TRIM28 Nucleus Transcription 
168 Q14444 cDNA FLJ46087 fis, clone TESTI2009497, highly similar to GPI-anchored protein p137 CAPRIN1 Plasma Membrane Transport 
169 Q07666 cDNA FLJ54590, highly similar to KH domain-containing, RNA-binding, signaltransduction-
associated protein 1 
KHDRBS1 Cytoplasm Signal Transduction 
170 O75569 cDNA FLJ60590, highly similar to Interferon-inducible double strandedRNA-dependent 
protein kinase activator A 
PRKRA Cytoplasm Immune Response 
171 B7Z599 Ectonucleoside triphosphate diphosphohydrolase 1, isoform CRA_d ENTPD1 Plasma Membrane Metabolism Energy 
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172 Q14677  cDNA FLJ61629, highly similar to Clathrin interactor 1 CLINT1 Plasma Membrane Transport 
173 B9EG90 Topoisomerase TOP1 Cytoplasm DNA topoisomerase 
174 O75475 PC4 and SFRS1-interacting protein PSIP1 Nucleus Transcription 
175 P02458 Collagen alpha-1(II) chain COL2A1 Extracellular Cell Growth 
176 P12107 Collagen alpha-1(XI) chain COL11A1 Extracellular Cell Growth 
177 P14174 Macrophage migration inhibitory factor MIF Extracellular Immune Response 
178 P31943 Heterogeneous nuclear ribonucleoprotein H HNRNPH1 Cytoplasm Protein Metabolism 
179 Q4LE83 Fatty acid synthase FASN Cytoplasm Metabolism Energy 
180 P49411 Elongation factor Tu, mitochondrial TUFM Cytoplasm Protein Metabolism 
181 P78527 DNA-dependent protein kinase catalytic subunit PRKDC Cytoplasm Signal Transduction 
182 Q09666 Neuroblast differentiation-associated protein AHNAK AHNAK Plasma Membrane Cell Development 
183 Q24JU4 Eukaryotic translation initiation factor 3, subunit A EIF3A Cytoplasm Protein Metabolism 
184 Q30159 HLA class II histocompatibility antigen, DRB1-16 beta chain HLA-DRB5 Plasma Membrane Immune Response 
185 Q53HL1 Myosin regulatory light chain MRCL3 variant MYL12A Cytoplasm Signal Transduction 
186 Q59F66 DEAD box polypeptide 17 isoform p82 variant DDX17 Nucleus ATP binding 
187 Q59G28 Amyloid beta A4 protein-binding, family A, member 2 variant APBA2 Plasma Membrane Signal Transduction 
188 Q5H9J7 Protein BEX5 BEX5 Cytoplasm  
189 Q5NKV8 Intercellular adhesion molecule 1 ICAM1 Plasma Membrane Signal Transduction 
190 Q5SR44 Complement component CR1 Plasma Membrane Immune Response 
191 Q5SR47 Complement component CR2 Plasma Membrane Immune Response 
192 Q7Z5P9 Mucin-19 MUC19 Extracellular Protein Metabolism 
193 Q86V86 Serine/threonine-protein kinase pim-3 PIM3 Cytoplasm Signal Transduction 
194 Q8NHX6 Cervical cancer proto-oncogene 5 MCM3 Nucleus DNA binding 
195 Q8TEM1 Nuclear pore membrane glycoprotein 210 NUP210 Nucleus/ER Transport 
196 Q8WU19 TUBA1B protein TUBA1B Plasma Membrane Cell Growth 
197 Q8WZ42 Titin TTN Cytoplasm Cell structure 
198 Q9BV61 TRAP1 protein TRAP1 Plasma Membrane Signal Transduction 
199 B9EGP0 PHD and RING finger domain-containing protein 1 PHRF1 Nucleus RNA binding 
i  Accession numbers of proteins were from the UniProtKB/Swiss-Prot database.   
ii, iii Sub-cellular location and biological process were obtained from The Human Protein Reference Database (http://www.hprd.org/).  
